3327 active
/
6371 total (since 2015)
2007
Phase 1 Active
4043 total
1738
Phase 2 Active
2990 total
328
Phase 3 Active
534 total
61
Phase 4 Active
151 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Merck 44 38 13
Sichuan Baili Pharmaceutical Co., Ltd. 31 0 1
Eli Lilly 30 21 12
GSK 29 14 18
AstraZeneca 25 14 5
Johnson & Johnson 23 12 1
Roche 22 42 14
Jiangsu HengRui Medicine Co., Ltd. 22 22 7
Pfizer 19 17 24
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 18 3 0
AbbVie 17 16 11
Novartis 17 11 11
Bristol-Myers Squibb 14 56 23
Daiichi Sankyo 14 1 2
Qilu Pharmaceutical Co., Ltd. 14 0 0
NCT05063552 ACTIVE NOT RECRUITING
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI) n=430
NCT03435796 RECRUITING
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene n=1,541
NCT05092958 ACTIVE NOT RECRUITING
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI) n=654
NCT06901531 RECRUITING
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc. n=500
NCT04444921 ACTIVE NOT RECRUITING
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
National Cancer Institute (NCI) n=205
NCT03244384 ACTIVE NOT RECRUITING
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
National Cancer Institute (NCI) n=739
NCT03233711 ACTIVE NOT RECRUITING
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI) n=344
NCT06926868 RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb n=500
NCT02595944 ACTIVE NOT RECRUITING
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI) n=903
NCT03793166 ACTIVE NOT RECRUITING
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI) n=1,175
NCT06661720 RECRUITING
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology n=1,040
NCT02193282 ACTIVE NOT RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI) n=390
NCT07028853 RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Pfizer n=1,000
NCT07445048 NOT YET RECRUITING
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University n=370
NCT03055013 ACTIVE NOT RECRUITING
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI) n=819
NCT02466971 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
National Cancer Institute (NCI) n=450
NCT07444775 RECRUITING
Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors
University Health Network, Toronto n=148
NCT07213804 RECRUITING
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Eli Lilly and Company n=1,080
NCT07174336 RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company n=920
NCT05721755 RECRUITING
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
ECOG-ACRIN Cancer Research Group n=290
NCT05863351 ACTIVE NOT RECRUITING
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
ECOG-ACRIN Cancer Research Group n=472
NCT07441681 NOT YET RECRUITING
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology n=454
NCT06966700 RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC n=2,400
NCT06346197 RECRUITING
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Centre Leon Berard n=132
NCT05863195 RECRUITING
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
ECOG-ACRIN Cancer Research Group n=408
NCT07218380 RECRUITING
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company n=450
NCT03875235 ACTIVE NOT RECRUITING
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
AstraZeneca n=810
NCT07060807 RECRUITING
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC n=1,000
NCT06532006 RECRUITING
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech n=550
NCT06915025 RECRUITING
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Imunon n=500
NCT05235165 RECRUITING
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Children's Oncology Group n=62
NCT05152147 ACTIVE NOT RECRUITING
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Jazz Pharmaceuticals n=920
NCT06312176 RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Merck Sharp & Dohme LLC n=1,200
NCT06841354 RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Merck Sharp & Dohme LLC n=1,000
NCT03486873 RECRUITING
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Merck Sharp & Dohme LLC n=3,500
NCT07440290 NOT YET RECRUITING
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Cancer Research UK n=30
NCT07434206 ACTIVE NOT RECRUITING
Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors
South Egypt Cancer Institute n=80
NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT06824467 RECRUITING
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme LLC n=770
NCT06960577 RECRUITING
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca n=150
NCT05113251 ACTIVE NOT RECRUITING
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca n=927
NCT07426094 NOT YET RECRUITING
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,600
NCT07426055 NOT YET RECRUITING
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,200
NCT05303532 ENROLLING BY INVITATION
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
AstraZeneca n=214
NCT06589804 RECRUITING
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI) n=158
NCT05445778 RECRUITING
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie n=520
NCT03194893 ACTIVE NOT RECRUITING
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche n=200
NCT07173751 RECRUITING
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
BioNTech SE n=558
NCT05239741 RECRUITING
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Merck Sharp & Dohme LLC n=100
NCT07099898 RECRUITING
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline n=300
NCT06662786 RECRUITING
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Janssen Research & Development, LLC n=1,000
NCT04251533 ACTIVE NOT RECRUITING
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Novartis Pharmaceuticals n=137
NCT06919965 RECRUITING
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Janssen Research & Development, LLC n=220
NCT04658862 ACTIVE NOT RECRUITING
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Janssen Research & Development, LLC n=518
NCT06319820 RECRUITING
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Janssen Research & Development, LLC n=641
NCT07410117 NOT YET RECRUITING
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Regeneron Pharmaceuticals n=860
NCT06750094 RECRUITING
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Janssen Research & Development, LLC n=700
NCT07408128 NOT YET RECRUITING
Partner4Exercise Randomized Controlled Trial
McMaster University n=183
NCT03504397 ACTIVE NOT RECRUITING
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Astellas Pharma Global Development, Inc. n=565
NCT03748641 ACTIVE NOT RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Janssen Research & Development, LLC n=765
NCT06593665 RECRUITING
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
Indiana University n=142
NCT05862285 RECRUITING
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Hoffmann-La Roche n=100
NCT02320435 ACTIVE NOT RECRUITING
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Hoffmann-La Roche n=154
NCT07402538 NOT YET RECRUITING
Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma
Sun Yat-sen University n=184
NCT04318886 ACTIVE NOT RECRUITING
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
University of Alabama at Birmingham n=387
NCT03686202 ACTIVE NOT RECRUITING
Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients
University Health Network, Toronto n=65
NCT03653507 ACTIVE NOT RECRUITING
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Astellas Pharma Global Development, Inc. n=507
NCT04749108 RECRUITING
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
Institut du Cancer de Montpellier - Val d'Aurelle n=1,075
NCT07005024 RECRUITING
DOAC - Dosing Options in AntiCoagulation Prophylaxis
University of Vermont n=996
NCT06349668 RECRUITING
Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery
Hans Bahlmann n=220
NCT05208047 ACTIVE NOT RECRUITING
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc. n=442
NCT04620239 RECRUITING
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Steba Biotech S.A. n=100
NCT03661320 ACTIVE NOT RECRUITING
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb n=855
NCT07385079 NOT YET RECRUITING
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University n=412
NCT07383441 NOT YET RECRUITING
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network n=718
NCT02655016 ACTIVE NOT RECRUITING
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc. n=733
NCT05843877 RECRUITING
Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula
Technische Universität Dresden n=32
NCT07222800 RECRUITING
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer n=800
NCT07218926 RECRUITING
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline n=450
NCT03768063 ACTIVE NOT RECRUITING
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Hoffmann-La Roche n=1,000
NCT05514054 ACTIVE NOT RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company n=8,000
NCT07373990 NOT YET RECRUITING
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University n=418
NCT04114981 ACTIVE NOT RECRUITING
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
Alliance for Clinical Trials in Oncology n=242
NCT07366528 RECRUITING
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital n=387
NCT05855200 RECRUITING
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline n=892
NCT06391242 RECRUITING
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
Canadian Cancer Trials Group n=230
NCT06211764 ACTIVE NOT RECRUITING
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Janssen Research & Development, LLC n=272
NCT03875781 RECRUITING
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
Assistance Publique - Hôpitaux de Paris n=540
NCT07342517 NOT YET RECRUITING
A Phase 3 Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
Relmada Therapeutics, Inc. n=85
NCT06745024 RECRUITING
Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial
NRG Oncology n=280
NCT06500481 RECRUITING
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NRG Oncology n=115
NCT04333537 RECRUITING
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NRG Oncology n=686
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
NCT04095364 ACTIVE NOT RECRUITING
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology n=450
NCT05053867 RECRUITING
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
M.D. Anderson Cancer Center n=60
NCT05438212 ACTIVE NOT RECRUITING
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NRG Oncology n=237
NCT04804644 RECRUITING
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NRG Oncology n=200
NCT03148418 ACTIVE NOT RECRUITING
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche n=382
NCT05451004 RECRUITING
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Canadian Cancer Trials Group n=510
NCT06111235 ACTIVE NOT RECRUITING
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology, Inc. n=367
NCT06161025 RECRUITING
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo n=860
NCT07333274 RECRUITING
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Shandong Cancer Hospital and Institute n=335
NCT04448184 RECRUITING
Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
Ottawa Hospital Research Institute n=662
NCT04095299 RECRUITING
Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients
Vejle Hospital n=162
NCT05112965 ACTIVE NOT RECRUITING
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche n=49
NCT05365178 ACTIVE NOT RECRUITING
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=432
NCT06072612 RECRUITING
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
BriaCell Therapeutics Corporation n=404
NCT07318558 NOT YET RECRUITING
A Clinical Trial of Sacituzumab Tirumotecan in People With Ovarian Cancer (MK-2870-021)
Merck Sharp & Dohme LLC n=900
NCT07313891 NOT YET RECRUITING
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
Relmada Therapeutics, Inc. n=302
NCT03602859 ACTIVE NOT RECRUITING
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Tesaro, Inc. n=1,400
NCT07310758 RECRUITING
Contrast-enhanced Ultrasound for Sentinel Node Detection
The Netherlands Cancer Institute n=91
NCT06998069 RECRUITING
Head and Neck Cancer Study Project in the Geriatric Population
Brown University n=20
NCT03743649 ACTIVE NOT RECRUITING
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
M.D. Anderson Cancer Center n=110
NCT03750227 RECRUITING
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
Mayo Clinic n=140
NCT05659381 RECRUITING
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
GOG Foundation n=220
NCT05629234 ACTIVE NOT RECRUITING
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
AstraZeneca n=37
NCT04592913 ACTIVE NOT RECRUITING
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
AstraZeneca n=957
NCT07290088 RECRUITING
Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
Intra-IMMUSG Pte Ltd n=52
NCT04269200 ACTIVE NOT RECRUITING
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
AstraZeneca n=805
NCT03997123 ACTIVE NOT RECRUITING
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
AstraZeneca n=923
NCT03533582 ACTIVE NOT RECRUITING
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group n=537
NCT07164443 RECRUITING
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development, LLC n=663
NCT06963268 RECRUITING
Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)
Instituto de Investigacion Sanitaria La Fe n=200
NCT07290491 RECRUITING
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
The Methodist Hospital Research Institute n=854
NCT05902533 ACTIVE NOT RECRUITING
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
University of Cincinnati n=33
NCT07287592 NOT YET RECRUITING
Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.
Ain Shams University n=70
NCT05253651 RECRUITING
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Seagen, a wholly owned subsidiary of Pfizer n=400
NCT06093425 NOT YET RECRUITING
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd. n=820
NCT07286266 NOT YET RECRUITING
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline n=450
NCT07286331 NOT YET RECRUITING
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)
GlaxoSmithKline n=600
NCT03422198 RECRUITING
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
University of Utah n=188
NCT07088263 RECRUITING
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Sun Yat-sen University n=192
NCT06905587 RECRUITING
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
Odense University Hospital n=50
NCT06790966 ACTIVE NOT RECRUITING
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
PDS Biotechnology Corp. n=351
NCT07271355 NOT YET RECRUITING
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center n=129
NCT06295809 ACTIVE NOT RECRUITING
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Merck Sharp & Dohme LLC n=46
NCT07174453 RECRUITING
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
University of Kansas Medical Center n=192
NCT03815643 ACTIVE NOT RECRUITING
Avelumab Program Rollover Study
EMD Serono Research & Development Institute, Inc. n=205
NCT05443737 RECRUITING
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
University of California, San Diego n=2,800
NCT02341989 ACTIVE NOT RECRUITING
Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
St. Olavs Hospital n=348
NCT05786716 RECRUITING
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Cancer Research UK n=30
NCT05918302 RECRUITING
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Grupo Espanol de Tumores Neuroendocrinos n=120
NCT06476639 NOT YET RECRUITING
A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer
Queensland Centre for Gynaecological Cancer n=640
NCT05770544 RECRUITING
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Cancer Research UK n=30
NCT05770037 RECRUITING
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Cancer Research UK n=30
NCT05768178 RECRUITING
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK n=30
NCT04447313 ACTIVE NOT RECRUITING
Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study
Fred Hutchinson Cancer Center n=418
NCT06988475 RECRUITING
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Cancer Research UK n=30
NCT05770102 RECRUITING
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
Cancer Research UK n=30
NCT07238569 NOT YET RECRUITING
Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University n=516
NCT07235319 RECRUITING
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
Sun Yat-sen University n=260
NCT06800092 NOT YET RECRUITING
Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
The University of Texas Medical Branch, Galveston n=30
NCT06706401 RECRUITING
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Centre Leon Berard n=460
NCT04228991 ACTIVE NOT RECRUITING
Hypofractionated LocoRegional Radiotherapy in Breast Cancer
Ontario Clinical Oncology Group (OCOG) n=588
NCT04464226 RECRUITING
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer n=402
NCT05474846 RECRUITING
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
M.D. Anderson Cancer Center n=188
NCT05281471 RECRUITING
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation n=186
NCT02491632 ACTIVE NOT RECRUITING
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center n=90
NCT03740165 ACTIVE NOT RECRUITING
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Merck Sharp & Dohme LLC n=1,367
NCT06593431 RECRUITING
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
M.D. Anderson Cancer Center n=80
NCT03525873 ACTIVE NOT RECRUITING
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
M.D. Anderson Cancer Center n=212
NCT06085716 RECRUITING
Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
M.D. Anderson Cancer Center n=240
NCT02632409 ACTIVE NOT RECRUITING
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Bristol-Myers Squibb n=709
NCT06174987 RECRUITING
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Daiichi Sankyo n=50
NCT03418961 RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network n=491
NCT07207824 NOT YET RECRUITING
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Fudan University n=182
NCT07166042 RECRUITING
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
University of Utah n=34
NCT02505750 ACTIVE NOT RECRUITING
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
Centre Antoine Lacassagne n=148
NCT07197580 NOT YET RECRUITING
Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Telix Pharmaceuticals (Innovations) Pty Limited n=40
NCT04111978 RECRUITING
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Swiss GO Trial Group n=540
NCT06256588 RECRUITING
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
GlaxoSmithKline n=864
NCT03842982 RECRUITING
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
Centre Oscar Lambret n=362
NCT04158362 ACTIVE NOT RECRUITING
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer
UNICANCER n=180
NCT07156786 NOT YET RECRUITING
N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial
Fakultas Kedokteran Universitas Indonesia n=72
NCT07155525 RECRUITING
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
Minia University n=194
NCT06124976 RECRUITING
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
University of British Columbia n=70
NCT04335669 ACTIVE NOT RECRUITING
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital n=325
NCT04575935 RECRUITING
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center n=580
NCT05009082 RECRUITING
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group n=970
NCT05335928 RECRUITING
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Massachusetts General Hospital n=390
NCT04510597 RECRUITING
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
SWOG Cancer Research Network n=364
NCT05860881 ACTIVE NOT RECRUITING
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
Melanoma and Skin Cancer Trials Limited n=146
NCT03021486 ACTIVE NOT RECRUITING
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
M.D. Anderson Cancer Center n=70
NCT03741673 RECRUITING
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
M.D. Anderson Cancer Center n=180
NCT03981796 ACTIVE NOT RECRUITING
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
Tesaro, Inc. n=785
NCT06207981 RECRUITING
Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
Federation Francophone de Cancerologie Digestive n=310
NCT07081360 RECRUITING
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Minia University n=262
NCT07132008 NOT YET RECRUITING
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
First Affiliated Hospital of Guangxi Medical University n=94
NCT03765918 ACTIVE NOT RECRUITING
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Merck Sharp & Dohme LLC n=714
NCT04380636 ACTIVE NOT RECRUITING
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Merck Sharp & Dohme LLC n=870
NCT06994195 RECRUITING
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd. n=384
NCT07124195 NOT YET RECRUITING
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
The First Affiliated Hospital of Xinxiang Medical College n=126
NCT07125755 NOT YET RECRUITING
Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University n=386
NCT04607421 ACTIVE NOT RECRUITING
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer n=831
NCT06379113 RECRUITING
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Xiaojun Chen n=29
NCT05316935 RECRUITING
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Xiaojun Chen n=80
NCT06867705 RECRUITING
Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only
Resilience n=1,458
NCT06866574 ACTIVE NOT RECRUITING
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University n=9,300
NCT07067749 RECRUITING
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
University of Rome Tor Vergata n=92
NCT07084454 ENROLLING BY INVITATION
Geriatric Oncology Care in Brazil: Remote Geriatric Assessment-Driven Interventions With Supportive Care
Cristiane Decat Bergerot, PhD n=350
NCT05429099 RECRUITING
Mandibular Reconstruction Preplanning (ViPMR)
University of British Columbia n=420
NCT04915755 ACTIVE NOT RECRUITING
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
GlaxoSmithKline n=40
NCT07062263 RECRUITING
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Tata Memorial Centre n=220
NCT05116189 ACTIVE NOT RECRUITING
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
Merck Sharp & Dohme LLC n=643
NCT04975308 ACTIVE NOT RECRUITING
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Company n=874
NCT05920343 RECRUITING
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
Ottawa Hospital Research Institute n=120
NCT04498117 ACTIVE NOT RECRUITING
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio Inc. n=615
NCT02885753 RECRUITING
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Federation Francophone de Cancerologie Digestive n=348
NCT05029063 RECRUITING
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
Ottawa Hospital Research Institute n=1,828
NCT05454280 RECRUITING
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Fox Chase Cancer Center n=880
NCT06506955 ENROLLING BY INVITATION
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc. n=15
NCT05796973 RECRUITING
Measuring Oncological Value of Exercise and Statin
Tampere University Hospital n=240
NCT05288166 ACTIVE NOT RECRUITING
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company n=925
NCT07035821 NOT YET RECRUITING
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy
Shanghai Children's Medical Center n=100
NCT05059522 ACTIVE NOT RECRUITING
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer n=68
NCT03522246 ACTIVE NOT RECRUITING
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
pharmaand GmbH n=1,097
NCT06401356 RECRUITING
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis Pharmaceuticals n=50
NCT02804815 ACTIVE NOT RECRUITING
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
University College, London n=11,000
NCT05346224 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Shanghai Henlius Biotech n=900
NCT04634877 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Merck Sharp & Dohme LLC n=990
NCT06279130 RECRUITING
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
The Netherlands Cancer Institute n=92
NCT07000253 NOT YET RECRUITING
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=290
NCT06999512 NOT YET RECRUITING
Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer
Assistance Publique - Hôpitaux de Paris n=526
NCT06208371 RECRUITING
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
Sun Yat-sen University n=117
NCT03478488 ACTIVE NOT RECRUITING
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
3D Medicines (Sichuan) Co., Ltd. n=480
NCT06749899 RECRUITING
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Sun Yat-sen University n=580
NCT04178174 RECRUITING
Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=360
NCT05141721 ACTIVE NOT RECRUITING
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Seattle Project Corporation n=700
NCT06768164 NOT YET RECRUITING
Quality of Life After Billroth II or Roux-en-Y for Gastric Cancer
Assistance Publique - Hôpitaux de Paris n=250
NCT04513418 RECRUITING
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
Hecheng Li M.D., Ph.D n=244
NCT06332274 RECRUITING
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Gustave Roussy, Cancer Campus, Grand Paris n=717
NCT06966232 RECRUITING
Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers
Sun Yat-sen University n=136
NCT06028737 RECRUITING
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Ukrainian Society of Clinical Oncology n=150
NCT05407987 RECRUITING
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
AHS Cancer Control Alberta n=82
NCT05506943 ACTIVE NOT RECRUITING
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics n=150
NCT05257408 ACTIVE NOT RECRUITING
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics n=381
NCT06834672 RECRUITING
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Innovent Biologics (Suzhou) Co. Ltd. n=450
NCT04711109 ACTIVE NOT RECRUITING
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Alliance for Clinical Trials in Oncology n=300
NCT06859190 RECRUITING
Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer
Qinghai Red Cross Hospital n=60
NCT06658353 RECRUITING
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
Jiangsu vcare pharmaceutical technology co., LTD n=54
NCT06857773 RECRUITING
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
The Netherlands Cancer Institute n=306
NCT06737822 RECRUITING
Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:
All India Institute of Medical Sciences, Jodhpur n=346
NCT04895358 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Merck Sharp & Dohme LLC n=340
NCT06845306 NOT YET RECRUITING
The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surgery
Vadim Kuznetsov n=1,268
NCT06836492 RECRUITING
A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
Yizhuo Zhang n=300
NCT02215265 ACTIVE NOT RECRUITING
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
Lisette Nixon n=1,269
NCT02859038 ACTIVE NOT RECRUITING
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
Shanghai Gynecologic Oncology Group n=489
NCT05587374 ACTIVE NOT RECRUITING
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
Sun Yat-sen University n=490
NCT06504732 RECRUITING
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
SUNHO（China）BioPharmaceutical CO., Ltd. n=90
NCT03840421 ACTIVE NOT RECRUITING
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University n=468
NCT06751485 NOT YET RECRUITING
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd n=430
NCT06740916 RECRUITING
Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients with Aspirin Resistance
Siriraj Hospital n=240
NCT06276465 RECRUITING
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
UNICANCER n=336
NCT06465914 ACTIVE NOT RECRUITING
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd. n=9,000
NCT03081143 ACTIVE NOT RECRUITING
Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=429
NCT04765020 RECRUITING
Cardiorespiratory Fitness in Children and Adolescents After Cancer Treatment.
Universität Duisburg-Essen n=56
NCT06717711 RECRUITING
Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers
Regina Elena Cancer Institute n=158
NCT06714604 RECRUITING
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Sahlgrenska University Hospital n=432
NCT04241185 ACTIVE NOT RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Merck Sharp & Dohme LLC n=520
NCT02758951 ACTIVE NOT RECRUITING
Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
Koen Rovers n=358
NCT05173987 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Merck Sharp & Dohme LLC n=280
NCT06496971 RECRUITING
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation n=32
NCT06672887 RECRUITING
Enhancing Successful Return to Work of Employees With Cancer, by Supporting Employers (MiLES Intervention)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=140
NCT04723875 ACTIVE NOT RECRUITING
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline
Huazhong University of Science and Technology n=306
NCT05744219 RECRUITING
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Jon Unosson n=338
NCT06275958 RECRUITING
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
Leiden University Medical Center n=587
NCT04523272 ACTIVE NOT RECRUITING
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=528
NCT06185556 RECRUITING
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
Amsterdam UMC, location VUmc n=78
NCT05939687 RECRUITING
Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection
Blokhin's Russian Cancer Research Center n=142
NCT05764044 RECRUITING
Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer
Hospital do Coracao n=365
NCT04116047 ACTIVE NOT RECRUITING
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
University of Birmingham n=785
NCT06509724 RECRUITING
Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy
Samsung Medical Center n=248
NCT06086457 RECRUITING
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=436
NCT05665348 RECRUITING
Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
Federation Francophone de Cancerologie Digestive n=574
NCT05847348 RECRUITING
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Telix Pharmaceuticals (Innovations) Pty Limited n=110
NCT05352178 RECRUITING
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Universitaire Ziekenhuizen KU Leuven n=873
NCT06478108 RECRUITING
Interventional Software for Multi-immunotherapy of Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=60
NCT03755739 RECRUITING
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT04422366 RECRUITING
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=8,000
NCT06441110 RECRUITING
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Fujian Medical University Union Hospital n=76
NCT05699655 RECRUITING
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital n=130
NCT06391892 RECRUITING
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Elisabethinen Hospital n=100
NCT06277050 RECRUITING
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital n=264
NCT03659448 RECRUITING
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Surgimab n=300
NCT05027776 RECRUITING
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd. n=1,348
NCT04895020 RECRUITING
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd. n=1,200
NCT04833023 RECRUITING
HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial
Tan Tock Seng Hospital n=72
NCT03427827 ACTIVE NOT RECRUITING
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University n=450
NCT06119867 RECRUITING
CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)
Russian Society of Colorectal Surgeons n=430
NCT06346366 ACTIVE NOT RECRUITING
Glucose Control Through a Bihormonal Artificial Pancreas in Patients After Total Pancreatectomy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=40
NCT06337695 NOT YET RECRUITING
VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer
University of Calgary n=298
NCT05057130 RECRUITING
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Blokhin's Russian Cancer Research Center n=50
NCT06338683 RECRUITING
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Qinghai Red Cross Hospital n=230
NCT03423199 ACTIVE NOT RECRUITING
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
National Cancer Center, Japan n=180
NCT06313463 RECRUITING
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=375
NCT04642027 RECRUITING
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
University Medical Center Groningen n=538
NCT06226857 RECRUITING
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
City Clinical Oncology Hospital No 1 n=355
NCT06208917 RECRUITING
Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children
Yizhuo Zhang n=376
NCT06149533 NOT YET RECRUITING
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=366
NCT06017583 RECRUITING
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
Yong Zhang,MD n=48
NCT05264896 RECRUITING
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong n=110
NCT04722692 RECRUITING
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Uppsala University n=500
NCT05430399 RECRUITING
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University n=349
NCT04019548 RECRUITING
Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy
Jules Bordet Institute n=110
NCT02429700 RECRUITING
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Beihua Kong n=132
NCT02429687 RECRUITING
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Beihua Kong n=129
NCT03458221 RECRUITING
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
Gynaecologisch Oncologisch Centrum Zuid n=148
NCT05754853 RECRUITING
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Shanghai Miracogen Inc. n=290
NCT05797077 RECRUITING
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
Sixth Affiliated Hospital, Sun Yat-sen University n=346
NCT05735145 RECRUITING
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
Fourth Affiliated Hospital of Guangxi Medical University n=108
NCT03697343 RECRUITING
Fractionated Stereotactic Radiotherapy vs. Single Session Radiosurgery in Patients With Larger Brain Metastases
University of Erlangen-Nürnberg Medical School n=382
NCT05484024 NOT YET RECRUITING
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
Chinese Academy of Medical Sciences n=588
NCT05172518 NOT YET RECRUITING
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University n=512
NCT04733820 RECRUITING
Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery
Huazhong University of Science and Technology n=340
NCT04453826 RECRUITING
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University n=388
NCT04515602 NOT YET RECRUITING
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
Shanghai Gynecologic Oncology Group n=410
NCT03961841 NOT YET RECRUITING
Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University n=900
NCT02497820 NOT YET RECRUITING
Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers
Tel-Aviv Sourasky Medical Center n=1,800
NCT03675737 COMPLETED
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Merck Sharp & Dohme LLC n=1,579
NCT04738487 COMPLETED
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC n=1,264
NCT04221945 COMPLETED
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Merck Sharp & Dohme LLC n=1,060
NCT03683329 COMPLETED
Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock
Institut Paoli-Calmettes n=398
NCT06235099 COMPLETED
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Curium US LLC n=235
NCT03143153 COMPLETED
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
Bristol-Myers Squibb n=970
NCT03258554 COMPLETED
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI) n=196
NCT04776148 COMPLETED
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Merck Sharp & Dohme LLC n=563
NCT03040999 COMPLETED
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Merck Sharp & Dohme LLC n=804
NCT06240741 COMPLETED
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Novartis Pharmaceuticals n=71
NCT05061823 COMPLETED
Bintrafusp Alfa Program Rollover Study
EMD Serono Research & Development Institute, Inc. n=22
NCT03884101 COMPLETED
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Merck Sharp & Dohme LLC n=842
NCT05177484 COMPLETED
Perioperative Iron for Colorectal Cancer (PICoC Study)
The Royal Wolverhampton Hospitals NHS Trust n=40
NCT04457297 COMPLETED
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
National Cancer Center Hospital East n=243
NCT03474107 COMPLETED
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Global Development, Inc. n=608
NCT05351294 SUSPENDED
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
Rutgers, The State University of New Jersey n=156
NCT04442048 COMPLETED
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
Canadian Cancer Trials Group n=195
NCT07279792 COMPLETED
Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection
Ain Shams University n=150
NCT02926196 COMPLETED
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Istituto Oncologico Veneto IRCCS n=474
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT03615326 COMPLETED
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Merck Sharp & Dohme LLC n=738
NCT03013010 COMPLETED
PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy
Shanghai Cancer Hospital, China n=204
NCT06007586 COMPLETED
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Sichuan Cancer Hospital and Research Institute n=143
NCT04865289 COMPLETED
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
Merck Sharp & Dohme LLC n=130
NCT02918955 COMPLETED
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Insel Gruppe AG, University Hospital Bern n=65
NCT02442375 COMPLETED
Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity
Radboud University Medical Center n=300
NCT02743494 COMPLETED
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
Bristol-Myers Squibb n=794
NCT03371017 COMPLETED
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
Hoffmann-La Roche n=595
NCT03036488 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Merck Sharp & Dohme LLC n=1,174
NCT03136445 COMPLETED
TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia
NHS Blood and Transplant n=616
NCT02297438 COMPLETED
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer n=340
NCT05694013 TERMINATED
Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
Hoffmann-La Roche n=49
NCT03269994 COMPLETED
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Memorial Sloan Kettering Cancer Center n=967
NCT04161885 TERMINATED
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie n=465
NCT05870748 TERMINATED
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc. n=600
NCT04327063 COMPLETED
MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery
Institut Curie n=182
NCT04149574 TERMINATED
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
Bristol-Myers Squibb n=13
NCT04534075 COMPLETED
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
Sahlgrenska University Hospital n=354
NCT02330926 COMPLETED
Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
Norwegian University of Science and Technology n=221
NCT05092360 TERMINATED
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Mural Oncology, Inc n=456
NCT04209855 COMPLETED
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
AbbVie n=453
NCT05328908 TERMINATED
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Bristol-Myers Squibb n=770
NCT04635423 COMPLETED
Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)
Merck Sharp & Dohme LLC n=1,059
NCT02684006 COMPLETED
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Pfizer n=886
NCT03829969 COMPLETED
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd. n=514
NCT04752332 TERMINATED
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Eli Lilly and Company n=111
NCT04616768 COMPLETED
PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers
Abramson Cancer Center at Penn Medicine n=108
NCT04503668 TERMINATED
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center n=62
NCT03517449 COMPLETED
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
Eisai Inc. n=827
NCT04588246 TERMINATED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology n=19
NCT04785768 COMPLETED
IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration
Fujian Cancer Hospital n=1,372
NCT05763667 COMPLETED
Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer
Tufts Medical Center n=15
NCT02360215 COMPLETED
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
NRG Oncology n=518
NCT06910514 COMPLETED
Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions
Nakafarma S.L. n=52
NCT03578081 COMPLETED
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology n=690
NCT04316013 TERMINATED
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
Peter MacCallum Cancer Centre, Australia n=254
NCT05236647 COMPLETED
Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer Patients
University Hospital, Akershus n=60
NCT03013946 TERMINATED
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
AIO-Studien-gGmbH n=121
NCT02908477 COMPLETED
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
Mayo Clinic n=228
NCT03692065 COMPLETED
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
Assistance Publique - Hôpitaux de Paris n=1,766
NCT04222972 COMPLETED
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche n=223
NCT03924986 COMPLETED
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
BeiGene n=263
NCT03839940 TERMINATED
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
Alliance for Clinical Trials in Oncology n=39
NCT04410042 TERMINATED
Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure
St. Jude Children's Research Hospital n=15
NCT04340193 COMPLETED
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
Bristol-Myers Squibb n=26
NCT04227522 COMPLETED
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
North Eastern German Society of Gynaecological Oncology n=42
NCT03189719 COMPLETED
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
Merck Sharp & Dohme LLC n=749
NCT05369234 COMPLETED
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
Covenant Health Cancer Center n=100
NCT04428333 TERMINATED
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
GlaxoSmithKline n=117
NCT03635489 COMPLETED
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche n=100
NCT02845479 COMPLETED
The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I
The Canadian College of Naturopathic Medicine n=22
NCT03747562 WITHDRAWN
Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients.
University Hospital, Ghent
NCT05865548 COMPLETED
Addition of Aspirin to Standard of Care in Oral Cancer
Banaras Hindu University n=60
NCT04296890 COMPLETED
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
ImmunoGen, Inc. n=106
NCT04538625 COMPLETED
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
Napo Pharmaceuticals, Inc. n=287
NCT02501954 COMPLETED
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
Women's Cancer Care Associates, LLC n=48
NCT03389451 COMPLETED
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
Michael Graham PhD, MD n=30
NCT04128696 TERMINATED
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
GlaxoSmithKline n=315
NCT03506815 COMPLETED
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Ottawa Hospital Research Institute n=105
NCT03425656 COMPLETED
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
AryoGen Pharmed Co. n=108
NCT03743051 COMPLETED
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA n=318
NCT03743064 COMPLETED
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA n=318
NCT03837171 COMPLETED
TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock
Assistance Publique - Hôpitaux de Paris n=192
NCT04676334 COMPLETED
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
pharmaand GmbH n=34
NCT02928406 COMPLETED
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Hoffmann-La Roche n=1,004
NCT05564286 COMPLETED
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
Shantou University Medical College n=116
NCT04844749 TERMINATED
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Veru Inc. n=105
NCT05372016 COMPLETED
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=1,200
NCT05329545 TERMINATED
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Mersana Therapeutics n=20
NCT03040726 COMPLETED
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
M.D. Anderson Cancer Center n=53
NCT04534725 COMPLETED
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
Peter MacCallum Cancer Centre, Australia n=441
NCT04822597 COMPLETED
Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
University of Wisconsin, Madison n=167
NCT02611960 COMPLETED
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
Merck Sharp & Dohme LLC n=233
NCT05096468 COMPLETED
Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.
Beijing Tiantan Hospital n=90
NCT02969681 COMPLETED
Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer
Sun Yat-sen University n=442
NCT02855944 COMPLETED
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH n=349
NCT04763135 TERMINATED
Mirtazapine in Cancer-related Poly-symptomatology
Hospices Civils de Lyon n=1
NCT03126435 COMPLETED
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
SynCore Biotechnology Co., Ltd. n=218
NCT02853474 COMPLETED
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
Centre Oscar Lambret n=480
NCT03495921 TERMINATED
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
Gradalis, Inc. n=32
NCT04703803 COMPLETED
Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care
University of Sao Paulo n=30
NCT05809336 COMPLETED
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital n=172
NCT03019588 TERMINATED
Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
Merck Sharp & Dohme LLC n=94
NCT04241315 COMPLETED
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
On Target Laboratories, LLC n=112
NCT03941964 COMPLETED
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie n=60
NCT02634294 COMPLETED
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine n=30
NCT04189107 COMPLETED
Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS
Rigshospitalet, Denmark n=18
NCT03969121 COMPLETED
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Kyoto Breast Cancer Research Network n=141
NCT03607539 COMPLETED
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd. n=397
NCT03038100 COMPLETED
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche n=1,301
NCT02609828 COMPLETED
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Pfizer n=156
NCT03674294 COMPLETED
Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy
Sun Yat-sen University n=248
NCT04613830 COMPLETED
Continuous Erector Spinae Block for Post Analgesia in Pediatric Patients
Assiut University n=60
NCT02623309 COMPLETED
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Institut Paoli-Calmettes n=108
NCT02997553 COMPLETED
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
Institut de Cancérologie de Lorraine n=744
NCT02819960 COMPLETED
Prevention of Irinotecan Induced Diarrhea by Probiotics
S&D Pharma SK s.r.o. n=233
NCT05325164 WITHDRAWN
Methadone for 'Adenocarcinopathic' Pain Treatment
Ottawa Hospital Research Institute
NCT05636566 COMPLETED
Comparing TIVA Using Propofol or Dexmedetomidine Versus Sevoflurane During Anaesthesia of Children Undergoing Bone-Marrow Aspiration
Alexandria University n=60
NCT04109391 COMPLETED
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Tanvex BioPharma USA, Inc. n=338
NCT04943627 WITHDRAWN
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
NCT02910726 COMPLETED
A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers
Memorial Sloan Kettering Cancer Center n=6
NCT03705429 COMPLETED
A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=51
NCT02201381 WITHDRAWN
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
Health Clinics Limited
NCT02548715 WITHDRAWN
Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery
University of Alberta
NCT02454855 TERMINATED
Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients
Centre Jean Perrin n=123
NCT04425291 COMPLETED
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd. n=1,680
NCT03359811 COMPLETED
Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway
M.D. Anderson Cancer Center n=75
NCT03269344 COMPLETED
Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Henry Ford Health System n=65
NCT02740127 COMPLETED
Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
M.D. Anderson Cancer Center n=52
NCT03278600 COMPLETED
Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary
Fudan University n=182
NCT03556358 COMPLETED
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Tanvex BioPharma USA, Inc. n=809
NCT03905902 WITHDRAWN
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
SOTIO a.s.
NCT04859582 WITHDRAWN
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
Merck Sharp & Dohme LLC
NCT05149248 COMPLETED
Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study
Instituto Nacional de Salud Publica, Mexico n=6,000
NCT04572776 WITHDRAWN
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
NCT02740114 TERMINATED
Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
M.D. Anderson Cancer Center n=105
NCT03829618 TERMINATED
Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound
Milton S. Hershey Medical Center n=29
NCT02231086 COMPLETED
Adjuvant HIPEC in High Risk Colon Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=204
NCT02903004 COMPLETED
Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=242
NCT03137121 COMPLETED
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
University of Alabama at Birmingham n=30
NCT04059809 COMPLETED
Photobiomodulation for Breast Cancer Radiodermatitis
AC Camargo Cancer Center n=48
NCT03329846 COMPLETED
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Bristol-Myers Squibb n=20
NCT03682367 TERMINATED
Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery
University of California, Davis n=8
NCT03031938 COMPLETED
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
Pfizer n=4
NCT02453334 COMPLETED
Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®
American Regent, Inc. n=244
NCT02583191 TERMINATED
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH n=246
NCT04549675 COMPLETED
Couple-focused Intervention for Sun Protection
Rutgers, The State University of New Jersey n=150
NCT03375515 COMPLETED
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
Fujian Cancer Hospital n=214
NCT02597478 COMPLETED
Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea
M.D. Anderson Cancer Center n=50
NCT04001010 SUSPENDED
Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
Tetra Bio-Pharma n=334
NCT02583932 COMPLETED
Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer
Jewish General Hospital n=179
NCT01906073 WITHDRAWN
Nasal Fentanyl for Chronic Cancer Pain
Norwegian University of Science and Technology
NCT02631876 COMPLETED
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
ImmunoGen, Inc. n=366
NCT04237090 COMPLETED
Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel
Ciusss de L'Est de l'Île de Montréal n=27
NCT04546607 COMPLETED
Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia
Natureceuticals Sdn Bhd n=110
NCT02585713 COMPLETED
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United n=300
NCT02979691 COMPLETED
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
Chinese Academy of Medical Sciences n=350
NCT03483194 COMPLETED
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
Weprom n=126
NCT04361552 WITHDRAWN
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Emory University
NCT03134872 COMPLETED
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd. n=419
NCT02650791 COMPLETED
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
Ottawa Hospital Research Institute n=100
NCT02604225 COMPLETED
Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B
University of Sydney n=420
NCT02236936 TERMINATED
Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
Arbeitsgemeinschaft medikamentoese Tumortherapie n=8
NCT03520959 TERMINATED
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=1
NCT03335059 TERMINATED
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
Medical Enterprises Ltd. n=5
NCT03453424 COMPLETED
Analgesic Efficacy of Dexmedetomidine Added to Fentanyl in PCEA
South Egypt Cancer Institute n=90
NCT02991209 COMPLETED
Study of Testosterone vs Placebo in Testicular Cancer Survivors
Mikkel Bandak n=69
NCT03331588 COMPLETED
Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China n=200
NCT03546842 COMPLETED
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
Merck Sharp & Dohme LLC n=201
NCT03881111 WITHDRAWN
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
Merck Sharp & Dohme LLC
NCT03254173 COMPLETED
Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia
Catherine Naseef Hunter n=120
NCT03158220 COMPLETED
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC n=1,212
NCT02776683 COMPLETED
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
Boehringer Ingelheim n=123
NCT03610100 SUSPENDED
Acelarin First Line Randomised Pancreatic Study
The Clatterbridge Cancer Centre NHS Foundation Trust n=328
NCT03339622 TERMINATED
Safety and Efficacy of Smoked Cannabis for Improving Quality of Life in Advanced Cancer Patients
Tetra Bio-Pharma n=8
NCT02578940 COMPLETED
Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
Blue Earth Diagnostics n=104
NCT02555878 COMPLETED
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Janssen Research & Development, LLC n=841
NCT02488330 COMPLETED
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
Hoffmann-La Roche n=12
NCT02408393 COMPLETED
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
Institut Curie n=380
NCT02935530 COMPLETED
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Huazhong University of Science and Technology n=315
NCT03936205 COMPLETED
Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer
Hotel Dieu de France Hospital n=18
NCT03003273 TERMINATED
Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study
All India Institute of Medical Sciences n=142
NCT03350490 COMPLETED
Bioinformation Therapy for Intestinal Cancer
Fuda Cancer Hospital, Guangzhou n=120
NCT02591017 TERMINATED
Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients
University Hospital, Basel, Switzerland n=11
NCT03637335 TERMINATED
Comparing Palliative Radiotherapy With or Without Carboplatin
Institut Cancerologie de l'Ouest n=26
NCT02635984 COMPLETED
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
Augusta University n=108
NCT03460561 COMPLETED
Peri-operative Rectus Sheath Block Versus TEA Abdominal Surgeries
South Egypt Cancer Institute n=100
NCT02603705 COMPLETED
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
Egalet Ltd n=281
NCT02564276 COMPLETED
Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=132
NCT02927379 COMPLETED
Effect of Wound Infiltration by Ketamine Versus Dexmedetomidine Added to Bupivacaine on Surgical Stress
Assiut University n=90
NCT03002454 TERMINATED
Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo
University of Manitoba n=4
NCT03060070 COMPLETED
Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block
Assiut University n=90
NCT02739243 WITHDRAWN
A Clinical Trial on a Group Treatment for Distressed Caregivers of Cancer Patients
Heidelberg University
NCT07450352 NOT YET RECRUITING
SEED-CRYO: Sequential 125I Seed Implantation Followed by Cryoablation vs Single-Modality Local Therapy in Unresectable Solid Tumors
Li Min
NCT03866382 RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
NCT02675829 ACTIVE NOT RECRUITING
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Memorial Sloan Kettering Cancer Center
NCT04090398 ACTIVE NOT RECRUITING
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
National Cancer Institute (NCI)
NCT07246863 RECRUITING
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
NCT02834013 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
NCT05335941 ACTIVE NOT RECRUITING
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT06009926 ACTIVE NOT RECRUITING
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
National Cancer Institute (NCI)
NCT07024784 RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
NCT03191149 RECRUITING
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
National Cancer Institute (NCI)
NCT03297606 RECRUITING
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Canadian Cancer Trials Group
NCT04981509 RECRUITING
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
NCT06966453 RECRUITING
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Pfizer
NCT06864169 ACTIVE NOT RECRUITING
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Merck Sharp & Dohme LLC
NCT07416188 NOT YET RECRUITING
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institute of Neurological Disorders and Stroke (NINDS)
NCT04449549 RECRUITING
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Cancer Institute (NCI)
NCT04071223 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
NCT04071236 RECRUITING
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
NCT05136196 RECRUITING
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
National Cancer Institute (NCI)
NCT05789589 RECRUITING
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Baptist Health South Florida
NCT06760819 RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
NCT07354100 NOT YET RECRUITING
Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
University of Chicago
NCT07195734 RECRUITING
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
NCT06268665 RECRUITING
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
University of California, Davis
NCT07449481 NOT YET RECRUITING
A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT02642042 ACTIVE NOT RECRUITING
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04929028 RECRUITING
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
NCT02888743 ACTIVE NOT RECRUITING
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05411081 ACTIVE NOT RECRUITING
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
National Cancer Institute (NCI)
NCT03237780 ACTIVE NOT RECRUITING
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT05004116 RECRUITING
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05681195 RECRUITING
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Baptist Health South Florida
NCT07028281 RECRUITING
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07446049 NOT YET RECRUITING
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.
NCT05546268 ACTIVE NOT RECRUITING
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics, Inc
NCT07446725 NOT YET RECRUITING
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT07446153 NOT YET RECRUITING
A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT07217938 RECRUITING
Novel Treatment of Radiation Associated Dysphagia With Statins
Peter MacCallum Cancer Centre, Australia
NCT07287995 RECRUITING
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT06657222 RECRUITING
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
NCT04683250 RECRUITING
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Taiho Pharmaceutical Co., Ltd.
NCT06253494 RECRUITING
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
NCT07302347 RECRUITING
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Merck Sharp & Dohme LLC
NCT06200155 RECRUITING
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
M.D. Anderson Cancer Center
NCT07447050 RECRUITING
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT03781986 ACTIVE NOT RECRUITING
APG-115 in Salivary Gland Cancer Trial
University of Michigan Rogel Cancer Center
NCT06166836 RECRUITING
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
InxMed (Shanghai) Co., Ltd.
NCT07072728 RECRUITING
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
NCT05579366 RECRUITING
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
NCT07444918 NOT YET RECRUITING
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT06685068 ACTIVE NOT RECRUITING
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
NCT06801041 RECRUITING
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
M.D. Anderson Cancer Center
NCT07262619 RECRUITING
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Eikon Therapeutics
NCT07196644 RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
AbbVie
NCT05413850 RECRUITING
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
NCT02734537 RECRUITING
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
ECOG-ACRIN Cancer Research Group
NCT07443475 RECRUITING
Electrochemotherapy for Recurrent Vulvar Cancer
Institute of Oncology Ljubljana
NCT07281417 NOT YET RECRUITING
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT07213817 RECRUITING
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
NCT04166318 ACTIVE NOT RECRUITING
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
ECOG-ACRIN Cancer Research Group
NCT06014658 RECRUITING
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
MBrace Therapeutics
NCT06979596 RECRUITING
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Merck Sharp & Dohme LLC
NCT02574728 ACTIVE NOT RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Emory University
NCT07169851 RECRUITING
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Eli Lilly and Company
NCT07047118 RECRUITING
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
NCT06941272 RECRUITING
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Merck Sharp & Dohme LLC
NCT03600883 ACTIVE NOT RECRUITING
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
NCT05768139 RECRUITING
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT07227415 RECRUITING
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
NCT03403465 ACTIVE NOT RECRUITING
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
Duke University
NCT06469944 RECRUITING
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Merck Sharp & Dohme LLC
NCT06075043 NOT YET RECRUITING
A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy
Kind Pharmaceuticals LLC
NCT07109726 RECRUITING
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
NCT06863272 RECRUITING
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Merck Sharp & Dohme LLC
NCT03270059 RECRUITING
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
OHSU Knight Cancer Institute
NCT07435038 NOT YET RECRUITING
Study of BPI-572070 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Betta Pharmaceuticals Co., Ltd.
NCT05063916 ACTIVE NOT RECRUITING
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
M.D. Anderson Cancer Center
NCT07282834 RECRUITING
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
Patrick Wagner, MD, FACS
NCT04469530 RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
Emory University
NCT05544136 RECRUITING
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT07213830 RECRUITING
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
NCT07435701 RECRUITING
Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07437625 NOT YET RECRUITING
Lesion-Allocated Therapy for Multiple Metastases and Tumor-Zoned Treatment for Bulky Tumors: A Phase II Study of Iodine-125 Seed Implantation Combined With Cryoablation in High-Burden Metastatic Disease
Li Min
NCT06833008 RECRUITING
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT05639972 RECRUITING
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Christian Hinrichs
NCT05083481 RECRUITING
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT05686226 RECRUITING
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Christian Hinrichs
NCT06596694 RECRUITING
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Merck Sharp & Dohme LLC
NCT06526819 RECRUITING
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT05739981 RECRUITING
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT07276373 RECRUITING
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
NCT04485286 RECRUITING
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Massachusetts General Hospital
NCT05664178 RECRUITING
Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology
H. Lee Moffitt Cancer Center and Research Institute
NCT07439094 NOT YET RECRUITING
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
NCT04321954 ACTIVE NOT RECRUITING
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
NCT06305247 RECRUITING
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT07209189 RECRUITING
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07441174 RECRUITING
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
InxMed (Shanghai) Co., Ltd.
NCT03393884 ACTIVE NOT RECRUITING
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Imunon
NCT04008797 ACTIVE NOT RECRUITING
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
NCT07098988 RECRUITING
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
NCT07123090 NOT YET RECRUITING
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Stephanie Berg
NCT04349436 RECRUITING
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Replimune Inc.
NCT05753306 RECRUITING
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
NCT07432295 RECRUITING
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
NCT04219254 RECRUITING
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
BioInvent International AB
NCT04605913 RECRUITING
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
NCT07432594 NOT YET RECRUITING
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07434180 NOT YET RECRUITING
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Peter MacCallum Cancer Centre, Australia
NCT04895709 RECRUITING
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT06703346 ACTIVE NOT RECRUITING
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM CT, LLC
NCT06911827 RECRUITING
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
NCT06695845 RECRUITING
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT05672459 ACTIVE NOT RECRUITING
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
M.D. Anderson Cancer Center
NCT03967223 ACTIVE NOT RECRUITING
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
USWM CT, LLC
NCT05261750 ACTIVE NOT RECRUITING
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
PT. Prodia Stem Cell Indonesia
NCT05593094 ACTIVE NOT RECRUITING
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Hoffmann-La Roche
NCT07433283 RECRUITING
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
NCT04870944 RECRUITING
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
NCT04620187 RECRUITING
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
NCT06890338 RECRUITING
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
NCT05286814 RECRUITING
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Cancer Institute (NCI)
NCT05438420 ACTIVE NOT RECRUITING
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co., Ltd.
NCT05081609 ACTIVE NOT RECRUITING
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Ascendis Pharma Oncology Division A/S
NCT05523947 RECRUITING
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Yuhan Corporation
NCT06005493 RECRUITING
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AstraZeneca
NCT04924075 RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Merck Sharp & Dohme LLC
NCT06058988 RECRUITING
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
NCT06634589 RECRUITING
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
NCT03174275 ACTIVE NOT RECRUITING
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT07288359 RECRUITING
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT04258462 ACTIVE NOT RECRUITING
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
Zhen Wang, MD
NCT06980038 RECRUITING
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
NCT07129252 RECRUITING
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Crinetics Pharmaceuticals Inc.
NCT07258407 RECRUITING
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
T.O.A.D. Oncology SA
NCT05778825 ACTIVE NOT RECRUITING
A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
Memorial Sloan Kettering Cancer Center
NCT07389239 NOT YET RECRUITING
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
University of Chicago
NCT07424664 NOT YET RECRUITING
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT07222488 RECRUITING
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Merck Sharp & Dohme LLC
NCT07193511 RECRUITING
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
NCT06096038 RECRUITING
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
UNC Lineberger Comprehensive Cancer Center
NCT07172919 RECRUITING
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
NCT07252739 RECRUITING
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
NCT05503797 RECRUITING
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
NCT04826341 RECRUITING
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
National Cancer Institute (NCI)
NCT04337580 RECRUITING
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Wake Forest University Health Sciences
NCT07038343 RECRUITING
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
NCT06051695 RECRUITING
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT04065269 ACTIVE NOT RECRUITING
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
Institute of Cancer Research, United Kingdom
NCT07425054 NOT YET RECRUITING
HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer
Jennifer Dorth
NCT06833073 RECRUITING
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Merck Sharp & Dohme LLC
NCT07335497 RECRUITING
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma, Inc.
NCT07063212 RECRUITING
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT07213609 RECRUITING
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT06818643 RECRUITING
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme LLC
NCT06167291 RECRUITING
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
M.D. Anderson Cancer Center
NCT04644068 ACTIVE NOT RECRUITING
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT07023731 RECRUITING
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
NCT04892953 RECRUITING
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
NCT07146646 RECRUITING
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NCT07020221 RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
NCT04848519 ACTIVE NOT RECRUITING
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
NCT06445062 RECRUITING
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
NCT07408583 NOT YET RECRUITING
Prenatal Transplantation for Fetuses With Fanconi Anemia
Agnieszka Czechowicz
NCT03686124 RECRUITING
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Immatics US, Inc.
NCT06237881 ACTIVE NOT RECRUITING
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT03742895 ACTIVE NOT RECRUITING
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Merck Sharp & Dohme LLC
NCT06797635 RECRUITING
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Merck Sharp & Dohme LLC
NCT05468359 RECRUITING
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
NCT04570423 RECRUITING
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
NCT07410676 RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Essen Biotech
NCT07417501 NOT YET RECRUITING
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
NCT06754501 ACTIVE NOT RECRUITING
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
M.D. Anderson Cancer Center
NCT05267626 RECRUITING
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
NCT06290687 RECRUITING
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Case Comprehensive Cancer Center
NCT07418034 NOT YET RECRUITING
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
University of Maryland, Baltimore
NCT07410494 RECRUITING
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT07417189 NOT YET RECRUITING
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Abbisko Therapeutics Co, Ltd
NCT07030257 RECRUITING
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT04761770 ACTIVE NOT RECRUITING
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
NCT07415681 NOT YET RECRUITING
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
University of Maryland, Baltimore
NCT03206060 RECRUITING
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Cancer Institute (NCI)
NCT05358249 ACTIVE NOT RECRUITING
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT06629584 RECRUITING
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06651593 RECRUITING
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
M.D. Anderson Cancer Center
NCT04919512 ACTIVE NOT RECRUITING
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Janssen Research & Development, LLC
NCT07415863 RECRUITING
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT05853575 RECRUITING
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
NCT03412877 RECRUITING
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
NCT06261814 RECRUITING
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
john eisenbrey
NCT07145255 RECRUITING
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
NCT04030455 ACTIVE NOT RECRUITING
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
NCT03822897 ACTIVE NOT RECRUITING
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
Canadian Cancer Trials Group
NCT02816021 ACTIVE NOT RECRUITING
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT06995508 RECRUITING
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Roswell Park Cancer Institute
NCT07293754 RECRUITING
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Repertoire Immune Medicines
NCT04432597 ACTIVE NOT RECRUITING
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Cancer Institute (NCI)
NCT07415031 NOT YET RECRUITING
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
NCT04331041 ACTIVE NOT RECRUITING
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
NCT02908906 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
NCT05316155 RECRUITING
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Janssen Research & Development, LLC
NCT04640623 ACTIVE NOT RECRUITING
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Janssen Research & Development, LLC
NCT05631262 ACTIVE NOT RECRUITING
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
NCT04325828 ACTIVE NOT RECRUITING
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Janssen Pharmaceutical K.K.
NCT06358677 RECRUITING
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
University of Utah
NCT06686394 RECRUITING
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Merck Sharp & Dohme LLC
NCT04041310 ACTIVE NOT RECRUITING
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Nouscom SRL
NCT05075980 RECRUITING
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
NCT02693535 RECRUITING
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
American Society of Clinical Oncology
NCT06036836 ACTIVE NOT RECRUITING
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Merck Sharp & Dohme LLC
NCT06885281 RECRUITING
A Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Shanghai) Co., Ltd.
NCT07406633 NOT YET RECRUITING
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
NCT05985655 RECRUITING
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT07405736 NOT YET RECRUITING
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
Sun Yat-sen University
NCT07406789 NOT YET RECRUITING
Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).
TNC Nutrición Terapéutica S.L.
NCT07407582 NOT YET RECRUITING
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
NCT06517212 RECRUITING
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Baylor Research Institute
NCT04348747 RECRUITING
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Roswell Park Cancer Institute
NCT07405086 NOT YET RECRUITING
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
NCT05460000 RECRUITING
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
North Eastern German Society of Gynaecological Oncology
NCT06330064 RECRUITING
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
NCT02934568 ACTIVE NOT RECRUITING
Ribociclib (LEE011) Rollover Study for Continued Access
Novartis Pharmaceuticals
NCT07328217 RECRUITING
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Dizal Pharmaceuticals
NCT02749903 ACTIVE NOT RECRUITING
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Alliance for Clinical Trials in Oncology
NCT07070232 RECRUITING
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BioNTech SE
NCT07404176 RECRUITING
Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors
Tata Memorial Hospital
NCT05999994 RECRUITING
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Eli Lilly and Company
NCT03008408 ACTIVE NOT RECRUITING
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
NCT05128825 RECRUITING
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT07157033 RECRUITING
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Xerient Pharma
NCT06244771 RECRUITING
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Frontier Medicines Corporation
NCT03917381 ACTIVE NOT RECRUITING
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
NCT06598371 RECRUITING
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT06644183 RECRUITING
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, MD, PhD
NCT06636734 RECRUITING
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Emory University
NCT03582124 RECRUITING
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford University
NCT06232577 ACTIVE NOT RECRUITING
5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial
M.D. Anderson Cancer Center
NCT04585750 RECRUITING
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
NCT04078295 ACTIVE NOT RECRUITING
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Co., Ltd.
NCT04930432 RECRUITING
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Betta Pharmaceuticals Co., Ltd.
NCT04862650 ACTIVE NOT RECRUITING
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Marcelo Bonomi
NCT06634849 RECRUITING
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Pathios Therapeutics Pty Ltd
NCT07151391 RECRUITING
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
NCT06162221 RECRUITING
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Revolution Medicines, Inc.
NCT05919264 RECRUITING
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
NCT04963283 ACTIVE NOT RECRUITING
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
NCT04068753 ACTIVE NOT RECRUITING
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
University of Oklahoma
NCT07400094 NOT YET RECRUITING
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
National Medical Research Radiological Centre of the Ministry of Health of Russia
NCT05605496 ACTIVE NOT RECRUITING
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
Centre Leon Berard
NCT06939283 ACTIVE NOT RECRUITING
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
Werewolf Therapeutics, Inc.
NCT07396584 NOT YET RECRUITING
A Phase I/Ⅱa Study of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Hutchmed
NCT07397338 RECRUITING
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
NCT05465941 RECRUITING
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Mayo Clinic
NCT06534190 RECRUITING
CD8 PET Imaging in Metastatic Solid Tumours
University Medical Center Groningen
NCT06914128 RECRUITING
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Bayer
NCT06289049 RECRUITING
Heavy Strength Training in Head and Neck Cancer Survivors
University of Alberta
NCT06432036 RECRUITING
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Jonsson Comprehensive Cancer Center
NCT04589845 RECRUITING
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
NCT04901702 RECRUITING
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
NCT05789485 RECRUITING
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Memorial Sloan Kettering Cancer Center
NCT05882058 RECRUITING
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Boehringer Ingelheim
NCT07062354 NOT YET RECRUITING
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
SWOG Cancer Research Network
NCT06953089 RECRUITING
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT07392736 RECRUITING
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Advenchen Laboratories, LLC
NCT07290621 RECRUITING
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
University of Chicago
NCT03203473 ACTIVE NOT RECRUITING
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Toni Choueiri, MD
NCT07394374 RECRUITING
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
Cullgen (Shanghai),Inc
NCT05533697 RECRUITING
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
NCT07392320 RECRUITING
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
NCT02884648 ACTIVE NOT RECRUITING
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
M.D. Anderson Cancer Center
NCT04375228 ACTIVE NOT RECRUITING
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
NCT05039632 RECRUITING
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
NCT07359066 RECRUITING
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Shanghai SciBrunch Therapeutics Co., Ltd.
NCT07227610 RECRUITING
Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
Medical University of South Carolina
NCT04417660 ACTIVE NOT RECRUITING
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
National Cancer Institute (NCI)
NCT04300556 RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
NCT06778408 RECRUITING
Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
University of Vermont Medical Center
NCT06710132 RECRUITING
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono Research & Development Institute, Inc.
NCT05787561 RECRUITING
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
NCT05386108 RECRUITING
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Stemline Therapeutics, Inc.
NCT03937830 ACTIVE NOT RECRUITING
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Cancer Institute (NCI)
NCT03944941 ACTIVE NOT RECRUITING
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Alliance for Clinical Trials in Oncology
NCT06648785 ENROLLING BY INVITATION
Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies
University of Vermont Medical Center
NCT06736704 RECRUITING
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
NCT03465592 RECRUITING
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05849480 RECRUITING
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Cancer Institute (NCI)
NCT07001241 RECRUITING
Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
University of Colorado, Denver
NCT05518045 ACTIVE NOT RECRUITING
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
LaNova Medicines Limited
NCT07242547 RECRUITING
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Fundación GECP
NCT07384416 NOT YET RECRUITING
Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer
Sun Yat-sen University
NCT07382531 RECRUITING
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Binhui Biopharmaceutical Co., Ltd.
NCT04083976 ACTIVE NOT RECRUITING
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Janssen Research & Development, LLC
NCT06771622 ACTIVE NOT RECRUITING
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
NCT07332247 RECRUITING
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
Sun Yat-sen University
NCT07266428 RECRUITING
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
NCT05443126 RECRUITING
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Ellipses Pharma
NCT07383285 NOT YET RECRUITING
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
Peking University Cancer Hospital & Institute
NCT06697197 RECRUITING
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT06898450 RECRUITING
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Nimbus Wadjet, Inc.
NCT06532279 RECRUITING
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
NCT03040973 ACTIVE NOT RECRUITING
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Novartis Pharmaceuticals
NCT05926765 RECRUITING
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
MeiraGTx, LLC
NCT07381231 RECRUITING
Immunotherapy With Adaptive Pulse Radiotherapy in Solid Tumors
Samsung Medical Center
NCT06810544 RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
NCT04626635 RECRUITING
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Regeneron Pharmaceuticals
NCT07346677 NOT YET RECRUITING
Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel
University of Basrah
NCT05744427 ACTIVE NOT RECRUITING
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT06077877 ACTIVE NOT RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
GlaxoSmithKline
NCT06710847 ACTIVE NOT RECRUITING
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT06866964 RECRUITING
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Wake Forest University Health Sciences
NCT05894083 RECRUITING
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
University of Michigan Rogel Cancer Center
NCT07380386 NOT YET RECRUITING
SKB105 for Injection in Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT03742102 ACTIVE NOT RECRUITING
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
AstraZeneca
NCT04895735 ACTIVE NOT RECRUITING
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
NCT07136779 RECRUITING
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
NCT05043922 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Haihe Biopharma Co., Ltd.
NCT03964727 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
Gilead Sciences
NCT04340882 ACTIVE NOT RECRUITING
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Emory University
NCT03459846 ACTIVE NOT RECRUITING
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
AstraZeneca
NCT04083599 ACTIVE NOT RECRUITING
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT05094336 ACTIVE NOT RECRUITING
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Amgen
NCT04390737 RECRUITING
Evaluate the Safety and Clinical Activity of HH2853
Haihe Biopharma Co., Ltd.
NCT06130553 RECRUITING
A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
AstraZeneca
NCT04305145 ACTIVE NOT RECRUITING
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Massachusetts General Hospital
NCT06974812 RECRUITING
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT02721732 ACTIVE NOT RECRUITING
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
NCT03943901 ACTIVE NOT RECRUITING
Split-Dose R-CHOP for Older Adults With DLBCL
University of Wisconsin, Madison
NCT07148128 RECRUITING
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Auricula Biosciences Inc.
NCT03796767 ACTIVE NOT RECRUITING
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
University of Utah
NCT06208657 RECRUITING
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
NCT07374419 NOT YET RECRUITING
Atamparib in Patients With Advanced Solid Tumors
Nerviano Medical Sciences (Shanghai) Ltd.
NCT06172478 RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT05150691 RECRUITING
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT06926075 RECRUITING
Early Phase Study of Kesonotide in Participants With Solid Tumours
Filamon LTD
NCT07371663 RECRUITING
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Beijing Tide Pharmaceutical Co., Ltd
NCT04858269 RECRUITING
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Wake Forest University Health Sciences
NCT07151040 RECRUITING
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
One-carbon Therapeutics AB
NCT04145622 RECRUITING
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
NCT06378593 RECRUITING
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
3H (Suzhou) Pharmaceuticals Co., Ltd.
NCT07192432 RECRUITING
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Vironexis Biotherapeutics Inc.
NCT07130786 RECRUITING
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
Ayal A. Aizer, MD
NCT07266025 NOT YET RECRUITING
Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study
Shanghai Zhongshan Hospital
NCT07057791 RECRUITING
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
PrECOG, LLC.
NCT03947385 RECRUITING
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
IDEAYA Biosciences
NCT05867420 RECRUITING
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
NCT04243499 ACTIVE NOT RECRUITING
First-in-Human Study of ICT01 in Patients With Advanced Cancer
ImCheck Therapeutics
NCT07132190 RECRUITING
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Ayal A. Aizer, MD
NCT07363057 RECRUITING
A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors
GI Innovation, Inc.
NCT04905914 ACTIVE NOT RECRUITING
Study Of ATRN-119 In Patients With Advanced Solid Tumors
Aprea Therapeutics
NCT05797246 ACTIVE NOT RECRUITING
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Cancer Institute (NCI)
NCT06912763 RECRUITING
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
M.D. Anderson Cancer Center
NCT05327023 RECRUITING
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
National Cancer Institute (NCI)
NCT05807880 ACTIVE NOT RECRUITING
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
NCT05502315 RECRUITING
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Rana McKay, MD
NCT06323473 RECRUITING
Maitake for Integrative Cancer Care
The Canadian College of Naturopathic Medicine
NCT06084780 NOT YET RECRUITING
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
Case Comprehensive Cancer Center
NCT05010031 RECRUITING
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Memorial Sloan Kettering Cancer Center
NCT05498272 RECRUITING
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD
NCT04165772 RECRUITING
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT07364305 RECRUITING
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Eastern Hepatobiliary Surgery Hospital
NCT07174583 RECRUITING
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
NCT03585465 ACTIVE NOT RECRUITING
Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
Centre Oscar Lambret
NCT06445972 RECRUITING
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Merck Sharp & Dohme LLC
NCT04992013 ACTIVE NOT RECRUITING
Niraparib in Tumors Metastatic to the CNS
Massachusetts General Hospital
NCT07203053 NOT YET RECRUITING
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
ETOP IBCSG Partners Foundation
NCT07359820 NOT YET RECRUITING
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Elevar Therapeutics
NCT05009069 ACTIVE NOT RECRUITING
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
NCT06386146 RECRUITING
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Jacobio Pharmaceuticals Co., Ltd.
NCT07093970 RECRUITING
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Lepu Biopharma Co., Ltd.
NCT05361798 RECRUITING
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
National Cancer Institute (NCI)
NCT07222215 RECRUITING
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT04948619 RECRUITING
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
Wake Forest University Health Sciences
NCT06475300 RECRUITING
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT03181867 ENROLLING BY INVITATION
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Cancer Institute (NCI)
NCT05673928 RECRUITING
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
M.D. Anderson Cancer Center
NCT03333616 ACTIVE NOT RECRUITING
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
NCT03173924 ACTIVE NOT RECRUITING
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT07356791 NOT YET RECRUITING
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety
RenJi Hospital
NCT07292168 RECRUITING
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
Kidney Cancer Research Bureau
NCT07339553 NOT YET RECRUITING
Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.
Peking University Third Hospital
NCT04959175 RECRUITING
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
National Cancer Institute (NCI)
NCT05423262 RECRUITING
A Study of TRK-950 in Patients With Advanced Solid Tumors
Toray Industries, Inc
NCT03096093 ACTIVE NOT RECRUITING
Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Cancer Vaccines Limited
NCT06959615 RECRUITING
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Jacobio Pharmaceuticals Co., Ltd.
NCT07353723 RECRUITING
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Tang-Du Hospital
NCT06223568 RECRUITING
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
National Cancer Institute (NCI)
NCT04733534 ACTIVE NOT RECRUITING
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
St. Jude Children's Research Hospital
NCT03937843 ACTIVE NOT RECRUITING
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Swiss Cancer Institute
NCT05584670 RECRUITING
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Sanofi
NCT06973564 RECRUITING
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Jacobio Pharmaceuticals Co., Ltd.
NCT05588141 RECRUITING
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Cancer Institute (NCI)
NCT02830724 RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
NCT04633252 RECRUITING
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
National Cancer Institute (NCI)
NCT07346209 NOT YET RECRUITING
Real-world Trial of Individualized Precision Oncology
University of California, San Diego
NCT02813135 RECRUITING
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Gustave Roussy, Cancer Campus, Grand Paris
NCT07339748 NOT YET RECRUITING
A Clinical Study of ZL-85FA Tablets
Chengdu Zenitar Biomedical Technology Co., Ltd
NCT05163041 ACTIVE NOT RECRUITING
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
BicycleTx Limited
NCT05741242 ENROLLING BY INVITATION
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Jaime Leandro Foundation for Therapeutic Cancer Vaccines
NCT07216560 RECRUITING
First-in-human Study of 7MW4911 in GI Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT06290193 RECRUITING
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
NCT05210413 ACTIVE NOT RECRUITING
Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
University Hospital, Bordeaux
NCT07339488 ACTIVE NOT RECRUITING
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Chuangzhen Chen
NCT06334432 ACTIVE NOT RECRUITING
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
NCT05922501 RECRUITING
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
NCT05363709 RECRUITING
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
M.D. Anderson Cancer Center
NCT06188702 RECRUITING
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Servier Bio-Innovation LLC
NCT05023486 RECRUITING
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
NCT05327686 RECRUITING
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NRG Oncology
NCT07253116 RECRUITING
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
Nanjing Jingao biomidical technology Co. Ltd.
NCT05408845 RECRUITING
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
NCT05924672 ACTIVE NOT RECRUITING
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
NCT07341100 NOT YET RECRUITING
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT07333469 NOT YET RECRUITING
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
NCT05944224 RECRUITING
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
Shanghai Pharmaceuticals Holding Co., Ltd
NCT03485209 ACTIVE NOT RECRUITING
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT03977233 RECRUITING
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT05651022 ACTIVE NOT RECRUITING
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc
NCT07056777 RECRUITING
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Zhejiang Doer Biologics Co., Ltd.
NCT03829254 RECRUITING
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
NCT05544552 ACTIVE NOT RECRUITING
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Tyra Biosciences, Inc
NCT07333664 NOT YET RECRUITING
Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions
Li Min
NCT04725474 ACTIVE NOT RECRUITING
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
CatalYm GmbH
NCT07333937 NOT YET RECRUITING
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
Xijing Hospital
NCT07334431 RECRUITING
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Henan Cancer Hospital
NCT05875168 RECRUITING
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT05852717 RECRUITING
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Dipenkumar Modi
NCT05588453 RECRUITING
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Kari Kendra
NCT07325539 NOT YET RECRUITING
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Sun Yat-sen University
NCT07268040 RECRUITING
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT07258160 RECRUITING
Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors
Second Affiliated Hospital of Soochow University
NCT05884320 RECRUITING
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
M.D. Anderson Cancer Center
NCT06062420 ACTIVE NOT RECRUITING
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
NCT06737731 RECRUITING
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07110571 RECRUITING
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06682988 RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
AbbVie
NCT03541902 ACTIVE NOT RECRUITING
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT07231211 RECRUITING
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shanghai Shengdi Pharmaceutical Co., Ltd
NCT06741644 RECRUITING
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
NCT05490472 RECRUITING
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT03587662 ACTIVE NOT RECRUITING
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
NCT06265727 RECRUITING
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals Inc.
NCT05723562 ACTIVE NOT RECRUITING
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
GlaxoSmithKline
NCT07327411 NOT YET RECRUITING
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
NCT06643884 RECRUITING
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Aura Biosciences
NCT02568267 ACTIVE NOT RECRUITING
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT07126561 NOT YET RECRUITING
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
University of Chicago
NCT07131202 RECRUITING
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd
NCT07326488 NOT YET RECRUITING
A Study of MHB009C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT06631079 ACTIVE NOT RECRUITING
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
NEC Bio B.V
NCT07327294 NOT YET RECRUITING
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
Evopoint Biosciences Inc.
NCT07322094 RECRUITING
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL Biotherapeutics, LLC
NCT07259473 NOT YET RECRUITING
Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital
NCT05405595 RECRUITING
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
NCT05222620 RECRUITING
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Mayo Clinic
NCT07321574 RECRUITING
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Shanghai AB PharmaTech Ltd.
NCT05332002 RECRUITING
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Rutgers, The State University of New Jersey
NCT05826600 ACTIVE NOT RECRUITING
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
iOmx Therapeutics AG
NCT07225114 RECRUITING
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
UNC Lineberger Comprehensive Cancer Center
NCT06726148 RECRUITING
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis Pharmaceuticals
NCT02690545 ACTIVE NOT RECRUITING
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
NCT07318649 NOT YET RECRUITING
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation
Suzhou Genhouse Bio Co., Ltd.
NCT06993844 RECRUITING
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
NCT07124117 RECRUITING
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
OBI Pharma, Inc
NCT07126158 NOT YET RECRUITING
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
NCT05584800 RECRUITING
Study of ZGGS18 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06938880 RECRUITING
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT04022343 ACTIVE NOT RECRUITING
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
NCT06927687 RECRUITING
Study of ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT04657068 RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
NCT05277168 RECRUITING
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Jiangsu HengRui Medicine Co., Ltd.
NCT07028268 RECRUITING
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT04141449 ACTIVE NOT RECRUITING
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
Brigham and Women's Hospital
NCT06003231 ACTIVE NOT RECRUITING
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen, a wholly owned subsidiary of Pfizer
NCT07313202 NOT YET RECRUITING
Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance
Fujian Cancer Hospital
NCT04708470 ACTIVE NOT RECRUITING
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Cancer Institute (NCI)
NCT02270814 ACTIVE NOT RECRUITING
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT07309185 RECRUITING
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
Shandong Tumor Hospital
NCT05480384 ACTIVE NOT RECRUITING
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
NCT06376292 RECRUITING
A Prospective Single Arm Phase II Exploratory Study on the Combination of Whole Brain Radiotherapy, Thiotepa Intrathecal Injection and Systemic Treatment of Primary Diseases in the Treatment of Solid Tumor Leptomeningeal Metastasis
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07299747 RECRUITING
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
VelaVigo Bio Inc
NCT07309770 RECRUITING
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Sheng Zhang
NCT05945823 ACTIVE NOT RECRUITING
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
NCT07228247 RECRUITING
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Hutchmed
NCT07265622 RECRUITING
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT06380660 RECRUITING
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Acerand Therapeutics (Shanghai) Limited
NCT07307053 NOT YET RECRUITING
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07306156 RECRUITING
GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
Zhimin Zhai
NCT02650401 ACTIVE NOT RECRUITING
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Hoffmann-La Roche
NCT05503251 ACTIVE NOT RECRUITING
Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases
Ohio State University Comprehensive Cancer Center
NCT07079462 RECRUITING
Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis
Fudan University
NCT04796012 RECRUITING
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
University of Texas Southwestern Medical Center
NCT04146298 RECRUITING
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Changhai Hospital
NCT04847466 ACTIVE NOT RECRUITING
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Cancer Institute (NCI)
NCT07303387 NOT YET RECRUITING
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Gustave Roussy, Cancer Campus, Grand Paris
NCT06640283 RECRUITING
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
Instituto do Cancer do Estado de São Paulo
NCT07300891 NOT YET RECRUITING
T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy
Samsung Medical Center
NCT07229638 NOT YET RECRUITING
A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT05256745 RECRUITING
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Georgetown University
NCT07197827 RECRUITING
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06576921 RECRUITING
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Xijing Hospital
NCT07298772 NOT YET RECRUITING
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06459973 RECRUITING
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06690775 RECRUITING
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC
NCT05975073 ACTIVE NOT RECRUITING
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
NCT06554795 RECRUITING
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT06712680 RECRUITING
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
Sichuan Huiyu Pharmaceutical Co., Ltd
NCT07282873 NOT YET RECRUITING
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
TYK Medicines, Inc
NCT04940299 ACTIVE NOT RECRUITING
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT06266338 RECRUITING
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
University of Texas Southwestern Medical Center
NCT07108270 RECRUITING
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline
NCT05420948 RECRUITING
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
University of Chicago
NCT03071406 ACTIVE NOT RECRUITING
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04495296 RECRUITING
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT07229586 RECRUITING
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT07192068 RECRUITING
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
UNICANCER
NCT04579380 ACTIVE NOT RECRUITING
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen, a wholly owned subsidiary of Pfizer
NCT07003321 RECRUITING
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
NCT04130516 RECRUITING
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Linnaeus Therapeutics, Inc.
NCT04198766 ACTIVE NOT RECRUITING
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
NCT07290894 NOT YET RECRUITING
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
National Cancer Institute, Naples
NCT03069469 ACTIVE NOT RECRUITING
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC
NCT03391479 ACTIVE NOT RECRUITING
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
University Health Network, Toronto
NCT02726997 ACTIVE NOT RECRUITING
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
M.D. Anderson Cancer Center
NCT04140500 ACTIVE NOT RECRUITING
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT06825494 RECRUITING
Clinical Studies for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT07227012 RECRUITING
A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
NCT05265091 ACTIVE NOT RECRUITING
A Study of KL590586 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT04083183 RECRUITING
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Fred Hutchinson Cancer Center
NCT02971501 ACTIVE NOT RECRUITING
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
NCT03736889 RECRUITING
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
BeiGene
NCT05257590 RECRUITING
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
NCT03224000 ACTIVE NOT RECRUITING
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
M.D. Anderson Cancer Center
NCT05731271 ACTIVE NOT RECRUITING
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT04396821 ACTIVE NOT RECRUITING
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT03934372 RECRUITING
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Biosciences International Sàrl
NCT02910700 ACTIVE NOT RECRUITING
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
NCT03092856 ACTIVE NOT RECRUITING
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
NCT06926634 RECRUITING
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Washington University School of Medicine
NCT05879822 ACTIVE NOT RECRUITING
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Incyte Corporation
NCT05566574 ACTIVE NOT RECRUITING
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT06519994 ACTIVE NOT RECRUITING
Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya
UNC Lineberger Comprehensive Cancer Center
NCT04086485 RECRUITING
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Cancer Institute (NCI)
NCT04858009 RECRUITING
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Mayo Clinic
NCT05296512 ACTIVE NOT RECRUITING
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
Elizabeth K. Lee MD
NCT02755896 ACTIVE NOT RECRUITING
Trial to Compare Radiation Fibrosis With Five Versus Three Fractions
Weill Medical College of Cornell University
NCT06385925 RECRUITING
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
NCT06730750 RECRUITING
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT06567782 RECRUITING
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
GlaxoSmithKline
NCT06630130 RECRUITING
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Jeeyun Lee
NCT05040360 RECRUITING
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
SWOG Cancer Research Network
NCT06411821 RECRUITING
Ulixertinib in People With Histiocytic Neoplasms
Memorial Sloan Kettering Cancer Center
NCT03131908 ACTIVE NOT RECRUITING
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
M.D. Anderson Cancer Center
NCT06383884 RECRUITING
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
Samsung Medical Center
NCT05886920 ACTIVE NOT RECRUITING
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd
NCT06413680 RECRUITING
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Regeneron Pharmaceuticals
NCT06416085 RECRUITING
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
NCT07279532 NOT YET RECRUITING
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06157892 RECRUITING
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07280377 RECRUITING
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Oncolytics Biotech
NCT06937177 RECRUITING
Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy
Endevica Bio
NCT03556228 RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
NCT07277972 NOT YET RECRUITING
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
NCT07276360 NOT YET RECRUITING
Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
Uganda Cancer Institute
NCT06922591 RECRUITING
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics, Inc.
NCT06518057 RECRUITING
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
University of Washington
NCT06059547 ACTIVE NOT RECRUITING
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
CatalYm GmbH
NCT07277764 RECRUITING
Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
Jiangxi Provincial Cancer Hospital
NCT07205536 RECRUITING
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Affiliated Hospital of Nantong University
NCT06104618 RECRUITING
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Mayo Clinic
NCT05522491 NOT YET RECRUITING
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Hebei Medical University Fourth Hospital
NCT04802174 RECRUITING
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
National Cancer Institute (NCI)
NCT06479239 RECRUITING
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
University of Virginia
NCT07274449 ACTIVE NOT RECRUITING
Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT07272590 NOT YET RECRUITING
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06230471 RECRUITING
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
NCT07087860 RECRUITING
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Mayo Clinic
NCT07273396 NOT YET RECRUITING
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
Seoul National University Hospital
NCT06341114 ACTIVE NOT RECRUITING
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
Bio-Thera Solutions
NCT06353906 RECRUITING
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
The Netherlands Cancer Institute
NCT07269158 NOT YET RECRUITING
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
NCT06910761 RECRUITING
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
City of Hope Medical Center
NCT06977737 RECRUITING
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Accession Therapeutics Limited
NCT03370276 ACTIVE NOT RECRUITING
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05256537 ACTIVE NOT RECRUITING
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Ronald Paquette
NCT04925609 RECRUITING
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Princess Maxima Center for Pediatric Oncology
NCT06758700 RECRUITING
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
NCT03607890 RECRUITING
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04090528 ACTIVE NOT RECRUITING
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
NCT02932280 ACTIVE NOT RECRUITING
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
NCT06735144 RECRUITING
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT07267234 NOT YET RECRUITING
PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
Second Affiliated Hospital of Soochow University
NCT06678659 RECRUITING
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Recursion Pharmaceuticals Inc.
NCT07264803 RECRUITING
A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to Guide Treatment in Previously Treated Cancers
Qilu Hospital of Shandong University
NCT06265285 RECRUITING
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
NCT07263594 NOT YET RECRUITING
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
DualityBio Inc.
NCT05194397 RECRUITING
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Children's Hospital of Philadelphia
NCT03564340 RECRUITING
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
NCT07186842 RECRUITING
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
NCT05867615 ACTIVE NOT RECRUITING
Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT06925581 RECRUITING
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT03595124 ACTIVE NOT RECRUITING
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
NCT06703177 RECRUITING
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06001658 RECRUITING
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07070518 RECRUITING
Study of GV20-0251 in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT04204850 RECRUITING
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
University Health Network, Toronto
NCT06753747 RECRUITING
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
West China Hospital
NCT03190941 RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT06040970 RECRUITING
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Icahn School of Medicine at Mount Sinai
NCT07259590 RECRUITING
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Genfleet Therapeutics (Shanghai) Inc.
NCT04373031 ACTIVE NOT RECRUITING
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Providence Health & Services
NCT07258121 NOT YET RECRUITING
Study of ZGGS34 in Participants With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06840821 RECRUITING
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Mainline Biosciences (Shanghai) Co., Ltd
NCT04452955 ACTIVE NOT RECRUITING
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Intra-IMMUSG Pte Ltd
NCT07260058 NOT YET RECRUITING
Immune Cell Therapy for Advanced Solid Tumors
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
NCT07257653 RECRUITING
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Zhejiang University
NCT06253130 RECRUITING
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Eikon Therapeutics
NCT07256782 RECRUITING
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06439888 RECRUITING
Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT07256223 NOT YET RECRUITING
A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
Fudan University
NCT07002203 RECRUITING
Personalized Neoantigen Peptide Vaccines for Solid Tumors
Seqker Biosciences, Inc.
NCT05098132 RECRUITING
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Synthekine
NCT06220318 ACTIVE NOT RECRUITING
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Fujian Haixi Pharmaceuticals Co., Ltd.
NCT07241936 RECRUITING
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT07254962 NOT YET RECRUITING
CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)
Sir Mortimer B. Davis - Jewish General Hospital
NCT07136181 RECRUITING
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Novelwise Pharmaceutical Corporation
NCT07105215 RECRUITING
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
NCT05985161 RECRUITING
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT06107686 RECRUITING
A Study of YL202 in Selected Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT05848011 ACTIVE NOT RECRUITING
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
NCT06458036 RECRUITING
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Children's Hospital of Philadelphia
NCT07249892 NOT YET RECRUITING
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
Chengdu Syncor Pharmaceutical Co., Ltd.
NCT07083323 RECRUITING
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
NCT06311851 RECRUITING
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Pardis Noor Medical Imaging and Cancer Center
NCT05947383 RECRUITING
Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer
Sunstone Medical
NCT02484404 ACTIVE NOT RECRUITING
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
National Cancer Institute (NCI)
NCT07245901 NOT YET RECRUITING
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT07245381 NOT YET RECRUITING
Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation
Dr. Itay GoorAryeh
NCT04412629 ACTIVE NOT RECRUITING
Cabozantinib in High Grade Neuroendocrine Neoplasms
Washington University School of Medicine
NCT06777433 RECRUITING
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Radiopharm Theranostics, Ltd
NCT07243951 NOT YET RECRUITING
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
NCT06574880 RECRUITING
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Angela Y. Jia, MD PhD
NCT07246668 RECRUITING
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Yonsei University
NCT05914116 RECRUITING
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT07095868 RECRUITING
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Everest Medicines (Beijing) Co., Ltd.
NCT04590326 RECRUITING
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
NCT04116541 RECRUITING
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Centre Leon Berard
NCT06184035 RECRUITING
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Spago Nanomedical AB
NCT04904302 ACTIVE NOT RECRUITING
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
NCT07071103 RECRUITING
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Chuangzhen Chen
NCT07032077 RECRUITING
A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors.
Shandong Suncadia Medicine Co., Ltd.
NCT04315701 ACTIVE NOT RECRUITING
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
University of Southern California
NCT06500676 RECRUITING
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.
NCT05786924 RECRUITING
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Institut de Recherches Internationales Servier
NCT06345482 ACTIVE NOT RECRUITING
A Study of MHB039A for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
NCT04299191 RECRUITING
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Laminar Pharmaceuticals
NCT05475171 RECRUITING
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
M.D. Anderson Cancer Center
NCT06373406 ACTIVE NOT RECRUITING
A Study of MHB036C for Advanced Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
NCT06759064 RECRUITING
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
Qilu Hospital of Shandong University
NCT05867251 RECRUITING
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
NCT04094610 RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
NCT07126665 RECRUITING
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT07130383 RECRUITING
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT06563362 RECRUITING
Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma
University of Zurich
NCT02479698 RECRUITING
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT05958121 RECRUITING
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Immatics Biotechnologies GmbH
NCT04624399 RECRUITING
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
Queen Mary University of London
NCT06819735 RECRUITING
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Domain Therapeutics Australia Pty Ltd
NCT06885034 RECRUITING
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
GlaxoSmithKline
NCT05887492 RECRUITING
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Tango Therapeutics, Inc.
NCT04180371 ACTIVE NOT RECRUITING
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
NCT06283719 RECRUITING
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06640049 ACTIVE NOT RECRUITING
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
GlaxoSmithKline
NCT05973864 RECRUITING
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
UNICANCER
NCT06962787 RECRUITING
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07019779 RECRUITING
Study of CM518D1 in Patients With Advanced Solid Tumors
Keymed Biosciences Co.Ltd
NCT05119907 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan in Patients With Solid Tumor
Gilead Sciences
NCT06848699 RECRUITING
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT07229612 NOT YET RECRUITING
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07208773 RECRUITING
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06384807 RECRUITING
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Biohaven Therapeutics Ltd.
NCT05275478 ACTIVE NOT RECRUITING
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
NCT04561362 ACTIVE NOT RECRUITING
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
NCT05783323 RECRUITING
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Children's Hospital of Philadelphia
NCT06785636 RECRUITING
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI, Inc.
NCT07178938 NOT YET RECRUITING
Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases
MedSIR
NCT05732831 RECRUITING
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
NCT05997017 RECRUITING
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience, Inc.
NCT03367156 ACTIVE NOT RECRUITING
Dexamethasone in Controlling Dyspnea in Patients With Cancer
M.D. Anderson Cancer Center
NCT06150417 RECRUITING
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
NCT05379985 RECRUITING
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
NCT02696993 ACTIVE NOT RECRUITING
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT07226544 NOT YET RECRUITING
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
City of Hope Medical Center
NCT06088381 RECRUITING
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
University of Maryland, Baltimore
NCT03288545 ACTIVE NOT RECRUITING
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Astellas Pharma Global Development, Inc.
NCT04982653 RECRUITING
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
M.D. Anderson Cancer Center
NCT06635785 RECRUITING
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
OncoC4, Inc.
NCT04067336 RECRUITING
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
NCT03747757 ACTIVE NOT RECRUITING
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT03674047 ACTIVE NOT RECRUITING
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Massachusetts General Hospital
NCT03035409 ACTIVE NOT RECRUITING
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
M.D. Anderson Cancer Center
NCT05434234 RECRUITING
A Study of YL201 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07055594 RECRUITING
A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors
Shine-On Biomedical Co., Ltd.
NCT04074967 ACTIVE NOT RECRUITING
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT05772546 ACTIVE NOT RECRUITING
Avatrombopag vs. Placebo for CIT in GI Malignancies
Hanny Al-Samkari, MD
NCT06677190 RECRUITING
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT05307939 RECRUITING
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
Memorial Sloan Kettering Cancer Center
NCT06749210 RECRUITING
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
Ohio State University Comprehensive Cancer Center
NCT03360890 ACTIVE NOT RECRUITING
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
University of Chicago
NCT05902988 RECRUITING
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics, Inc.
NCT06445114 RECRUITING
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Zachary Zumsteg
NCT06616766 RECRUITING
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
Yuhan Corporation
NCT04643418 RECRUITING
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
MegaPro Biomedical Co. Ltd.
NCT04225117 ACTIVE NOT RECRUITING
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Global Development, Inc.
NCT03175432 ACTIVE NOT RECRUITING
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT04181463 NOT YET RECRUITING
Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer
M.D. Anderson Cancer Center
NCT07222969 NOT YET RECRUITING
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Vibrant Sciences Limited
NCT05607004 RECRUITING
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Atossa Therapeutics, Inc.
NCT05384626 RECRUITING
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
NCT07222631 NOT YET RECRUITING
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
University of California, San Diego
NCT02713269 ACTIVE NOT RECRUITING
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
NCT05887609 RECRUITING
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
NCT05205330 ACTIVE NOT RECRUITING
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Rottapharm Biotech
NCT06249048 RECRUITING
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Strand Therapeutics Inc.
NCT02346747 ACTIVE NOT RECRUITING
A Trial of Vigil for Participants With Ovarian Cancer
Gradalis, Inc.
NCT04665206 RECRUITING
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
NCT05456685 ACTIVE NOT RECRUITING
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie
NCT06617923 RECRUITING
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03284385 ACTIVE NOT RECRUITING
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
National Cancer Institute (NCI)
NCT04713046 RECRUITING
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05118789 RECRUITING
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Nuvalent Inc.
NCT06228326 RECRUITING
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Krystal Biotech, Inc.
NCT02896335 RECRUITING
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
NCT06974604 RECRUITING
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Brown University
NCT06906341 RECRUITING
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
NCT05512208 RECRUITING
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
University of Oklahoma
NCT06271837 RECRUITING
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
AstraZeneca
NCT06493019 RECRUITING
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Dustin Deming
NCT04925544 ACTIVE NOT RECRUITING
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
NCT05706129 RECRUITING
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
NCT07092514 RECRUITING
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Washington University School of Medicine
NCT03909334 ACTIVE NOT RECRUITING
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Xiuning Le
NCT05405413 RECRUITING
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
Dartmouth-Hitchcock Medical Center
NCT03157128 ACTIVE NOT RECRUITING
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company
NCT03505320 ACTIVE NOT RECRUITING
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Astellas Pharma Global Development, Inc.
NCT07218692 NOT YET RECRUITING
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
NCT06544798 ENROLLING BY INVITATION
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
MeiraGTx, LLC
NCT04639219 ACTIVE NOT RECRUITING
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
AstraZeneca
NCT05565417 ACTIVE NOT RECRUITING
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
NCT06873789 ACTIVE NOT RECRUITING
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT05898399 ACTIVE NOT RECRUITING
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Artios Pharma Ltd
NCT05642780 ACTIVE NOT RECRUITING
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Klus Pharma Inc.
NCT06660654 RECRUITING
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Daiichi Sankyo
NCT07173101 RECRUITING
Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
University of Utah
NCT06116136 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Servier Bio-Innovation LLC
NCT04892017 ACTIVE NOT RECRUITING
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
NCT04095234 ACTIVE NOT RECRUITING
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)
Memorial Sloan Kettering Cancer Center
NCT06597734 RECRUITING
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
NCT02444741 ACTIVE NOT RECRUITING
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT06814496 RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT04953104 ACTIVE NOT RECRUITING
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
NCT04009044 ACTIVE NOT RECRUITING
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
Northwestern University
NCT02387905 ACTIVE NOT RECRUITING
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases
M.D. Anderson Cancer Center
NCT03355976 ACTIVE NOT RECRUITING
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Brown University
NCT04370587 RECRUITING
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co. Ltd
NCT07212933 RECRUITING
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
Chinese PLA General Hospital
NCT03118986 RECRUITING
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
The Hospital for Sick Children
NCT06778382 RECRUITING
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Shandong Cancer Hospital and Institute
NCT04954599 RECRUITING
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
NCT04209660 ACTIVE NOT RECRUITING
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Memorial Sloan Kettering Cancer Center
NCT06807593 NOT YET RECRUITING
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
M.D. Anderson Cancer Center
NCT03383094 ACTIVE NOT RECRUITING
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Loren Mell, MD
NCT05663710 RECRUITING
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
NCT03693014 ACTIVE NOT RECRUITING
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
NCT05036226 RECRUITING
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
Medical University of South Carolina
NCT03915678 RECRUITING
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
Institut Bergonié
NCT04752137 RECRUITING
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Massachusetts General Hospital
NCT05296564 RECRUITING
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
NCT04098744 RECRUITING
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Frantz Viral Therapeutics, LLC
NCT06804655 NOT YET RECRUITING
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
University of Zurich
NCT04705818 ACTIVE NOT RECRUITING
Combining Epigenetic And Immune Therapy to Beat Cancer.
Institut Bergoni��
NCT05040815 RECRUITING
Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer
AHS Cancer Control Alberta
NCT06967155 ACTIVE NOT RECRUITING
A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
NCT04095208 ACTIVE NOT RECRUITING
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study
Institut Bergonié
NCT06260774 ACTIVE NOT RECRUITING
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
TransCode Therapeutics
NCT07090174 NOT YET RECRUITING
Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
Weill Medical College of Cornell University
NCT07147348 RECRUITING
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
BioNTech SE
NCT07202364 NOT YET RECRUITING
A Study of YL202 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT04557449 ACTIVE NOT RECRUITING
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Pfizer
NCT07172412 NOT YET RECRUITING
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT07198321 NOT YET RECRUITING
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
NCT03785249 ACTIVE NOT RECRUITING
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
NCT07196540 NOT YET RECRUITING
IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx
Sun Yat-sen University
NCT04641247 RECRUITING
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
NCT05145400 RECRUITING
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
NCT05803018 RECRUITING
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05785039 RECRUITING
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05965856 RECRUITING
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05012371 ACTIVE NOT RECRUITING
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
NCT07191977 NOT YET RECRUITING
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma
West China Hospital
NCT04956640 RECRUITING
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
NCT06682780 RECRUITING
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
NCT07192107 RECRUITING
A Study of MHB042C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT02498613 ACTIVE NOT RECRUITING
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT07192120 RECRUITING
A Study of MHB048C in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT04446962 ACTIVE NOT RECRUITING
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
Institut Curie
NCT07039526 RECRUITING
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
John Waters
NCT06335069 RECRUITING
18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
Maastricht University Medical Center
NCT05941507 RECRUITING
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
NCT06212076 RECRUITING
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Nanjing Immunophage Biotech Co., Ltd
NCT07189793 NOT YET RECRUITING
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
First Affiliated Hospital of Wenzhou Medical University
NCT03745326 RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT05356741 RECRUITING
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Vir Biotechnology, Inc.
NCT06124378 ACTIVE NOT RECRUITING
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
NCT05381038 RECRUITING
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
National University Hospital, Singapore
NCT07037004 NOT YET RECRUITING
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
City of Hope Medical Center
NCT04912765 RECRUITING
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
National Cancer Centre, Singapore
NCT05305131 RECRUITING
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
National University Hospital, Singapore
NCT05652686 RECRUITING
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
NCT06027983 NOT YET RECRUITING
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
National University Hospital, Singapore
NCT05877521 ACTIVE NOT RECRUITING
Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief
Memorial Sloan Kettering Cancer Center
NCT02701088 ACTIVE NOT RECRUITING
Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Centre Francois Baclesse
NCT02628067 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Merck Sharp & Dohme LLC
NCT04614480 RECRUITING
Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine
Centre Georges Francois Leclerc
NCT06520488 RECRUITING
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT04273061 RECRUITING
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
British Columbia Cancer Agency
NCT06385678 ACTIVE NOT RECRUITING
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Jiangsu HengRui Medicine Co., Ltd.
NCT05735080 RECRUITING
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT03029403 ACTIVE NOT RECRUITING
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
University Health Network, Toronto
NCT05104736 RECRUITING
PT-112 in Subjects With Thymoma and Thymic Carcinoma
National Cancer Institute (NCI)
NCT06577194 RECRUITING
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT03283384 ACTIVE NOT RECRUITING
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
Borstkanker Onderzoek Groep
NCT06205706 ACTIVE NOT RECRUITING
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
BioInvent International AB
NCT06767813 RECRUITING
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT06985355 RECRUITING
A Study of MHB046C Injection in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT05329532 RECRUITING
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Scancell Ltd
NCT06362369 RECRUITING
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
NCT05838729 RECRUITING
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Coordination Pharmaceuticals, Inc.
NCT06143748 ACTIVE NOT RECRUITING
Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)
Sun Yat-sen University
NCT07010692 RECRUITING
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Bruce Robinson, MD
NCT05172258 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
NCT03647163 ACTIVE NOT RECRUITING
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Vyriad, Inc.
NCT07172802 RECRUITING
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
GI Innovation, Inc.
NCT07170293 RECRUITING
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Tianjin Medical University Second Hospital
NCT05934331 RECRUITING
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
LaNova Medicines Zhejiang Co., Ltd.
NCT07169994 RECRUITING
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07170787 NOT YET RECRUITING
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT07034950 ACTIVE NOT RECRUITING
Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation
The First Affiliated Hospital of Xiamen University
NCT05745623 RECRUITING
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
NCT04632108 ACTIVE NOT RECRUITING
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
NCT06468358 RECRUITING
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
L & L Bio Co., Ltd., Ningbo, China
NCT07168226 NOT YET RECRUITING
Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101
MetaFines
NCT04511013 RECRUITING
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
NCT05845814 ACTIVE NOT RECRUITING
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Merck Sharp & Dohme LLC
NCT05903833 RECRUITING
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
AGO Research GmbH
NCT07162246 RECRUITING
Combined Gamma Knife/Linac Radiosurgery for Large Brain Tumors / Metastases
Sunnybrook Health Sciences Centre
NCT06866262 RECRUITING
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
NCT03531645 ACTIVE NOT RECRUITING
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
M.D. Anderson Cancer Center
NCT02880319 ACTIVE NOT RECRUITING
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Dana-Farber Cancer Institute
NCT06682793 RECRUITING
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT02992210 RECRUITING
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
Shenzhen Geno-Immune Medical Institute
NCT04606914 RECRUITING
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
University of Alabama at Birmingham
NCT07158918 RECRUITING
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
NCT07160283 NOT YET RECRUITING
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
The Second Affiliated Hospital of Shandong First Medical University
NCT06990880 RECRUITING
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
GlaxoSmithKline
NCT07040644 NOT YET RECRUITING
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04516070 ACTIVE NOT RECRUITING
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
NCT03028337 RECRUITING
Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases
M.D. Anderson Cancer Center
NCT07007182 NOT YET RECRUITING
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Jinbo Yue
NCT07157956 NOT YET RECRUITING
CVL006 Combination Therapy in Advanced Solid Tumors
Convalife (Shanghai) Co., Ltd.
NCT07129772 NOT YET RECRUITING
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The University of Hong Kong
NCT04977453 RECRUITING
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
GI Innovation, Inc.
NCT05481476 ACTIVE NOT RECRUITING
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
NCT07128576 NOT YET RECRUITING
Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors
Zhujiang Hospital
NCT06365788 RECRUITING
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Universitaire Ziekenhuizen KU Leuven
NCT03457948 ACTIVE NOT RECRUITING
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
Nicholas Fidelman, MD
NCT06237920 RECRUITING
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
The Netherlands Cancer Institute
NCT07151586 NOT YET RECRUITING
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
UNICANCER
NCT07153289 NOT YET RECRUITING
CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)
University Hospital Tuebingen
NCT07150416 NOT YET RECRUITING
Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
The First Affiliated Hospital of Guangzhou Medical University
NCT05585320 ACTIVE NOT RECRUITING
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
NCT03310879 RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
NCT05669482 ACTIVE NOT RECRUITING
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Verastem, Inc.
NCT04685226 RECRUITING
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
NCT07000162 RECRUITING
LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial
Azienda USL Reggio Emilia - IRCCS
NCT07145931 NOT YET RECRUITING
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
Sun Yat-sen University
NCT07146672 RECRUITING
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
Shanghai Cell Therapy Group Co.,Ltd
NCT05491512 RECRUITING
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Memorial Sloan Kettering Cancer Center
NCT07146919 NOT YET RECRUITING
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
Centre Leon Berard
NCT05451849 ACTIVE NOT RECRUITING
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT07142837 NOT YET RECRUITING
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT07142200 NOT YET RECRUITING
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
RenJi Hospital
NCT07140393 NOT YET RECRUITING
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT06088004 RECRUITING
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
NCT07136142 NOT YET RECRUITING
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT07137039 NOT YET RECRUITING
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen
The First Affiliated Hospital of Xiamen University
NCT06250036 RECRUITING
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Royal Marsden NHS Foundation Trust
NCT04319783 ACTIVE NOT RECRUITING
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Trans Tasman Radiation Oncology Group
NCT06425926 RECRUITING
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune Inc
NCT06907043 RECRUITING
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Eikon Therapeutics
NCT04434040 RECRUITING
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
NCT06057675 RECRUITING
Tranexamic Acid in Nasal Mohs Reconstruction
Vanderbilt University Medical Center
NCT05761223 RECRUITING
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
1ST Biotherapeutics, Inc.
NCT05394103 RECRUITING
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Qurient Co., Ltd.
NCT07127822 NOT YET RECRUITING
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
Peking University
NCT05864144 ACTIVE NOT RECRUITING
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT07125547 RECRUITING
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Tianjin Medical University Second Hospital
NCT06075264 RECRUITING
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
Frantz Viral Therapeutics, LLC
NCT07122063 ACTIVE NOT RECRUITING
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06376136 RECRUITING
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
Bio-Thera Solutions
NCT05827835 RECRUITING
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Zhejiang University
NCT05888857 NOT YET RECRUITING
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
Institut Bergonié
NCT06953323 RECRUITING
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
NCT07121595 RECRUITING
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
University of Michigan Rogel Cancer Center
NCT07118566 NOT YET RECRUITING
Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases
China Medical University, China
NCT07070349 RECRUITING
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT05057013 ACTIVE NOT RECRUITING
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
NCT06356714 RECRUITING
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
Sun Jing
NCT07047183 RECRUITING
Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes
Yehui Tan
NCT06480240 ACTIVE NOT RECRUITING
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
OBI Pharma, Inc
NCT04042753 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Memorial Sloan Kettering Cancer Center
NCT06715592 ACTIVE NOT RECRUITING
ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT05574101 ACTIVE NOT RECRUITING
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
NCT06008288 RECRUITING
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Allist Pharmaceuticals, Inc.
NCT06499350 RECRUITING
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
FindCure Biosciences (ZhongShan) Co., Ltd.
NCT03611868 ACTIVE NOT RECRUITING
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group Inc.
NCT06688175 ENROLLING BY INVITATION
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
The First Affiliated Hospital of Xiamen University
NCT07109167 NOT YET RECRUITING
The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors
The Second Affiliated Hospital of Shandong First Medical University
NCT05732389 RECRUITING
Immunotherapy in Patients With Early dMMR Rectal Cancer
Odense University Hospital
NCT04728633 ACTIVE NOT RECRUITING
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
Thomas Jefferson University
NCT07107633 RECRUITING
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
NCT06395519 RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics, Inc.
NCT05315700 RECRUITING
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
ORIC Pharmaceuticals
NCT04430699 ACTIVE NOT RECRUITING
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Massachusetts General Hospital
NCT02711553 ACTIVE NOT RECRUITING
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
NCT07101848 NOT YET RECRUITING
A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER
Hospital Israelita Albert Einstein
NCT07102004 RECRUITING
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
Qilu Pharmaceutical Co., Ltd.
NCT07101822 NOT YET RECRUITING
A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER
Hospital Israelita Albert Einstein
NCT06975410 RECRUITING
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Yuhan Corporation
NCT05318027 RECRUITING
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Abramson Cancer Center at Penn Medicine
NCT07095309 NOT YET RECRUITING
Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer
Metanoic Health Ltd.
NCT07096583 ACTIVE NOT RECRUITING
An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer
Anhui Provincial Cancer Hospital
NCT06105021 ACTIVE NOT RECRUITING
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Affini-T Therapeutics, Inc.
NCT06543056 RECRUITING
A Study of ES014 in Subjects With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06627270 RECRUITING
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Case Comprehensive Cancer Center
NCT06777316 RECRUITING
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
NCT06805617 RECRUITING
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Glenn J. Hanna
NCT04609280 ACTIVE NOT RECRUITING
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
University of Maryland, Baltimore
NCT05446298 ACTIVE NOT RECRUITING
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
OncoC4, Inc.
NCT06732856 RECRUITING
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
Asan Medical Center
NCT02476786 RECRUITING
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
NCT06208410 RECRUITING
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Risen (Suzhou) Pharma Tech Co., Ltd.
NCT05275777 ACTIVE NOT RECRUITING
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
National University Hospital, Singapore
NCT04262466 RECRUITING
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
NCT05035745 RECRUITING
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
National University Hospital, Singapore
NCT04341181 RECRUITING
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Ulrik Lassen
NCT05491083 RECRUITING
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
National University Hospital, Singapore
NCT03806309 ACTIVE NOT RECRUITING
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT06923826 RECRUITING
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
National University Hospital, Singapore
NCT06224244 ACTIVE NOT RECRUITING
External Hypofractionated Radiotherapy With Simultaneous Integrated Boost in Early Breast Cancer Patients
Regina Elena Cancer Institute
NCT06663956 RECRUITING
A Randomized Controlled Trial of a Web-based Platform for Cancer Pain Management
West China Hospital
NCT05023655 RECRUITING
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
NCT03350126 ACTIVE NOT RECRUITING
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT04552288 ACTIVE NOT RECRUITING
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Memorial Sloan Kettering Cancer Center
NCT05978102 RECRUITING
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NCT04268121 RECRUITING
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT05361720 RECRUITING
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
NCT03446157 ACTIVE NOT RECRUITING
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
NCT07077564 NOT YET RECRUITING
The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06010342 RECRUITING
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
Teligene US
NCT06050317 RECRUITING
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
NCT05046171 ACTIVE NOT RECRUITING
Decreasing Polypharmacy in Older Adults With Curable Cancers Trial
University of Rochester
NCT02671435 ACTIVE NOT RECRUITING
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
NCT07077252 NOT YET RECRUITING
Phase I/II Study of SCTB39G in Advanced Solid Tumours
Sinocelltech Ltd.
NCT03529422 ACTIVE NOT RECRUITING
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
NCT07046221 NOT YET RECRUITING
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
NCT06895031 RECRUITING
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Guangzhou JOYO Pharma Co., Ltd
NCT05406674 ACTIVE NOT RECRUITING
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
The Netherlands Cancer Institute
NCT06932458 RECRUITING
A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
Western University, Canada
NCT04022213 ACTIVE NOT RECRUITING
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
Memorial Sloan Kettering Cancer Center
NCT03304080 ACTIVE NOT RECRUITING
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Icahn School of Medicine at Mount Sinai
NCT05837455 RECRUITING
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Washington University School of Medicine
NCT07058948 RECRUITING
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT07070466 NOT YET RECRUITING
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Massachusetts General Hospital
NCT07064863 NOT YET RECRUITING
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
Queen's University
NCT07062536 NOT YET RECRUITING
mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line
Seoul National University Bundang Hospital
NCT06997068 RECRUITING
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Mayo Clinic
NCT07059832 ACTIVE NOT RECRUITING
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
First Hospital of China Medical University
NCT07061535 NOT YET RECRUITING
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT05894824 RECRUITING
T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Yonsei University
NCT05605535 ACTIVE NOT RECRUITING
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
CanariaBio Inc.
NCT07060989 NOT YET RECRUITING
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
Nutshell Therapeutics (Shanghai) Co., LTD.
NCT07061639 NOT YET RECRUITING
A Study of QLS5133 Monotherapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT03801083 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Udai Kammula
NCT05335993 ACTIVE NOT RECRUITING
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
NCT03467516 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
Udai Kammula
NCT03935893 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT06975293 RECRUITING
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
STORM Therapeutics LTD
NCT03093116 RECRUITING
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Turning Point Therapeutics, Inc.
NCT05592626 RECRUITING
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics, Inc.
NCT06277219 RECRUITING
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Latticon Antibody Therapeutics, Inc
NCT03709446 ACTIVE NOT RECRUITING
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Joseph Sparano
NCT06540729 RECRUITING
RC48 in Combination With AK104 and Bevacizumab in OCCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT02332668 RECRUITING
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme LLC
NCT06790082 RECRUITING
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Aalborg University Hospital
NCT05521997 NOT YET RECRUITING
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Washington University School of Medicine
NCT06482515 RECRUITING
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
University of Maryland, Baltimore
NCT06669117 RECRUITING
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Pierre Fabre Medicament
NCT07023484 RECRUITING
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
The University of Hong Kong
NCT07035249 NOT YET RECRUITING
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
West China Hospital
NCT03093688 RECRUITING
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Shanghai Public Health Clinical Center
NCT04594772 ACTIVE NOT RECRUITING
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
NCT07043608 NOT YET RECRUITING
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Kelly Fitzgerald, MD
NCT07022535 RECRUITING
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
The University of Hong Kong
NCT07046650 RECRUITING
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
Sheng Zhang
NCT06811844 RECRUITING
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
The First Affiliated Hospital of Xiamen University
NCT07044349 NOT YET RECRUITING
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
NCT07043894 NOT YET RECRUITING
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07033026 RECRUITING
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NGM Biopharmaceuticals, Inc
NCT07041788 NOT YET RECRUITING
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Second Affiliated Hospital of Nanchang University
NCT06602063 NOT YET RECRUITING
Surgery for Relapsed Ovarian Cancer in Precision
Shanghai Gynecologic Oncology Group
NCT03175224 RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
NCT02817958 ACTIVE NOT RECRUITING
Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis
UNICANCER
NCT05451043 RECRUITING
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
NCT06580002 RECRUITING
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT07039968 RECRUITING
Standard Dose Versus High Dose Stereotactic Spine Radiosurgery for Metastatic Spinal Neoplasms
National Taiwan University Hospital
NCT05787639 RECRUITING
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
University of California, San Diego
NCT03314974 RECRUITING
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT06713798 NOT YET RECRUITING
Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
Gustave Roussy, Cancer Campus, Grand Paris
NCT07032142 NOT YET RECRUITING
Dose Optimization and Efficacy Assessment of a Fluoropyrimidine Antidote
D'Or Institute for Research and Education
NCT05071937 RECRUITING
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
NCT07030478 NOT YET RECRUITING
A Study to Evaluate the Safety and Tolerability of EP0089
Ellipses Pharma
NCT06239194 RECRUITING
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT02637687 ACTIVE NOT RECRUITING
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Bayer
NCT04699188 ACTIVE NOT RECRUITING
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT05388773 RECRUITING
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Heath Skinner
NCT06365840 RECRUITING
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
ImmuneOncia Therapeutics Inc.
NCT04544189 ACTIVE NOT RECRUITING
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis Pharmaceuticals
NCT07026422 RECRUITING
Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)
Shandong Cancer Hospital and Institute
NCT07024537 ACTIVE NOT RECRUITING
HAIP Combined With Fuquinitinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial
Meng Qiu
NCT04916249 ACTIVE NOT RECRUITING
Testing an Herbal Pain Relief Patch to Reduce Pain in Cancer Survivors
Memorial Sloan Kettering Cancer Center
NCT06936748 NOT YET RECRUITING
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
Second Affiliated Hospital of Nanchang University
NCT02650986 ACTIVE NOT RECRUITING
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
NCT06390995 ACTIVE NOT RECRUITING
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Takeda
NCT06559228 RECRUITING
ConnectedNest: a Digital Platform Connecting Individuals With Cancer to Social Care
University of Minnesota
NCT06023862 RECRUITING
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Yonsei University
NCT05413473 RECRUITING
Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2)
AHS Cancer Control Alberta
NCT07019181 NOT YET RECRUITING
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
The First Affiliated Hospital of Xiamen University
NCT04420884 ACTIVE NOT RECRUITING
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Takeda
NCT06862323 NOT YET RECRUITING
Time Restricted Eating in Haematological Malignancies
British Columbia Cancer Agency
NCT06447103 RECRUITING
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT07018063 NOT YET RECRUITING
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
zhoujing
NCT07018622 ACTIVE NOT RECRUITING
Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
NCT03847649 RECRUITING
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
NCT04118114 RECRUITING
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
National Cancer Centre, Singapore
NCT05888831 ACTIVE NOT RECRUITING
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT07002502 NOT YET RECRUITING
Immune Modulation With PRaG-1 Treatment
Second Affiliated Hospital of Soochow University
NCT02873962 ACTIVE NOT RECRUITING
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
NCT03448835 ACTIVE NOT RECRUITING
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
The Netherlands Cancer Institute
NCT02122185 ACTIVE NOT RECRUITING
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT07008703 RECRUITING
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
Shenyang Sunshine Pharmaceutical Co., LTD.
NCT07007728 NOT YET RECRUITING
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Peking University Cancer Hospital & Institute
NCT03089554 RECRUITING
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Rachel Miller
NCT03682289 RECRUITING
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT06904300 NOT YET RECRUITING
Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer
Sun Yat-sen University
NCT06653777 RECRUITING
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells
UNICANCER
NCT05241249 RECRUITING
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Susan E. Bates
NCT06578624 RECRUITING
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Lamassu Bio Inc
NCT05440227 RECRUITING
PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients
PhytoHealth Corporation
NCT07003815 NOT YET RECRUITING
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
NCT07003022 RECRUITING
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Fudan University
NCT06603844 RECRUITING
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Corbus Pharmaceuticals Inc.
NCT06831175 RECRUITING
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
West China Hospital
NCT05010629 ACTIVE NOT RECRUITING
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Glenn J. Hanna
NCT06848439 NOT YET RECRUITING
Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer
Jiangsu Cancer Institute & Hospital
NCT04706715 ACTIVE NOT RECRUITING
LAG3 PET Imaging in Advanced Solid Tumors
University Medical Center Groningen
NCT05265052 NOT YET RECRUITING
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
3D Medicines
NCT05024214 RECRUITING
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT04896697 RECRUITING
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Xilio Development, Inc.
NCT06823479 RECRUITING
Towards Cure Via Only Ultra-short ICB in CSCC
The Netherlands Cancer Institute
NCT06991478 NOT YET RECRUITING
SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites
Tianjin Medical University Cancer Institute and Hospital
NCT06638931 ACTIVE NOT RECRUITING
Agnostic Therapy in Rare Solid Tumors
Instituto do Cancer do Estado de São Paulo
NCT05101070 RECRUITING
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shionogi
NCT06992687 ENROLLING BY INVITATION
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
NCT04575961 ACTIVE NOT RECRUITING
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
NCT04140526 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4, Inc.
NCT02571725 ACTIVE NOT RECRUITING
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
New Mexico Cancer Research Alliance
NCT04322006 ACTIVE NOT RECRUITING
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
NCT05541822 RECRUITING
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Abion Inc
NCT05694819 ACTIVE NOT RECRUITING
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
NCT05170958 RECRUITING
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
NCT05724563 ACTIVE NOT RECRUITING
Domvanalimab and Zimberelimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT03833479 ACTIVE NOT RECRUITING
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
Grupo Español de Investigación en Cáncer de Ovario
NCT04007770 ACTIVE NOT RECRUITING
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
NCT05555862 ACTIVE NOT RECRUITING
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
Frantz Viral Therapeutics, LLC
NCT05970497 RECRUITING
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Krystal Biotech, Inc.
NCT06978400 RECRUITING
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
NCT05251714 ACTIVE NOT RECRUITING
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Treadwell Therapeutics, Inc
NCT05375994 ACTIVE NOT RECRUITING
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Verastem, Inc.
NCT06809530 RECRUITING
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
NCT06976021 NOT YET RECRUITING
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
Maria Sklodowska-Curie National Research Institute of Oncology
NCT04104776 RECRUITING
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT05674825 RECRUITING
Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
Medical College of Wisconsin
NCT06971523 RECRUITING
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
CytosinLab Therapeutics Co., Ltd.
NCT03673787 ACTIVE NOT RECRUITING
A Trial of Ipatasertib in Combination With Atezolizumab
Institute of Cancer Research, United Kingdom
NCT06922357 RECRUITING
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
NCT06532617 RECRUITING
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT06908031 RECRUITING
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
NCT06970132 NOT YET RECRUITING
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
Shouyao Holdings (Beijing) Co. LTD
NCT06234748 ACTIVE NOT RECRUITING
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
University of Michigan Rogel Cancer Center
NCT05795244 RECRUITING
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Yonsei University
NCT06742411 RECRUITING
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
West China Hospital
NCT05263960 RECRUITING
A Study of CM350 in Patients With Advanced Solid Tumors
Keymed Biosciences Co.Ltd
NCT05559879 RECRUITING
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
NCT06949982 RECRUITING
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
Sergey Orlov, MD
NCT04375904 RECRUITING
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
Cancer Trials Ireland
NCT06955390 NOT YET RECRUITING
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
Henan Cancer Hospital
NCT06234098 RECRUITING
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
Alyssum Therapeutics
NCT04503265 RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AtlasMedx, Incorporated
NCT06078813 RECRUITING
Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases
Cancer Trials Ireland
NCT05038150 RECRUITING
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
NCT05982522 NOT YET RECRUITING
IN10018 Combination Therapy in Previously-treated Solid Tumors
InxMed (Shanghai) Co., Ltd.
NCT06951243 NOT YET RECRUITING
A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer
Beijing GoBroad Hospital
NCT05103345 RECRUITING
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
NCT06949761 NOT YET RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Qilu Pharmaceutical Co., Ltd.
NCT02314169 ACTIVE NOT RECRUITING
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
NCT06947226 NOT YET RECRUITING
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT05736731 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT06669975 RECRUITING
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
AP Biosciences Inc.
NCT05964361 ACTIVE NOT RECRUITING
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
University Hospital, Antwerp
NCT04068649 RECRUITING
Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer
Roswell Park Cancer Institute
NCT04647916 ACTIVE NOT RECRUITING
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
SWOG Cancer Research Network
NCT04875611 RECRUITING
Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
Maria Sklodowska-Curie National Research Institute of Oncology
NCT05584826 RECRUITING
MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other
Sunstone Medical
NCT06940349 RECRUITING
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
Rabin Medical Center
NCT06067503 RECRUITING
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison
NCT06895928 RECRUITING
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06415318 RECRUITING
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Sun Yat-sen University
NCT06939270 NOT YET RECRUITING
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT06935175 NOT YET RECRUITING
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
Shanghai Zhongshan Hospital
NCT04280081 ACTIVE NOT RECRUITING
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Eli Lilly and Company
NCT03594396 ACTIVE NOT RECRUITING
Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer
Seoul National University Hospital
NCT06623110 RECRUITING
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
Glenn J. Hanna
NCT04333706 RECRUITING
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
University of Southern California
NCT05915351 ACTIVE NOT RECRUITING
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
University of Kansas Medical Center
NCT03919292 RECRUITING
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University
NCT06926751 NOT YET RECRUITING
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06928363 NOT YET RECRUITING
A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
NCT04287868 ACTIVE NOT RECRUITING
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Cancer Institute (NCI)
NCT02437851 ACTIVE NOT RECRUITING
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
AIDS Malignancy Consortium
NCT06431243 RECRUITING
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Chengdu Zenitar Biomedical Technology Co., Ltd
NCT04775485 RECRUITING
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT05275374 NOT YET RECRUITING
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
Xynomic Pharmaceuticals, Inc.
NCT04634357 RECRUITING
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Eureka Therapeutics Inc.
NCT04776447 ACTIVE NOT RECRUITING
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Fundación GECP
NCT03213002 RECRUITING
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Northwell Health
NCT05576974 RECRUITING
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
University of Texas Southwestern Medical Center
NCT05379946 ACTIVE NOT RECRUITING
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
InventisBio Co., Ltd
NCT06915116 RECRUITING
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT06914674 RECRUITING
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Fudan University
NCT05194995 ACTIVE NOT RECRUITING
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Allist Pharmaceuticals, Inc.
NCT04513444 RECRUITING
Interest of Medical Hypnosis in Anxious Patients Treated by Radiotherapy
Institut Claudius Regaud
NCT06911333 RECRUITING
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Avelos Therapeutics Inc.
NCT05969496 RECRUITING
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
University of Colorado, Denver
NCT05009329 ACTIVE NOT RECRUITING
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Allist Pharmaceuticals, Inc.
NCT06909383 NOT YET RECRUITING
Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
Guangzhou Institute of Respiratory Disease
NCT06502743 RECRUITING
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Yonsei University
NCT04969315 RECRUITING
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT06906731 NOT YET RECRUITING
A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT05269316 RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
NCT05979610 RECRUITING
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
University of Utah
NCT05896371 NOT YET RECRUITING
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
CHU de Quebec-Universite Laval
NCT05784688 RECRUITING
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
NCT05483400 RECRUITING
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
University Medical Center Groningen
NCT06895733 RECRUITING
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Tianjin Medical University Second Hospital
NCT05473156 RECRUITING
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
AP Biosciences Inc.
NCT06721689 RECRUITING
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Theodore Laetsch
NCT06805396 NOT YET RECRUITING
Timely Integration of Palliative Care in Oncology Care for Patients Referred for Palliative Radiotherapy on Bone Metastases: a Randomized Trial
Roxanne Gal
NCT02644369 ACTIVE NOT RECRUITING
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
University Health Network, Toronto
NCT06896552 NOT YET RECRUITING
Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.
Rabin Medical Center
NCT06892860 RECRUITING
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
Queen Mary University of London
NCT06892431 NOT YET RECRUITING
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
NCT05101096 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
Gilead Sciences
NCT06891521 NOT YET RECRUITING
Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy
Qinghai Red Cross Hospital
NCT06892223 RECRUITING
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Istituto Clinico Humanitas
NCT05599048 RECRUITING
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
Robert Bok, MD, PhD
NCT05970016 RECRUITING
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
Beijing Tide Pharmaceutical Co., Ltd
NCT06888531 ACTIVE NOT RECRUITING
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
NCT06889649 RECRUITING
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Peking University First Hospital
NCT03759431 ACTIVE NOT RECRUITING
Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
NCT05146440 RECRUITING
Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor
Grupo Espanol de Investigacion en Sarcomas
NCT05636215 RECRUITING
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT05485766 RECRUITING
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Okayama University
NCT04143711 RECRUITING
Study of DF1001 in Patients with Advanced Solid Tumors
Dragonfly Therapeutics
NCT06873555 RECRUITING
A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Heronova Pharmaceuticals
NCT06775236 NOT YET RECRUITING
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06417476 RECRUITING
Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
Pei-Rong Ding
NCT06757244 RECRUITING
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Hopital Foch
NCT06880757 NOT YET RECRUITING
177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.
Ankara University
NCT04585035 ACTIVE NOT RECRUITING
Study to Evaluate D-1553 in Subjects With Solid Tumors
InventisBio Co., Ltd
NCT04123366 ACTIVE NOT RECRUITING
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
Merck Sharp & Dohme LLC
NCT06876038 NOT YET RECRUITING
Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions
University of Massachusetts, Boston
NCT06799637 RECRUITING
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
Evopoint Biosciences Inc.
NCT03965234 RECRUITING
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Roswell Park Cancer Institute
NCT06873854 NOT YET RECRUITING
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
NCT05142423 RECRUITING
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Akeso
NCT06214143 RECRUITING
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
NCT06244992 RECRUITING
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
Pyrotech Therapeutics, Inc.
NCT06869174 NOT YET RECRUITING
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
Zhiguo Luo, MD, PhD
NCT06871527 NOT YET RECRUITING
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
NCT04301765 RECRUITING
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Seattle Institute for Biomedical and Clinical Research
NCT05185947 ACTIVE NOT RECRUITING
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Cancer Institute (NCI)
NCT06470763 RECRUITING
A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)
Anaveon AG
NCT05704621 RECRUITING
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
Korea University Guro Hospital
NCT05487170 RECRUITING
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Ranok Therapeutics (Hangzhou) Co., Ltd.
NCT06692270 NOT YET RECRUITING
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital
NCT06032845 RECRUITING
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)
Fudan University
NCT05438329 RECRUITING
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT05020860 RECRUITING
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Baylor Breast Care Center
NCT06173219 RECRUITING
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
China-Japan Friendship Hospital
NCT04393350 ACTIVE NOT RECRUITING
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
NCT04191460 RECRUITING
Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
Erasmus Medical Center
NCT06667960 RECRUITING
Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT04785196 RECRUITING
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Ascentage Pharma Group Inc.
NCT06239155 ACTIVE NOT RECRUITING
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
Ascentawits Pharmaceuticals, Ltd
NCT04165330 ACTIVE NOT RECRUITING
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Sarcoma Oncology Research Center, LLC
NCT06728631 ACTIVE NOT RECRUITING
Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT05992220 RECRUITING
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
Asan Medical Center
NCT05306028 ACTIVE NOT RECRUITING
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
Fudan University
NCT05214820 RECRUITING
68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
NCT06809946 NOT YET RECRUITING
Feasibility of Fluorescence Imaging with Bevacizumab-800CW During Bronchoscopy
University Medical Center Groningen
NCT06812728 RECRUITING
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
Menoufia University
NCT06756061 RECRUITING
Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity
Byung-Sik Cho
NCT06813079 NOT YET RECRUITING
Using Tumor Models to Determine Treatments
University Health Network, Toronto
NCT05729399 RECRUITING
Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors
Grit Biotechnology
NCT06827080 NOT YET RECRUITING
Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer
Zhengguo Chen
NCT05862324 ACTIVE NOT RECRUITING
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Triumvira Immunologics, Inc.
NCT05669430 RECRUITING
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
GV20 Therapeutics
NCT06293651 RECRUITING
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Dong-A ST Co., Ltd.
NCT06640166 RECRUITING
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT06820320 NOT YET RECRUITING
Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06057922 RECRUITING
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06819215 RECRUITING
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
NCT05200260 RECRUITING
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
NCT06464055 RECRUITING
A Study of GQ1010 in Subjects With Advanced Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd.
NCT05773820 RECRUITING
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
NCT06814158 NOT YET RECRUITING
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
NCT05301881 RECRUITING
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
The Netherlands Cancer Institute
NCT06808412 RECRUITING
To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer
xiaohua li
NCT03373097 ACTIVE NOT RECRUITING
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
Bambino Gesù Hospital and Research Institute
NCT05033392 RECRUITING
PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
Wan He
NCT05662397 ACTIVE NOT RECRUITING
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
HotSpot Therapeutics, Inc
NCT03839342 ACTIVE NOT RECRUITING
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
University Health Network, Toronto
NCT05841420 RECRUITING
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Morten Ladekarl
NCT03526835 RECRUITING
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT06038396 RECRUITING
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
NCT04308174 ACTIVE NOT RECRUITING
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Asan Medical Center
NCT03708224 RECRUITING
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Alain Algazi
NCT06643793 RECRUITING
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Affiliated Hospital of Nantong University
NCT05205850 RECRUITING
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
RemeGen Co., Ltd.
NCT06475352 RECRUITING
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme
UNICANCER
NCT06527300 RECRUITING
A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer
Zhejiang Wenda Pharma Technology LTD.
NCT04902872 ACTIVE NOT RECRUITING
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
NCT06016062 RECRUITING
A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
RemeGen Co., Ltd.
NCT06002789 RECRUITING
Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC
Sixth Affiliated Hospital, Sun Yat-sen University
NCT06764628 RECRUITING
A Study of SHR-4375 in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT04974008 ACTIVE NOT RECRUITING
Osteosarcoma Maintenance Therapy With OST31-164
Emerald Clinical Inc.
NCT06787950 NOT YET RECRUITING
Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors
Jiangsu Yahong Meditech Co., Ltd aka Asieris
NCT03707808 RECRUITING
Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab
Universitair Ziekenhuis Brussel
NCT06783153 NOT YET RECRUITING
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Mansoura University
NCT06581419 RECRUITING
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
NCT06649708 RECRUITING
HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
NCT03709680 ACTIVE NOT RECRUITING
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
NCT06771596 ACTIVE NOT RECRUITING
Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06572813 RECRUITING
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Zhejiang University
NCT04440735 ACTIVE NOT RECRUITING
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Kahr Medical
NCT06761417 NOT YET RECRUITING
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05688280 ACTIVE NOT RECRUITING
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Immunophotonics, Inc.
NCT06643754 RECRUITING
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06090266 RECRUITING
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
NCT06760702 RECRUITING
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers
Aurigene Discovery Technologies Limited
NCT02503423 ACTIVE NOT RECRUITING
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
NCT06762327 NOT YET RECRUITING
Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer
Nanjing First Hospital, Nanjing Medical University
NCT06759155 NOT YET RECRUITING
Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma
University of Vermont Medical Center
NCT05417321 RECRUITING
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
NCT06417554 RECRUITING
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05218889 RECRUITING
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
NCT06414577 ACTIVE NOT RECRUITING
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
XIANG YANQUN
NCT06750952 NOT YET RECRUITING
Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
Sun Yat-sen University
NCT06430658 RECRUITING
Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06748508 NOT YET RECRUITING
Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
Fudan University
NCT06405490 RECRUITING
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05800574 RECRUITING
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Fox Chase Cancer Center
NCT03634540 ACTIVE NOT RECRUITING
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT06139211 RECRUITING
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT03866525 RECRUITING
OH2 Oncolytic Viral Therapy in Solid Tumors
Binhui Biopharmaceutical Co., Ltd.
NCT05882292 RECRUITING
c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration
Yonsei University
NCT05877430 RECRUITING
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience, Inc.
NCT06684327 RECRUITING
Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors
Fudan University
NCT06281678 RECRUITING
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
NCT06739395 RECRUITING
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
NCT05052255 ACTIVE NOT RECRUITING
RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors
Ryvu Therapeutics SA
NCT05121038 ACTIVE NOT RECRUITING
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
Anup Kasi
NCT05315167 RECRUITING
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
Zhuhai Yufan Biotechnologies Co., Ltd
NCT06735326 RECRUITING
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Qilu Hospital of Shandong University
NCT05572684 ACTIVE NOT RECRUITING
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure, Inc.
NCT04278287 RECRUITING
Chemoradiotherapy in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT03569241 ACTIVE NOT RECRUITING
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
University Hospital, Ghent
NCT06645691 RECRUITING
Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body
National Heart Centre Singapore
NCT03379428 ACTIVE NOT RECRUITING
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
US Oncology Research
NCT05656651 ACTIVE NOT RECRUITING
Acute Immunological Effects of Exercise in Cancer Patients
Universität Duisburg-Essen
NCT06150885 RECRUITING
A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors
Ever Supreme Bio Technology Co., Ltd.
NCT06112704 RECRUITING
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06704828 NOT YET RECRUITING
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05128487 ACTIVE NOT RECRUITING
A Study of NDI 1150-101 in Patients With Solid Tumors
Nimbus Saturn, Inc.
NCT06656390 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
NCT05824975 RECRUITING
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
NCT06117566 RECRUITING
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
NCT03813394 ACTIVE NOT RECRUITING
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
National University Hospital, Singapore
NCT06292689 RECRUITING
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
Zhejiang Cancer Hospital
NCT05878288 ACTIVE NOT RECRUITING
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
Peter MacCallum Cancer Centre, Australia
NCT05682950 ACTIVE NOT RECRUITING
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Peking Union Medical College Hospital
NCT05869123 ACTIVE NOT RECRUITING
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Peking Union Medical College Hospital
NCT05990452 ACTIVE NOT RECRUITING
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT06696742 RECRUITING
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
The First Affiliated Hospital with Nanjing Medical University
NCT02387203 ACTIVE NOT RECRUITING
Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin
Mercy Medical Center
NCT06117540 RECRUITING
A Study of WX390 in Patients With Advanced Solid Tumors
Shanghai Jiatan Pharmatech Co., Ltd
NCT05262400 ACTIVE NOT RECRUITING
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Pfizer
NCT04787042 RECRUITING
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
NCT05199272 ACTIVE NOT RECRUITING
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
NCT06643689 NOT YET RECRUITING
Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06012695 RECRUITING
NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
NCT06682611 NOT YET RECRUITING
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
NCT06681636 NOT YET RECRUITING
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
National Institute of Hygiene and Epidemiology, Vietnam
NCT06622486 RECRUITING
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
Egle Therapeutics
NCT03979131 ACTIVE NOT RECRUITING
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Vall d'Hebron Institute of Oncology
NCT03678883 ACTIVE NOT RECRUITING
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
NCT06530303 RECRUITING
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Essen Biotech
NCT03556384 ACTIVE NOT RECRUITING
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Adam Burgoyne, MD, PhD
NCT06598007 RECRUITING
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Crossignal Therapeutics, Inc.
NCT06410703 RECRUITING
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Canwell Biotech Limited
NCT03837899 ACTIVE NOT RECRUITING
Durvalumab and Tremelimumab for Pediatric Malignancies
AstraZeneca
NCT04673942 RECRUITING
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
EpicentRx, Inc.
NCT05522582 ACTIVE NOT RECRUITING
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
Yancheng First People's Hospital
NCT04899908 RECRUITING
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Dana-Farber Cancer Institute
NCT05993299 ACTIVE NOT RECRUITING
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Adaptimmune
NCT04492488 ACTIVE NOT RECRUITING
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Shanghai Miracogen Inc.
NCT06607692 RECRUITING
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Fundación de investigación HM
NCT06605222 RECRUITING
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06646588 RECRUITING
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
NCT06464913 RECRUITING
Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04767048 RECRUITING
Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination with Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy
Centre Francois Baclesse
NCT05620134 ACTIVE NOT RECRUITING
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT06506643 RECRUITING
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Vector Vitale LLC
NCT06620029 NOT YET RECRUITING
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
BioMimetix JV, LLC
NCT06322095 RECRUITING
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT06614140 ACTIVE NOT RECRUITING
Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors
Seqker Biosciences, Inc.
NCT06611137 RECRUITING
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Sun Yat-sen University
NCT05765032 ACTIVE NOT RECRUITING
Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06413615 RECRUITING
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT06611826 NOT YET RECRUITING
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
Zhejiang Cancer Hospital
NCT06612632 RECRUITING
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04970121 RECRUITING
Efficacy and Safety of Duloxetine in Chinese Solid Tumor Patients with Taxanes-induced Painful Peripheral Neuropathy
Yan Yang, MD, Ph.D
NCT05638698 ACTIVE NOT RECRUITING
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
University of Kansas Medical Center
NCT06137378 RECRUITING
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
University of Leipzig
NCT06525298 RECRUITING
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Eisbach Bio GmbH
NCT05865990 ACTIVE NOT RECRUITING
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
MedSIR
NCT05139043 ACTIVE NOT RECRUITING
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors
City of Hope Medical Center
NCT05068752 ACTIVE NOT RECRUITING
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
NCT05367778 RECRUITING
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT03519074 ACTIVE NOT RECRUITING
Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction
National University Hospital, Singapore
NCT04166006 RECRUITING
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT04230759 ACTIVE NOT RECRUITING
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
Goethe University
NCT04205227 ACTIVE NOT RECRUITING
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
ENB Therapeutics, Inc
NCT06593548 NOT YET RECRUITING
Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer
Fudan University
NCT04539496 ACTIVE NOT RECRUITING
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors
Sihuan Pharmaceutical Holdings Group Ltd.
NCT06580574 RECRUITING
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Peking University
NCT06014190 RECRUITING
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Hansoh BioMedical R&D Company
NCT06564298 NOT YET RECRUITING
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
The First Affiliated Hospital with Nanjing Medical University
NCT06538623 RECRUITING
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
NCT04866134 ACTIVE NOT RECRUITING
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Erasca, Inc.
NCT05176665 RECRUITING
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Shanghai EpimAb Biotherapeutics Co., Ltd.
NCT06471673 RECRUITING
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
BriaCell Therapeutics Corporation
NCT04891198 RECRUITING
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT06224387 RECRUITING
CTS2190 Phase I /II Clinical Study in Patients
CytosinLab Therapeutics Co., Ltd.
NCT04185831 ACTIVE NOT RECRUITING
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
Uppsala University Hospital
NCT06416007 RECRUITING
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
University of Cincinnati
NCT05913674 RECRUITING
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
Ciusss de L'Est de l'Île de Montréal
NCT04770207 RECRUITING
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
Second Affiliated Hospital of Guangzhou Medical University
NCT06380816 RECRUITING
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
NCT03967938 ACTIVE NOT RECRUITING
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
AZ-VUB
NCT05399654 ACTIVE NOT RECRUITING
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Tallac Therapeutics
NCT04680260 RECRUITING
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Karen-Lise Garm Spindler
NCT04910386 NOT YET RECRUITING
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines (Sichuan) Co., Ltd.
NCT06554028 NOT YET RECRUITING
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
Henan Cancer Hospital
NCT06551896 NOT YET RECRUITING
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06006390 RECRUITING
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT05749549 ACTIVE NOT RECRUITING
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
Shanghai Blueray Biopharma Co., Ltd.
NCT04282031 RECRUITING
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.
NCT06539559 NOT YET RECRUITING
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
Wang Jiayu
NCT06015048 RECRUITING
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Jiangsu HengRui Medicine Co., Ltd.
NCT06537505 NOT YET RECRUITING
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors
Beidahuang Industry Group General Hospital
NCT06534762 RECRUITING
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
NCT06532539 RECRUITING
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Shandong Cancer Hospital and Institute
NCT06531486 NOT YET RECRUITING
A Study of XS-02 Capsules in Patients With Advanced Solid Tumors
NovaOnco Therapeutics Co., Ltd.
NCT06531291 NOT YET RECRUITING
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
NCT05412589 RECRUITING
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06530719 NOT YET RECRUITING
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
Jin Ying
NCT06530524 NOT YET RECRUITING
Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery
Sir Mortimer B. Davis - Jewish General Hospital
NCT05842785 RECRUITING
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Tyligand Bioscience (Shanghai) Limited
NCT06519110 NOT YET RECRUITING
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Convalife (Shanghai) Co., Ltd.
NCT06516926 NOT YET RECRUITING
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT03991832 RECRUITING
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
University Health Network, Toronto
NCT05159245 RECRUITING
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Helsinki University Central Hospital
NCT04706598 ACTIVE NOT RECRUITING
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
Fudan University
NCT06495515 NOT YET RECRUITING
Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study
Tianjin Medical University Cancer Institute and Hospital
NCT05880043 RECRUITING
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
GI Cell, Inc.
NCT06492408 RECRUITING
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Second Affiliated Hospital of Guangzhou Medical University
NCT06310382 RECRUITING
GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
Suzhou Genhouse Bio Co., Ltd.
NCT06435455 NOT YET RECRUITING
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT06490068 RECRUITING
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06439589 RECRUITING
Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT04807166 ACTIVE NOT RECRUITING
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Wenjun Cheng
NCT05215470 ACTIVE NOT RECRUITING
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Hospital das Clínicas de Ribeirão Preto
NCT03694249 ACTIVE NOT RECRUITING
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Vanderbilt-Ingram Cancer Center
NCT03882840 RECRUITING
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
Second Affiliated Hospital of Guangzhou Medical University
NCT05187338 RECRUITING
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT04803318 RECRUITING
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT06474455 NOT YET RECRUITING
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05198804 ACTIVE NOT RECRUITING
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT05532696 RECRUITING
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Anbogen Therapeutics, Inc.
NCT06385691 RECRUITING
Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.
Centre Leon Berard
NCT05060432 ACTIVE NOT RECRUITING
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
iTeos Belgium SA
NCT04343157 RECRUITING
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
Jona Hattangadi-Gluth
NCT06239298 RECRUITING
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06233292 RECRUITING
A Study of ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06456892 RECRUITING
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
Sun Yat-sen University
NCT05269381 RECRUITING
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT06451211 RECRUITING
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
Sun Yat-sen University
NCT06447636 NOT YET RECRUITING
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
NCT04592653 ACTIVE NOT RECRUITING
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Mural Oncology, Inc
NCT06018896 RECRUITING
Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
Fudan University
NCT06446388 NOT YET RECRUITING
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT05051696 ACTIVE NOT RECRUITING
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
Liu Zi
NCT05103358 ACTIVE NOT RECRUITING
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc.
NCT06081907 RECRUITING
The Efficacy and Safety of IBI363 in Solid Tumors
Hunan Province Tumor Hospital
NCT05493800 ACTIVE NOT RECRUITING
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
MitoImmune Therapeutics
NCT03714490 RECRUITING
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05964101 RECRUITING
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
The First Affiliated Hospital of Guangzhou Medical University
NCT04092673 RECRUITING
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Effector Therapeutics
NCT04444869 RECRUITING
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
University of Missouri-Columbia
NCT06416358 NOT YET RECRUITING
A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed
AlaMab Therapeutics (Shanghai) Inc.
NCT06019130 RECRUITING
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
German Society for Pediatric Oncology and Hematology GPOH gGmbH
NCT03441113 ACTIVE NOT RECRUITING
Extended Access of Momelotinib in Adults With Myelofibrosis
GlaxoSmithKline
NCT05693844 RECRUITING
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT04713371 ACTIVE NOT RECRUITING
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
NCT06408116 RECRUITING
Predicting Esophageal Cancer Borders Using PET-Imaging
University Hospital Heidelberg
NCT05033756 ACTIVE NOT RECRUITING
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
Institut fuer Frauengesundheit
NCT06394128 RECRUITING
Cangpo Liujun Prescription on Cancer-related Fatigue in Advanced Colorectal Cancer With Spleen Deficiency and Dampness Excess
First People's Hospital of Hangzhou
NCT06394713 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06390982 NOT YET RECRUITING
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
Fudan University
NCT06206096 RECRUITING
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
Chinese PLA General Hospital
NCT06385990 RECRUITING
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
Hunan Cancer Hospital
NCT03767075 RECRUITING
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Vall d'Hebron Institute of Oncology
NCT05865925 ENROLLING BY INVITATION
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
Luye Pharma Group Ltd.
NCT03046862 ACTIVE NOT RECRUITING
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Seoul National University Hospital
NCT06366945 NOT YET RECRUITING
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06361979 NOT YET RECRUITING
SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases
Huihua Xiong
NCT04776590 ACTIVE NOT RECRUITING
Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT05080556 RECRUITING
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
University College, London
NCT06362317 RECRUITING
Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
NCT06350162 RECRUITING
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
Zhejiang Cancer Hospital
NCT05664009 RECRUITING
The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults
Canada Royal Enoch Phytomedicine Co., Ltd.
NCT05048524 RECRUITING
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
NCT06329570 NOT YET RECRUITING
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
NCT04510636 RECRUITING
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
University Health Network, Toronto
NCT06314373 RECRUITING
A Study for HSK39775 in Participants With Solid Tumors
Xizang Haisco Pharmaceutical Co., Ltd
NCT06310473 NOT YET RECRUITING
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
Nanfang Hospital, Southern Medical University
NCT04903873 RECRUITING
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Eutilex
NCT05289856 ACTIVE NOT RECRUITING
Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
Johannes Gutenberg University Mainz
NCT06237413 RECRUITING
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT04817956 RECRUITING
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Oslo University Hospital
NCT04392505 ACTIVE NOT RECRUITING
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
Oslo University Hospital
NCT04300244 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Åslaug Helland
NCT06022757 RECRUITING
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Evopoint Biosciences Inc.
NCT06255912 NOT YET RECRUITING
Clinical Trial for Advanced or Metastatic Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04165590 RECRUITING
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
CAS Lamvac Biotech Co., Ltd.
NCT05205200 RECRUITING
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
Fudan University
NCT05515315 RECRUITING
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Fuzhou General Hospital
NCT03838042 RECRUITING
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
University Hospital Heidelberg
NCT06245330 RECRUITING
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
Ascentawits Pharmaceuticals, Ltd
NCT05753826 RECRUITING
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Fujian Cancer Hospital
NCT06229340 RECRUITING
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
N.N. Petrov National Medical Research Center of Oncology
NCT02735057 RECRUITING
Chemoradiotherapy in Elderly Patients With Oesophagus Cancer
Centre Hospitalier Universitaire de Besancon
NCT05492123 RECRUITING
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
Hospital Israelita Albert Einstein
NCT06088030 RECRUITING
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Yang Li
NCT06183736 NOT YET RECRUITING
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Convalife (Shanghai) Co., Ltd.
NCT04889742 NOT YET RECRUITING
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
Charite University, Berlin, Germany
NCT06144671 RECRUITING
GT201 Injection For The Treatment Of Advanced Solid Tumors
Grit Biotechnology
NCT06177925 RECRUITING
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
NCT05801237 RECRUITING
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Shanghai HyaMab Biotech Co.,Ltd.
NCT04989725 RECRUITING
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
NCT05681650 RECRUITING
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Chinese PLA General Hospital
NCT04901234 RECRUITING
Adaptive RadioTherapy for OroPharynx Cancer
Centre hospitalier de l'Université de Montréal (CHUM)
NCT06154109 NOT YET RECRUITING
Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial
Zhiyu Wang
NCT05280275 RECRUITING
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
NCT05978648 RECRUITING
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
wang shusen
NCT05876806 RECRUITING
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Se Jun Park
NCT05923008 RECRUITING
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT04984733 RECRUITING
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
University of Southampton
NCT06144723 NOT YET RECRUITING
Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.
Hansoh BioMedical R&D Company
NCT02290145 RECRUITING
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
Shanghai Jiao Tong University School of Medicine
NCT06140576 NOT YET RECRUITING
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Zhejiang Cancer Hospital
NCT06132217 NOT YET RECRUITING
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Shanghai Runshi Pharmaceutical Technology Co., Ltd
NCT06130332 RECRUITING
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06121700 RECRUITING
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
Fudan University
NCT05494060 RECRUITING
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
NCT06112041 NOT YET RECRUITING
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
Second Affiliated Hospital of Soochow University
NCT06099821 RECRUITING
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Peking University Cancer Hospital & Institute
NCT05573802 RECRUITING
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
NCT06056323 RECRUITING
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
NCT04277858 RECRUITING
Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
Nader Sadeghi
NCT05624099 RECRUITING
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Fujian Cancer Hospital
NCT05260671 RECRUITING
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Eye & ENT Hospital of Fudan University
NCT06078670 NOT YET RECRUITING
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
Fujian Cancer Hospital
NCT06063070 NOT YET RECRUITING
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Sun Yat-sen University
NCT05602935 ACTIVE NOT RECRUITING
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
The Second Affiliated Hospital of Fujian Medical University
NCT05525247 RECRUITING
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Selecxine
NCT06041490 NOT YET RECRUITING
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Peking Union Medical College Hospital
NCT06039111 NOT YET RECRUITING
Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma
Hamilton Health Sciences Corporation
NCT06039631 RECRUITING
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Fudan University
NCT06037655 NOT YET RECRUITING
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
The First Affiliated Hospital with Nanjing Medical University
NCT05980702 RECRUITING
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06026501 NOT YET RECRUITING
A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd.
NCT05805358 NOT YET RECRUITING
Hyperpolarized 13C MRI for Cancer Immunotherapy
Chang Gung Memorial Hospital
NCT05981001 RECRUITING
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05981014 RECRUITING
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT04764227 ACTIVE NOT RECRUITING
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Fudan University
NCT05076942 RECRUITING
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
University Medical Center Groningen
NCT05951608 NOT YET RECRUITING
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Akeso
NCT05947487 RECRUITING
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT05941338 RECRUITING
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05909436 RECRUITING
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
Guangzhou Gloria Biosciences Co., Ltd.
NCT05904015 NOT YET RECRUITING
The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05898373 NOT YET RECRUITING
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
Peking Union Medical College
NCT04519151 RECRUITING
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
NCT04617756 RECRUITING
Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
Centre Hospitalier Universitaire de Nīmes
NCT03488667 ACTIVE NOT RECRUITING
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
University of Kansas Medical Center
NCT05824494 NOT YET RECRUITING
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
Women's Hospital School Of Medicine Zhejiang University
NCT05699811 RECRUITING
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT05687357 RECRUITING
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT05204862 RECRUITING
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
TiumBio Co., Ltd.
NCT05732051 RECRUITING
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
University Hospital, Akershus
NCT05754801 NOT YET RECRUITING
Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer
Chinese University of Hong Kong
NCT04870905 NOT YET RECRUITING
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
NCT04931979 RECRUITING
SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy
Prof. Dr. med. Christian Gratzke
NCT04014530 RECRUITING
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT05642949 NOT YET RECRUITING
Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors
Minghui Pharmaceutical Pty Ltd
NCT05652855 NOT YET RECRUITING
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
Minghui Pharmaceutical Pty Ltd
NCT05252078 RECRUITING
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
Jiangxi Provincial Cancer Hospital
NCT05651672 RECRUITING
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Tianjin Medical University Cancer Institute and Hospital
NCT05000892 RECRUITING
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05628922 RECRUITING
Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
Fudan University
NCT05451602 RECRUITING
HEC169096 in Participants With Advanced Solid Tumors
Sunshine Lake Pharma Co., Ltd.
NCT05581875 NOT YET RECRUITING
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Hellenic Society of Hematology
NCT03280511 RECRUITING
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Michael Bau Mortensen
NCT03286634 RECRUITING
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
National Hospital Organization Nagoya Medical Center
NCT04983121 RECRUITING
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
Shengjing Hospital
NCT04996121 RECRUITING
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05439993 RECRUITING
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Hallym University Medical Center
NCT05438368 RECRUITING
GD2/CD70 Bi-specific CAR-T Cell Therapy
Shenzhen Geno-Immune Medical Institute
NCT05437315 RECRUITING
GD2/PSMA Bi-specific CAR-T Cell Therapy
Shenzhen Geno-Immune Medical Institute
NCT05437341 RECRUITING
PSMA/CD70 Bi-specific CAR-T Cell Therapy
Shenzhen Geno-Immune Medical Institute
NCT05422911 NOT YET RECRUITING
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
James J. Peters Veterans Affairs Medical Center
NCT03947775 NOT YET RECRUITING
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
University Health Network, Toronto
NCT05241561 NOT YET RECRUITING
Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
Centre Hospitalier Universitaire de Besancon
NCT05395962 RECRUITING
Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT03983226 RECRUITING
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Shanghai Gynecologic Oncology Group
NCT03617133 RECRUITING
Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer
Medical University of Vienna
NCT03865082 ACTIVE NOT RECRUITING
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Idera Pharmaceuticals, Inc.
NCT05072600 RECRUITING
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
Peking University First Hospital
NCT05095467 NOT YET RECRUITING
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
Xuefei.Wang
NCT04831437 RECRUITING
Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer
Tehran University of Medical Sciences
NCT05067530 NOT YET RECRUITING
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
Medical University of Gdansk
NCT04109755 RECRUITING
Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
University Hospital, Geneva
NCT05055635 RECRUITING
Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)
University of Aarhus
NCT04993014 RECRUITING
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
AC Camargo Cancer Center
NCT04237805 RECRUITING
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT04825938 NOT YET RECRUITING
Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT03985891 RECRUITING
The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Xiangya Hospital of Central South University
NCT03315546 RECRUITING
Radiotherapy Delivery in Deep Inspiration for Pediatric Patients
Rigshospitalet, Denmark
NCT04301375 NOT YET RECRUITING
Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)
David Garcia Cinca
NCT04034173 NOT YET RECRUITING
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Ludwig-Maximilians - University of Munich
NCT03919461 RECRUITING
Colorectal Metastasis Prevention International Trial 2
Assaf-Harofeh Medical Center
NCT03827616 ENROLLING BY INVITATION
Moderately Hypofractionated Radiotherapy for Prostate Cancer.
Tatarstan Cancer Center
NCT02487992 ACTIVE NOT RECRUITING
The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer
The First People's Hospital of Changzhou
NCT02489890 ACTIVE NOT RECRUITING
CIK in Treating Patients With Bladder Cancer
The First People's Hospital of Changzhou
NCT02485015 ACTIVE NOT RECRUITING
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
The First People's Hospital of Changzhou
NCT03994796 SUSPENDED
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
NCT03519412 COMPLETED
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
IFOM ETS - The AIRC Institute of Molecular Oncology
NCT04191135 COMPLETED
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Merck Sharp & Dohme LLC
NCT04238819 COMPLETED
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
NCT05148078 COMPLETED
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
NCT04415944 COMPLETED
Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy
Wake Forest University Health Sciences
NCT04526106 COMPLETED
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
NCT05316688 TERMINATED
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
University of Washington
NCT04172675 COMPLETED
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
NCT03400332 COMPLETED
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
NCT03785210 TERMINATED
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Cancer Institute (NCI)
NCT06005974 TERMINATED
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Recursion Pharmaceuticals Inc.
NCT04426669 COMPLETED
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
NCT04461509 COMPLETED
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Alessandro D'Agnolo
NCT04282018 COMPLETED
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeiGene
NCT03165721 TERMINATED
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Cancer Institute (NCI)
NCT05000294 SUSPENDED
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
NCT02738606 TERMINATED
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT04950608 COMPLETED
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
Yvan Beaussant, MD, MSci
NCT03993353 COMPLETED
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
NCT04221438 TERMINATED
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
ECOG-ACRIN Cancer Research Group
NCT04482933 WITHDRAWN
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Pediatric Brain Tumor Consortium
NCT05661578 COMPLETED
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
Hoffmann-La Roche
NCT05551117 TERMINATED
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
MacroGenics
NCT04332653 COMPLETED
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NCT04754425 TERMINATED
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT05499663 COMPLETED
Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors
University of Maryland, Baltimore
NCT05325866 COMPLETED
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Amgen
NCT02979977 COMPLETED
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
NCT05756907 TERMINATED
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
NCT04634071 COMPLETED
Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment
Joseph Valentino, MD
NCT06682806 TERMINATED
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
NCT06771921 TERMINATED
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
Genmab
NCT05731947 COMPLETED
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Syndax Pharmaceuticals
NCT04157517 TERMINATED
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D LLC
NCT04260529 COMPLETED
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
Cytovation AS
NCT03872778 COMPLETED
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
Advanced Accelerator Applications
NCT03082534 COMPLETED
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
NCT03697304 COMPLETED
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
NCT06254911 SUSPENDED
Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma
Emory University
NCT04504942 COMPLETED
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
CytoDyn, Inc.
NCT05070247 TERMINATED
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
NCT05512377 COMPLETED
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
NCT05262530 TERMINATED
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
NCT04617054 TERMINATED
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Nuvation Bio Inc.
NCT04627740 COMPLETED
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
Xinqiao Hospital of Chongqing
NCT03994601 COMPLETED
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
NCT04799054 TERMINATED
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma Oncology Division A/S
NCT06553157 COMPLETED
Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy
Minia University
NCT06556108 COMPLETED
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
NCT02668666 COMPLETED
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Oana Danciu, MD
NCT05466994 COMPLETED
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)
M.D. Anderson Cancer Center
NCT02296684 COMPLETED
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT04773782 COMPLETED
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
NCT05002270 COMPLETED
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jacobio Pharmaceuticals Co., Ltd.
NCT07335237 COMPLETED
Clinical Study on the Prevention and Treatment of Postoperative Gastrointestinal Dysfunction by Acupuncture Under ERAS Management Based on Artificial Intelligence Monitoring
Jiangsu Province Hospital of Traditional Chinese Medicine
NCT04260802 TERMINATED
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
NCT06478862 TERMINATED
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
Lipomedix Pharmaceuticals Inc.
NCT05041257 COMPLETED
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
AbbVie
NCT03873818 COMPLETED
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
NCT04284488 TERMINATED
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
NCT06545617 WITHDRAWN
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
NCT04175847 COMPLETED
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
NCT06173037 COMPLETED
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
NCT05774873 COMPLETED
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Innovent Biologics (Suzhou) Co. Ltd.
NCT05174585 COMPLETED
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT07071909 WITHDRAWN
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
NCT05628857 COMPLETED
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
RemeGen Co., Ltd.
NCT06162351 TERMINATED
A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer
Institut Curie
NCT03844750 TERMINATED
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
Chloe Atreya, MD, PhD
NCT03993678 COMPLETED
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
Swiss Cancer Institute
NCT06198426 TERMINATED
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT05898854 COMPLETED
[68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer
Aalborg University Hospital
NCT06562673 COMPLETED
Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma
Shanghai 6th People's Hospital
NCT03993379 TERMINATED
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
NCT06322342 COMPLETED
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
NCT06391775 TERMINATED
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab
NCT05307874 COMPLETED
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
ImCheck Therapeutics
NCT03225547 TERMINATED
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
University of Chicago
NCT03290079 COMPLETED
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT02829918 COMPLETED
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
NCT03172624 COMPLETED
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
NCT04349267 COMPLETED
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT03534947 COMPLETED
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
Melanoma Institute Australia
NCT05001347 COMPLETED
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
NCT03310957 COMPLETED
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Seagen Inc.
NCT04004871 COMPLETED
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Guangxi Medical University
NCT04381650 COMPLETED
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Takeda
NCT05289830 TERMINATED
Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
Case Comprehensive Cancer Center
NCT03526679 COMPLETED
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
National Taiwan University Hospital
NCT04844073 TERMINATED
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Takeda
NCT05358704 SUSPENDED
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Rutgers, The State University of New Jersey
NCT05134948 COMPLETED
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04021043 COMPLETED
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
NCT03274258 TERMINATED
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
M.D. Anderson Cancer Center
NCT07069062 WITHDRAWN
A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
NCT06116578 WITHDRAWN
Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
Gustave Roussy, Cancer Campus, Grand Paris
NCT04276376 TERMINATED
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
Gustave Roussy, Cancer Campus, Grand Paris
NCT06924749 COMPLETED
Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia
Shandong Cancer Hospital and Institute
NCT06964165 TERMINATED
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Tesaro, Inc.
NCT05346380 COMPLETED
Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download
Massachusetts General Hospital
NCT05991349 COMPLETED
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT04725331 TERMINATED
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
NCT04370509 TERMINATED
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
NCT03498521 COMPLETED
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Hoffmann-La Roche
NCT03011372 COMPLETED
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Incyte Corporation
NCT03777813 COMPLETED
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
UNICANCER
NCT03369223 COMPLETED
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT06170190 COMPLETED
A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours
Innovent Biologics (Suzhou) Co. Ltd.
NCT05383482 COMPLETED
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
NCT05407311 COMPLETED
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Clarity Pharmaceuticals Ltd
NCT03797326 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Merck Sharp & Dohme LLC
NCT04106492 TERMINATED
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
NCT05935748 TERMINATED
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
NCT02576431 COMPLETED
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Bayer
NCT03656718 COMPLETED
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Bristol-Myers Squibb
NCT05119335 TERMINATED
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
NCT05194735 TERMINATED
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
NCT03280563 COMPLETED
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Hoffmann-La Roche
NCT05798611 TERMINATED
Study of ART0380 in Patients With Biologically Selected Solid Tumors
Artios Pharma Ltd
NCT02875548 COMPLETED
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
Epizyme, Inc.
NCT03822117 TERMINATED
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Incyte Corporation
NCT04668833 TERMINATED
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
M.D. Anderson Cancer Center
NCT04972110 TERMINATED
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors
Repare Therapeutics
NCT05169437 TERMINATED
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Tempus AI
NCT03575611 SUSPENDED
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT04208958 COMPLETED
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Vedanta Biosciences, Inc.
NCT05091346 COMPLETED
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
NCT02959437 TERMINATED
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
NCT02711137 TERMINATED
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
NCT03188432 COMPLETED
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Wake Forest University Health Sciences
NCT05613088 COMPLETED
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
NCT05027139 COMPLETED
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Jazz Pharmaceuticals
NCT03939689 COMPLETED
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Progenics Pharmaceuticals, Inc.
NCT05337735 SUSPENDED
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
NCT02285439 COMPLETED
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
NCT04616547 TERMINATED
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
National Cancer Institute (NCI)
NCT04447755 COMPLETED
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
Merck Sharp & Dohme LLC
NCT03755895 COMPLETED
Contribution of Hypnosis to Anxiety and Pain in Brachytherapy Patients
Institut de Cancérologie de Lorraine
NCT05407675 COMPLETED
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT03744468 COMPLETED
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
NCT04985604 TERMINATED
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT03680092 COMPLETED
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Dimitrios Tzachanis, MD PhD
NCT05326035 TERMINATED
A Study of WJ05129 in Advanced Malignant Solid Tumors
Suzhou Junjing BioSciences Co., Ltd.
NCT04260126 COMPLETED
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
PDS Biotechnology Corp.
NCT05510895 COMPLETED
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
AIO-Studien-gGmbH
NCT04257448 COMPLETED
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
GWT-TUD GmbH
NCT02843165 COMPLETED
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
University of California, San Diego
NCT03493945 COMPLETED
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
National Cancer Institute (NCI)
NCT05271604 COMPLETED
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BioAtla, Inc.
NCT05221320 TERMINATED
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
BioMed Valley Discoveries, Inc
NCT05821777 TERMINATED
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
Centessa Pharmaceuticals (UK) Limited
NCT02938793 TERMINATED
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Prisma Health-Upstate
NCT05980624 COMPLETED
ONS in Gastrointestinal Cancer Patients Undergoing Chemotherapy
Beni-Suef University
NCT03446040 TERMINATED
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT04784221 WITHDRAWN
Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse
Centre Francois Baclesse
NCT05036681 TERMINATED
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
NCT06242691 COMPLETED
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
Merck Sharp & Dohme LLC
NCT03711058 COMPLETED
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04278144 TERMINATED
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
NCT03195478 COMPLETED
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
NCT05678257 TERMINATED
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
NCT05161390 COMPLETED
Study of LM-302 in Patients With Advance Solid Tumors
LaNova Medicines Zhejiang Co., Ltd.
NCT04892342 COMPLETED
Study of ESG401 in Adults With Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
NCT05199753 COMPLETED
Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
LaNova Australia Pty Limited
NCT06690281 WITHDRAWN
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Cancer Institute (NCI)
NCT06226766 TERMINATED
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT03838367 TERMINATED
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
CytoDyn, Inc.
NCT02858310 COMPLETED
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Cancer Institute (NCI)
NCT03037437 COMPLETED
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The University of Texas Health Science Center at San Antonio
NCT04356170 COMPLETED
Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma
Groupe Oncologie Radiotherapie Tete et Cou
NCT03207555 COMPLETED
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
NCT02905578 COMPLETED
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
Joseph J. Cullen
NCT03977467 COMPLETED
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
SCRI Development Innovations, LLC
NCT05578872 COMPLETED
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Anaveon AG
NCT02923349 COMPLETED
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Biosciences International Sàrl
NCT05014828 COMPLETED
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
NCT05208177 TERMINATED
A Study of SHR-1802 in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT05259696 COMPLETED
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Palleon Pharmaceuticals, Inc.
NCT05109442 TERMINATED
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
NCT04080284 COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Northwell Health
NCT02807597 TERMINATED
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
Samuel Achilefu
NCT03126110 COMPLETED
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Biosciences International Sàrl
NCT05007106 COMPLETED
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Merck Sharp & Dohme LLC
NCT04611126 TERMINATED
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Inge Marie Svane
NCT03314935 COMPLETED
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
NCT01931098 COMPLETED
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Cancer Institute (NCI)
NCT04837196 COMPLETED
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Astellas Pharma Global Development, Inc.
NCT04141995 TERMINATED
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
NCT04717375 TERMINATED
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi
NCT04865731 COMPLETED
Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
NCT05949632 TERMINATED
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
NCT05980598 TERMINATED
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
Ascendis Pharma A/S
NCT03326193 COMPLETED
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
NCT05017246 TERMINATED
Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy
Washington University School of Medicine
NCT02205047 COMPLETED
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT05571293 SUSPENDED
Combination Immunotherapy in Colorectal Cancer
Weill Medical College of Cornell University
NCT02428712 COMPLETED
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
Fore Biotherapeutics
NCT02769962 COMPLETED
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03909152 COMPLETED
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Memorial Sloan Kettering Cancer Center
NCT04729348 TERMINATED
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Massachusetts General Hospital
NCT06024174 TERMINATED
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
NCT04381832 COMPLETED
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
NCT05714553 TERMINATED
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
NCT04923529 COMPLETED
TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
The University of Hong Kong
NCT04247282 COMPLETED
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
National Cancer Institute (NCI)
NCT03574779 COMPLETED
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
Tesaro, Inc.
NCT04577963 TERMINATED
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
NCT06498518 WITHDRAWN
A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
Karen Carty
NCT05879484 WITHDRAWN
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
National Cancer Institute (NCI)
NCT02836548 COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
The Netherlands Cancer Institute
NCT02611024 COMPLETED
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
NCT04330781 COMPLETED
Radiotherapy of Head and Neck Cancer Using an Intraoral Stent
Oslo University Hospital
NCT05159388 COMPLETED
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
Servier Bio-Innovation LLC
NCT06926673 COMPLETED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
GlaxoSmithKline
NCT04455620 TERMINATED
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
BioNTech SE
NCT03440437 TERMINATED
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
invoX Pharma Limited
NCT04926324 TERMINATED
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
University of Iowa
NCT03081858 COMPLETED
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
NCT03519295 COMPLETED
A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT03357757 COMPLETED
Avelumab With Valproic Acid in Virus-associated Cancer
AHS Cancer Control Alberta
NCT02601950 COMPLETED
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
Epizyme, Inc.
NCT02432378 TERMINATED
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
NCT05161572 TERMINATED
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
Fudan University
NCT05188729 COMPLETED
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
NCT06728657 SUSPENDED
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma
Fudan University
NCT03013491 TERMINATED
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
CytomX Therapeutics
NCT03739710 COMPLETED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
NCT05253053 COMPLETED
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT06067061 TERMINATED
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Institut Curie
NCT03783949 COMPLETED
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
Universitaire Ziekenhuizen KU Leuven
NCT06087289 COMPLETED
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Novakand Pharma AB
NCT02520154 COMPLETED
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
NCT06592664 WITHDRAWN
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
Lisata Therapeutics, Inc.
NCT04902040 TERMINATED
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
NCT03314805 COMPLETED
PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
PhytoHealth Corporation
NCT03611712 COMPLETED
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
PhytoHealth Corporation
NCT06790303 TERMINATED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
NCT03037385 COMPLETED
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Hoffmann-La Roche
NCT04821765 COMPLETED
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04393298 COMPLETED
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Biopharma SRL
NCT05481463 COMPLETED
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
Sun Yat-sen University
NCT03108131 COMPLETED
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
NCT04671901 TERMINATED
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT05840770 WITHDRAWN
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
NCT02713386 COMPLETED
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
NCT02329847 COMPLETED
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Janssen Research & Development, LLC
NCT04442126 TERMINATED
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
NCT02494258 COMPLETED
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
NCT03406299 COMPLETED
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
National Health Research Institutes, Taiwan
NCT04347226 TERMINATED
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
Columbia University
NCT03416153 COMPLETED
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
University of Michigan Rogel Cancer Center
NCT02799095 COMPLETED
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Mural Oncology, Inc
NCT02899078 COMPLETED
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
University of California, Davis
NCT02595905 COMPLETED
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
NCT03274414 COMPLETED
A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
Memorial Sloan Kettering Cancer Center
NCT05972720 TERMINATED
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
CARGO Therapeutics
NCT03618641 COMPLETED
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
Diwakar Davar
NCT04914286 COMPLETED
A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
NCT04383938 COMPLETED
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Aprea Therapeutics
NCT05311176 TERMINATED
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
Imugene Limited
NCT03570619 COMPLETED
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
University of Michigan Rogel Cancer Center
NCT04579757 TERMINATED
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
NCT04420689 COMPLETED
Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Alume Biosciences, Inc.
NCT04642287 WITHDRAWN
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
NCT04329221 WITHDRAWN
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
NCT04203641 TERMINATED
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Helix BioPharma Corporation
NCT05251233 TERMINATED
Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Washington University School of Medicine
NCT05388435 TERMINATED
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
SK Life Science, Inc.
NCT05830539 COMPLETED
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
InxMed (Shanghai) Co., Ltd.
NCT02632448 COMPLETED
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
NCT04479514 COMPLETED
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
Dana-Farber Cancer Institute
NCT03050879 COMPLETED
Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection
Fujian Medical University
NCT03110107 TERMINATED
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04491955 COMPLETED
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
National Cancer Institute (NCI)
NCT02566304 COMPLETED
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03472586 COMPLETED
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04514692 TERMINATED
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
Stanford University
NCT03428958 COMPLETED
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
NCT04552990 COMPLETED
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT05435339 TERMINATED
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
Genmab
NCT04875806 TERMINATED
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT02913313 COMPLETED
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT03523351 COMPLETED
Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain
Memorial Sloan Kettering Cancer Center
NCT04704154 COMPLETED
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
NCT04925986 TERMINATED
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Sarah Goldberg
NCT03314324 COMPLETED
A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT03242616 COMPLETED
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Seoul National University Hospital
NCT03735095 TERMINATED
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
Roswell Park Cancer Institute
NCT05217069 COMPLETED
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
NCT02795988 COMPLETED
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
NCT02487095 COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Cancer Institute (NCI)
NCT04720976 COMPLETED
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
NCT03690869 TERMINATED
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
NCT03179436 COMPLETED
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Merck Sharp & Dohme LLC
NCT05126342 WITHDRAWN
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
NCT03903705 COMPLETED
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Hutchmed
NCT04383210 TERMINATED
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
NCT04180761 WITHDRAWN
Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
University Hospital Tuebingen
NCT03459222 COMPLETED
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT03733990 COMPLETED
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Faron Pharmaceuticals Ltd
NCT03829501 TERMINATED
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
NCT05963386 COMPLETED
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
The First Affiliated Hospital of Xiamen University
NCT04084366 TERMINATED
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
OBI Pharma, Inc
NCT04716634 COMPLETED
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
NCT02272998 COMPLETED
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Sameek Roychowdhury
NCT03024437 TERMINATED
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Roberto Pili
NCT02684227 COMPLETED
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
M.D. Anderson Cancer Center
NCT05315999 COMPLETED
Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care
Gerhild Becker
NCT04256707 COMPLETED
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
Karyopharm Therapeutics Inc
NCT05223088 COMPLETED
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Fujian Cancer Hospital
NCT05543629 TERMINATED
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
NCT04101357 TERMINATED
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
BioNTech SE
NCT06083662 COMPLETED
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Korea University Guro Hospital
NCT02694822 COMPLETED
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Agenus Inc.
NCT06257758 TERMINATED
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Valerio Therapeutics
NCT04761198 COMPLETED
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
NCT02489903 COMPLETED
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
NCT04172506 COMPLETED
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
Akeso
NCT03158129 COMPLETED
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03838263 COMPLETED
Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
UNICANCER
NCT02535338 COMPLETED
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05126433 TERMINATED
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Jazz Pharmaceuticals
NCT03744676 COMPLETED
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
NCT03250676 COMPLETED
Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Eisai Inc.
NCT03659136 COMPLETED
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Boehringer Ingelheim
NCT04804696 TERMINATED
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
NCT03647423 WITHDRAWN
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
ImmunityBio, Inc.
NCT04357873 COMPLETED
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
UNICANCER
NCT05559541 TERMINATED
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Akeso
NCT04718675 TERMINATED
A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)
Kronos Bio
NCT03691493 COMPLETED
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
Emory University
NCT05580770 TERMINATED
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
NCT05188664 COMPLETED
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
LaNova Australia Pty Limited
NCT03822936 TERMINATED
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
CNAO National Center of Oncological Hadrontherapy
NCT04162873 TERMINATED
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
NCT04666688 COMPLETED
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
NCT04230408 COMPLETED
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers
Latin American Cooperative Oncology Group
NCT03662659 COMPLETED
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
NCT04016142 TERMINATED
Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer
Centre Oscar Lambret
NCT04574583 COMPLETED
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
National Cancer Institute (NCI)
NCT02780700 TERMINATED
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Boehringer Ingelheim
NCT05497453 TERMINATED
A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene
Omega Therapeutics
NCT02533765 COMPLETED
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02819843 COMPLETED
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT04492033 TERMINATED
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
NCT03674567 COMPLETED
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
NCT04350463 COMPLETED
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Celgene
NCT03127007 COMPLETED
Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer
Grand Hôpital de Charleroi
NCT06782022 COMPLETED
DPD Guided 5-FU Precision Treatment in Gastro-intestinal Cancer Patients
Jan Gerard Maring
NCT04535414 COMPLETED
Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
National Cancer Institute (NCI)
NCT03891576 TERMINATED
Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
Mario Negri Institute for Pharmacological Research
NCT03518606 COMPLETED
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
UNICANCER
NCT04622774 COMPLETED
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
ImmunoGen, Inc.
NCT02761057 COMPLETED
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
NCT03314740 COMPLETED
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
Mario Negri Institute for Pharmacological Research
NCT03477175 COMPLETED
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Eisai Inc.
NCT04271436 WITHDRAWN
Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT
Washington University School of Medicine
NCT05007613 COMPLETED
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
NCT04791228 WITHDRAWN
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
NCT05302921 COMPLETED
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
NCT03535727 COMPLETED
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03950570 COMPLETED
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Orinove, Inc.
NCT05456165 WITHDRAWN
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
NCT03601897 TERMINATED
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
NCT02573493 COMPLETED
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Washington University School of Medicine
NCT05663801 COMPLETED
Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy
Beni-Suef University
NCT03717415 TERMINATED
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
NCT04731467 COMPLETED
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Famewave Ltd.
NCT06331598 WITHDRAWN
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
Hoffmann-La Roche
NCT03084536 COMPLETED
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Washington University School of Medicine
NCT05500508 TERMINATED
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
NCT03946358 COMPLETED
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
Centre Hospitalier Universitaire de Besancon
NCT04029688 TERMINATED
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
NCT04534218 COMPLETED
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
Centre Hospitalier Universitaire de Besancon
NCT02861300 COMPLETED
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
David Bajor, MD
NCT06524804 TERMINATED
A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
NCT04214418 TERMINATED
Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Columbia University
NCT04789668 COMPLETED
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT04020185 COMPLETED
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
ImmuneSensor Therapeutics Inc.
NCT04939701 TERMINATED
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Astellas Pharma Global Development, Inc.
NCT04168528 COMPLETED
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Universitair Ziekenhuis Brussel
NCT02362464 COMPLETED
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
National Cancer Institute (NCI)
NCT03316638 TERMINATED
A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors
Pierre Fabre Medicament
NCT06290388 TERMINATED
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
23andMe, Inc.
NCT05000372 COMPLETED
68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy
Peking University Cancer Hospital & Institute
NCT05060471 COMPLETED
PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
Sun Yat-sen University
NCT05328973 COMPLETED
Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial
M.D. Anderson Cancer Center
NCT03009058 TERMINATED
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
Immodulon Therapeutics Ltd
NCT04918810 TERMINATED
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
NCT03631407 COMPLETED
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
Merck Sharp & Dohme LLC
NCT05525455 TERMINATED
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
Teon Therapeutics, Inc.
NCT05416749 SUSPENDED
A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT03248570 COMPLETED
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
NCT03015740 COMPLETED
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
NCT05261490 TERMINATED
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
NCT03648372 TERMINATED
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda
NCT02561455 COMPLETED
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Astellas Pharma Global Development, Inc.
NCT03769467 TERMINATED
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
NCT04933227 TERMINATED
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Hoffmann-La Roche
NCT05394350 TERMINATED
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
Merck Sharp & Dohme LLC
NCT01969578 COMPLETED
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT04493619 TERMINATED
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Opna Bio LLC
NCT04580836 WITHDRAWN
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
M.D. Anderson Cancer Center
NCT05610826 WITHDRAWN
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
University of Chicago
NCT03379259 TERMINATED
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
NCT04068519 COMPLETED
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
BeiGene
NCT04690699 TERMINATED
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
Istari Oncology, Inc.
NCT04987281 WITHDRAWN
Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study
M.D. Anderson Cancer Center
NCT05589857 WITHDRAWN
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use
M.D. Anderson Cancer Center
NCT02860039 COMPLETED
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
NCT03843775 COMPLETED
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Memorial Sloan Kettering Cancer Center
NCT06648902 COMPLETED
Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue
Kidney Cancer Research Bureau
NCT03973333 WITHDRAWN
Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Immunocore Ltd
NCT03204812 COMPLETED
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT03592264 TERMINATED
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
OBI Pharma, Inc
NCT03164993 COMPLETED
Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer
Oslo University Hospital
NCT03207867 TERMINATED
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis Pharmaceuticals
NCT03714828 COMPLETED
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
University of Arizona
NCT02187991 COMPLETED
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
US Oncology Research
NCT04536077 TERMINATED
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Washington University School of Medicine
NCT04683939 TERMINATED
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
NCT05249127 COMPLETED
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Clarity Pharmaceuticals Ltd
NCT05397171 TERMINATED
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
AstraZeneca
NCT04174716 COMPLETED
Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS)
Idience Co., Ltd.
NCT03869762 TERMINATED
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
Cancer Trials Ireland
NCT02264210 COMPLETED
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Sun Yat-sen University
NCT03565003 COMPLETED
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Jacobio Pharmaceuticals Co., Ltd.
NCT03648489 COMPLETED
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Imperial College London
NCT03475004 COMPLETED
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
University of Colorado, Denver
NCT04474470 COMPLETED
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
TyrNovo Ltd.
NCT04945733 TERMINATED
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Janssen Pharmaceutical K.K.
NCT04065139 COMPLETED
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study
Assistance Publique - Hôpitaux de Paris
NCT04721223 COMPLETED
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT05824455 TERMINATED
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
NCT03422536 COMPLETED
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
NCT04752358 TERMINATED
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
Adaptimmune
NCT03003195 WITHDRAWN
The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients
University of Arkansas
NCT06438614 COMPLETED
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma
Fundació Sant Joan de Déu
NCT02875613 TERMINATED
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
Assuntina Sacco, M.D.
NCT03473925 COMPLETED
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
Merck Sharp & Dohme LLC
NCT03693612 COMPLETED
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
NCT04847050 COMPLETED
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Cancer Institute (NCI)
NCT03219333 COMPLETED
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Astellas Pharma Inc
NCT06105008 WITHDRAWN
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
RemeGen Co., Ltd.
NCT04946864 SUSPENDED
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Ascentage Pharma Group Inc.
NCT06110598 WITHDRAWN
CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
Case Comprehensive Cancer Center
NCT04770688 COMPLETED
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
Shanghai Chest Hospital
NCT04645069 COMPLETED
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
Adagene Inc
NCT02773238 COMPLETED
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
University of Washington
NCT06065059 TERMINATED
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Tango Therapeutics, Inc.
NCT03181035 SUSPENDED
Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer
Sunnybrook Health Sciences Centre
NCT05001282 TERMINATED
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
NCT04534283 TERMINATED
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Anita Turk
NCT02649855 COMPLETED
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Cancer Institute (NCI)
NCT04121442 COMPLETED
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
Buzzard Pharmaceuticals
NCT05898828 WITHDRAWN
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
National Cancer Institute (NCI)
NCT03852251 COMPLETED
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Akeso
NCT05574504 WITHDRAWN
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
AdventHealth
NCT03423264 WITHDRAWN
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
University of Chicago
NCT04931420 WITHDRAWN
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
University of Chicago
NCT03323398 TERMINATED
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
NCT02554812 TERMINATED
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Pfizer
NCT03339635 COMPLETED
Short-term Testosterone Replacement in Testicular Cancer Survivors
University Medical Center Groningen
NCT03513952 COMPLETED
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
NCT04408599 TERMINATED
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT04393454 TERMINATED
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Albert Einstein College of Medicine
NCT02024009 COMPLETED
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
University of Oxford
NCT06084845 WITHDRAWN
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
NCT02923934 COMPLETED
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Olivia Newton-John Cancer Research Institute
NCT04570839 COMPLETED
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Compugen Ltd
NCT03759600 COMPLETED
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
Takeda
NCT02842580 TERMINATED
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
NCT02384759 COMPLETED
Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
Federation Francophone de Cancerologie Digestive
NCT03439085 TERMINATED
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
NCT03802123 COMPLETED
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
ImaginAb, Inc.
NCT04111107 TERMINATED
Precision Medicine for Patients With Identified Actionable Mutations
Wake Forest University Health Sciences
NCT04541355 COMPLETED
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
Hyunseok Kang, MD
NCT04856774 COMPLETED
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT02490800 COMPLETED
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Basilea Pharmaceutica
NCT04518852 COMPLETED
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Sichuan Cancer Hospital and Research Institute
NCT05905614 COMPLETED
Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
NCT02606305 COMPLETED
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
NCT04161391 TERMINATED
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
NCT05531422 COMPLETED
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Lee's Pharmaceutical Limited
NCT06454071 COMPLETED
Immunologic Changes and Recovery-related Factors in Elderly Colon Cancer Patients
Soonchunhyang University Hospital
NCT05153304 WITHDRAWN
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
University of California, San Diego
NCT05093322 COMPLETED
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
NCT03759587 COMPLETED
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
Takeda
NCT02759835 COMPLETED
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
National Cancer Institute (NCI)
NCT06446570 COMPLETED
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Seoul National University Hospital
NCT05160168 TERMINATED
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals
NCT04488003 TERMINATED
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
BioMed Valley Discoveries, Inc
NCT02902484 TERMINATED
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
University of Texas Southwestern Medical Center
NCT04319224 TERMINATED
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
Jounce Therapeutics, Inc.
NCT03416335 TERMINATED
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
NCT03126812 COMPLETED
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
The Netherlands Cancer Institute
NCT04618393 TERMINATED
A Study of EMB-02 in Participants With Advanced Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.
NCT05807542 COMPLETED
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
Shanghai Zhongshan Hospital
NCT04207918 COMPLETED
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT03093155 COMPLETED
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
NCT05493995 COMPLETED
A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT04396886 COMPLETED
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
The University of Hong Kong
NCT03127215 COMPLETED
Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
National Center for Tumor Diseases, Heidelberg
NCT05716295 TERMINATED
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
Medikine, Inc.
NCT02624388 TERMINATED
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
University of Virginia
NCT03044795 WITHDRAWN
Response to PARP Inhibitor Predicted by the RAD51 Assay
University Medical Center Groningen
NCT03035357 WITHDRAWN
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
M.D. Anderson Cancer Center
NCT04738292 TERMINATED
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
NCT03077243 COMPLETED
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
NCT02718300 TERMINATED
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Incyte Corporation
NCT03572387 COMPLETED
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
NCT05900648 WITHDRAWN
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
M.D. Anderson Cancer Center
NCT04742959 COMPLETED
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT04927910 TERMINATED
Self-applied Acupressure for Arthralgia-fatigue-sleep Disturbance in Breast Cancer
The Hong Kong Polytechnic University
NCT02705105 COMPLETED
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin, Inc.
NCT04808362 TERMINATED
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
Peptomyc S.L.
NCT05538624 TERMINATED
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Avenge Bio, Inc
NCT02798029 COMPLETED
Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT03311334 TERMINATED
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT05581719 TERMINATED
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Enlivex Therapeutics RDO Ltd.
NCT03272477 COMPLETED
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
Palleos Healthcare GmbH
NCT03257631 COMPLETED
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
NCT04001075 COMPLETED
Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors
TJ Biopharma Co., Ltd.
NCT05148533 TERMINATED
A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor
TJ Biopharma Co., Ltd.
NCT02920996 TERMINATED
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
Dana-Farber Cancer Institute
NCT02340884 COMPLETED
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Seattle Children's Hospital
NCT04669899 COMPLETED
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
Jounce Therapeutics, Inc.
NCT03861156 COMPLETED
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
InventisBio Co., Ltd
NCT04430036 TERMINATED
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
NCT03890731 COMPLETED
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
NCT02325557 COMPLETED
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Advaxis, Inc.
NCT05071183 TERMINATED
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
NCT03007979 COMPLETED
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Washington University School of Medicine
NCT05067257 SUSPENDED
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Sorrento Therapeutics, Inc.
NCT03110159 COMPLETED
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
Medical Dermatology Specialists
NCT04172597 TERMINATED
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
Spectrum Pharmaceuticals, Inc
NCT03342937 COMPLETED
KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
Duke University
NCT05148195 TERMINATED
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT03665285 COMPLETED
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
NCT03861793 COMPLETED
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Mural Oncology, Inc
NCT05099549 TERMINATED
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
NKGen Biotech, Inc.
NCT03012581 COMPLETED
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
UNICANCER
NCT02359968 COMPLETED
PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer
Centre Oscar Lambret
NCT03012620 COMPLETED
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
UNICANCER
NCT03709706 TERMINATED
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
GlaxoSmithKline
NCT05357898 TERMINATED
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
NCT03461952 TERMINATED
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
Canadian Cancer Trials Group
NCT03573544 TERMINATED
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
OBI Pharma, Inc
NCT02830594 COMPLETED
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
NCT04814875 TERMINATED
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
NCT04337931 TERMINATED
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Apexigen America, Inc.
NCT03393858 TERMINATED
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Capital Medical University
NCT03360630 COMPLETED
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
Capital Medical University
NCT03834220 TERMINATED
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Debiopharm International SA
NCT03559543 COMPLETED
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
Catalysis SL
NCT04071756 TERMINATED
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Dana-Farber Cancer Institute
NCT04310410 COMPLETED
Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis
UMC Utrecht
NCT03651271 COMPLETED
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
Parker Institute for Cancer Immunotherapy
NCT03190811 COMPLETED
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
Capital Medical University
NCT05430555 TERMINATED
A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors
T-knife GmbH
NCT04694183 COMPLETED
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
Quan Wang
NCT03549494 COMPLETED
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Catalysis SL
NCT03757858 COMPLETED
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Capital Medical University
NCT05100316 TERMINATED
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
GlaxoSmithKline
NCT02478502 TERMINATED
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer
University Hospital, Akershus
NCT04250805 TERMINATED
Trial Evaluating the Efficacy of the Combination of ROpivacaine With Reference XYlocaine in the Evaluation of Pain During the Installation of Percutaneous Radiological GASTrostomy
Centre Hospitalier Universitaire de Saint Etienne
NCT03698461 COMPLETED
Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab
Asan Medical Center
NCT02399410 COMPLETED
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis
University Hospital, Ghent
NCT05074472 COMPLETED
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
ZielBio, Inc.
NCT05331131 WITHDRAWN
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial
Northwell Health
NCT04092179 TERMINATED
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
University Health Network, Toronto
NCT03543813 COMPLETED
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
CytomX Therapeutics
NCT03297359 TERMINATED
WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism
Ottawa Hospital Research Institute
NCT04596150 COMPLETED
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
CytomX Therapeutics
NCT02829723 TERMINATED
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Novartis Pharmaceuticals
NCT05154630 TERMINATED
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT03992131 TERMINATED
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
pharmaand GmbH
NCT02865135 COMPLETED
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Dana-Farber Cancer Institute
NCT02915523 COMPLETED
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
NCT04508400 COMPLETED
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
Sun Yat-sen University
NCT03149549 TERMINATED
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
CytomX Therapeutics
NCT04999605 TERMINATED
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Akeso
NCT03749460 COMPLETED
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
NCT03123783 COMPLETED
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Apexigen America, Inc.
NCT04634825 TERMINATED
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
MacroGenics
NCT05363605 TERMINATED
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
NCT04405349 COMPLETED
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
Nykode Therapeutics ASA
NCT02318784 COMPLETED
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC
NCT02859064 TERMINATED
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
NCT02363374 COMPLETED
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
Prof. Dr. med. Claus Rödel
NCT03458728 TERMINATED
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Bayer
NCT03367923 COMPLETED
Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors
Stanford University
NCT02567253 COMPLETED
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
University Hospital, Ghent
NCT03531320 COMPLETED
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
InnoPharmax Inc.
NCT02258451 COMPLETED
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
NCT02285543 TERMINATED
A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
Shanghai Jiao Tong University School of Medicine
NCT03735589 WITHDRAWN
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
NCT03684811 COMPLETED
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Forma Therapeutics, Inc.
NCT03618134 TERMINATED
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Jonsson Comprehensive Cancer Center
NCT02432690 TERMINATED
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
Sumitomo Pharma America, Inc.
NCT02488759 COMPLETED
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
Bristol-Myers Squibb
NCT03649321 TERMINATED
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
NCT04166383 COMPLETED
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
National Cancer Institute (NCI)
NCT02834975 TERMINATED
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
NCT03260712 COMPLETED
Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT05120622 WITHDRAWN
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
University of British Columbia
NCT02484443 COMPLETED
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
National Cancer Institute (NCI)
NCT03649841 TERMINATED
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
NCT05255484 TERMINATED
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours
LaNova Medicines Limited
NCT03206073 COMPLETED
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
National Cancer Institute (NCI)
NCT04246489 COMPLETED
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
EMD Serono Research & Development Institute, Inc.
NCT03003637 COMPLETED
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
The Netherlands Cancer Institute
NCT04288518 COMPLETED
Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.
Tomsk National Research Medical Center of the Russian Academy of Sciences
NCT03274661 COMPLETED
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Baptist Health South Florida
NCT04666623 WITHDRAWN
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
University Hospital, Basel, Switzerland
NCT06090318 WITHDRAWN
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
NCT03366103 TERMINATED
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
National Cancer Institute (NCI)
NCT03468985 COMPLETED
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03308942 COMPLETED
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
NCT03054909 COMPLETED
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
Masonic Cancer Center, University of Minnesota
NCT03330405 TERMINATED
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
NCT02248597 COMPLETED
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
Wake Forest University Health Sciences
NCT04455139 TERMINATED
A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
Prof. Beck Popovic Maja
NCT02272790 COMPLETED
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AstraZeneca
NCT04259658 COMPLETED
Histopathologic Effect of Calcium Electroporation on Cancer in the Skin
Zealand University Hospital
NCT04171700 TERMINATED
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
pharmaand GmbH
NCT04471818 COMPLETED
Ketamine or Placebo in Patients With Major Depression and Advanced Cancer
Instituto Nacional de Cancerologia de Mexico
NCT03565991 TERMINATED
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Pfizer
NCT03186638 COMPLETED
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
University of Rochester NCORP Research Base
NCT03803761 WITHDRAWN
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
National Cancer Institute (NCI)
NCT04534738 COMPLETED
The Effect of a Mediterranean Diet Intervention on Cancer-related Fatigue and Mitochondrial Function During Chemotherapy
University of Rochester
NCT02971956 COMPLETED
Pembrolizumab in Refractory Advanced Esophageal Cancer
Dana-Farber Cancer Institute
NCT03686332 COMPLETED
PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study
The Netherlands Cancer Institute
NCT04521179 COMPLETED
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT04346381 COMPLETED
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT05284214 WITHDRAWN
Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors
Partner Therapeutics, Inc.
NCT05435053 TERMINATED
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
Ismail Gögenur
NCT03953235 COMPLETED
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
Gritstone bio, Inc.
NCT04538950 COMPLETED
PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
Mayo Clinic
NCT05535023 WITHDRAWN
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
M.D. Anderson Cancer Center
NCT03860207 TERMINATED
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
Y-mAbs Therapeutics
NCT03245151 COMPLETED
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
NCT02658890 COMPLETED
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT03180684 COMPLETED
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Inovio Pharmaceuticals
NCT04566133 TERMINATED
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Cancer Institute (NCI)
NCT03682055 TERMINATED
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
NCT03882203 COMPLETED
CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia
Shanghai Jiao Tong University School of Medicine
NCT03636256 COMPLETED
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NanOlogy, LLC
NCT04398368 TERMINATED
Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study
Mayo Clinic
NCT04644315 TERMINATED
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Hoffmann-La Roche
NCT03926143 TERMINATED
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Bayer
NCT04157088 TERMINATED
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Bayer
NCT03602079 COMPLETED
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
NCT03520842 COMPLETED
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Stanford University
NCT02499835 COMPLETED
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
NCT02988817 COMPLETED
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
NCT02506517 COMPLETED
A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene
University Health Network, Toronto
NCT05190575 COMPLETED
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
NCT04424641 TERMINATED
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Genmab
NCT03572582 COMPLETED
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
AIO-Studien-gGmbH
NCT02478320 TERMINATED
Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
M.D. Anderson Cancer Center
NCT05109052 WITHDRAWN
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
University of Rochester
NCT05191004 WITHDRAWN
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Nuvation Bio Inc.
NCT03283488 COMPLETED
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
University of Sao Paulo
NCT05116891 COMPLETED
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
NCT02904226 COMPLETED
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Jounce Therapeutics, Inc.
NCT05216120 WITHDRAWN
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
HonorHealth Research Institute
NCT02579811 COMPLETED
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
NCT03690921 COMPLETED
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
M.D. Anderson Cancer Center
NCT02784288 COMPLETED
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
University of Michigan Rogel Cancer Center
NCT02640534 TERMINATED
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
Swiss Cancer Institute
NCT03989115 COMPLETED
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
NCT04194034 TERMINATED
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
Transgene
NCT02797977 COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Sierra Oncology LLC - a GSK company
NCT05159778 COMPLETED
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
HiberCell, Inc.
NCT02797964 COMPLETED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
Sierra Oncology LLC - a GSK company
NCT03428126 COMPLETED
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
M.D. Anderson Cancer Center
NCT04471415 TERMINATED
Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
Dracen Pharmaceuticals, Inc.
NCT04122625 COMPLETED
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
Debiopharm International SA
NCT03824704 TERMINATED
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
NCT02440685 TERMINATED
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
NCT05582031 WITHDRAWN
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
Translational Research in Oncology
NCT04510584 WITHDRAWN
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
University Health Network, Toronto
NCT03020823 TERMINATED
To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer
SynCore Biotechnology Co., Ltd.
NCT03637803 TERMINATED
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
4D pharma plc
NCT03519256 TERMINATED
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
Bristol-Myers Squibb
NCT02344810 WITHDRAWN
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
Eastern Cooperative Oncology Group
NCT04603365 WITHDRAWN
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
NCT03970070 COMPLETED
Perioperative Ostomy Self-Management Telehealth for Cancer Patients and Family Caregivers
City of Hope Medical Center
NCT02643550 COMPLETED
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Innate Pharma
NCT02895360 COMPLETED
Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Basilea Pharmaceutica
NCT04291300 COMPLETED
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
Radboud University Medical Center
NCT03657043 COMPLETED
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
Seagen Inc.
NCT02297139 COMPLETED
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Bristol-Myers Squibb
NCT03469284 COMPLETED
MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
M.D. Anderson Cancer Center
NCT04775680 TERMINATED
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
Adagene (Suzhou) Limited
NCT04696848 TERMINATED
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
Tae Won Kim
NCT02932332 COMPLETED
High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
M.D. Anderson Cancer Center
NCT02426892 COMPLETED
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
M.D. Anderson Cancer Center
NCT03410030 COMPLETED
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
HonorHealth Research Institute
NCT03180476 COMPLETED
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute
NCT03841760 TERMINATED
SUV on PSMA PET/CT in Non-Prostate Tumors
Sir Mortimer B. Davis - Jewish General Hospital
NCT03577704 COMPLETED
The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.
Shanghai Henlius Biotech
NCT03712397 COMPLETED
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
National Health Research Institutes, Taiwan
NCT02992743 COMPLETED
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
GlaxoSmithKline
NCT04489940 TERMINATED
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
EMD Serono Research & Development Institute, Inc.
NCT03073525 COMPLETED
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
Gradalis, Inc.
NCT02754141 COMPLETED
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
Bristol-Myers Squibb
NCT04208334 COMPLETED
The Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Patients With Stage III-IV of Head and Neck Cancer
Phramongkutklao College of Medicine and Hospital
NCT03427411 COMPLETED
M7824 in Subjects With HPV Associated Malignancies
National Cancer Institute (NCI)
NCT02821754 COMPLETED
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Cancer Institute (NCI)
NCT03717298 COMPLETED
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
Catalysis SL
NCT02872701 COMPLETED
OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
On Target Laboratories, LLC
NCT04730349 TERMINATED
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Bristol-Myers Squibb
NCT02970500 TERMINATED
Effect of Methylphenidate on Cancer-related Cognitive Impairment
CHU de Quebec-Universite Laval
NCT03616834 COMPLETED
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Effector Therapeutics
NCT02291055 TERMINATED
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
Advaxis, Inc.
NCT02399813 COMPLETED
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Advaxis, Inc.
NCT05010525 TERMINATED
A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Shanghai Antengene Corporation Limited
NCT02659384 COMPLETED
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT05008445 TERMINATED
Study of LM-102 in Patients With Advance Solid Tumors
LaNova Medicines Development Co., Ltd.
NCT04749602 COMPLETED
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Kidney Cancer Research Bureau
NCT02598960 COMPLETED
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
Bristol-Myers Squibb
NCT02454972 COMPLETED
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
PharmaMar
NCT04169672 COMPLETED
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Hutchison Medipharma Limited
NCT03251924 TERMINATED
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
NCT05419817 WITHDRAWN
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
Haider Mahdi
NCT05222165 WITHDRAWN
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
Helsinn Healthcare SA
NCT03356223 COMPLETED
Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6
Centre Leon Berard
NCT03437200 TERMINATED
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT03121534 TERMINATED
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
M.D. Anderson Cancer Center
NCT02756364 COMPLETED
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
Calithera Biosciences, Inc
NCT04592484 COMPLETED
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
Codiak BioSciences
NCT03614728 TERMINATED
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
GlaxoSmithKline
NCT03043729 COMPLETED
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
AIO-Studien-gGmbH
NCT03193931 TERMINATED
Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers
AIO-Studien-gGmbH
NCT04510285 TERMINATED
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
NCT04518137 TERMINATED
A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)
Shanghai Antengene Corporation Limited
NCT03477019 COMPLETED
Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer
St. Olavs Hospital
NCT05553808 COMPLETED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
GlaxoSmithKline
NCT04657315 COMPLETED
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
CHA University
NCT03582618 TERMINATED
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
NCT02393248 TERMINATED
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
NCT03617913 COMPLETED
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
NCT02759588 COMPLETED
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
NCT02963831 COMPLETED
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Ludwig Institute for Cancer Research
NCT04515394 TERMINATED
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
EMD Serono Research & Development Institute, Inc.
NCT04042116 SUSPENDED
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Clovis Oncology, Inc.
NCT04851834 TERMINATED
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
NCT03873493 COMPLETED
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
AbbVie
NCT02996110 COMPLETED
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
Bristol-Myers Squibb
NCT03258008 TERMINATED
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
M.D. Anderson Cancer Center
NCT04372706 TERMINATED
RTX-240 Monotherapy and in Combination With Pembrolizumab
Rubius Therapeutics
NCT04481009 COMPLETED
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT02762981 COMPLETED
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
NCT04251949 COMPLETED
Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis.
Centre Oscar Lambret
NCT02643303 COMPLETED
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
NCT04866056 TERMINATED
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT02657889 COMPLETED
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Tesaro, Inc.
NCT03980041 COMPLETED
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
Infinity Pharmaceuticals, Inc.
NCT02343549 TERMINATED
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
NCT02612194 TERMINATED
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Wake Forest University Health Sciences
NCT02387996 COMPLETED
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
Bristol-Myers Squibb
NCT03101566 COMPLETED
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
University of Michigan Rogel Cancer Center
NCT02489448 COMPLETED
Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
Yale University
NCT02593786 COMPLETED
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
NCT02873975 COMPLETED
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
Dana-Farber Cancer Institute
NCT04928820 TERMINATED
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
Jonsson Comprehensive Cancer Center
NCT04547101 TERMINATED
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
Akeso
NCT02866006 COMPLETED
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
Cellid Co., Ltd.
NCT04172454 COMPLETED
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
Akeso
NCT03287375 COMPLETED
Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy -
Michael Bau Mortensen
NCT03781778 TERMINATED
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
Fred Hutchinson Cancer Center
NCT04333914 COMPLETED
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
Centre Leon Berard
NCT03085914 COMPLETED
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
NCT03965845 COMPLETED
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
NCT02639546 COMPLETED
Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Hoffmann-La Roche
NCT02354586 COMPLETED
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Tesaro, Inc.
NCT05041972 WITHDRAWN
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Ambrx, Inc.
NCT02865811 COMPLETED
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Dana-Farber Cancer Institute
NCT03989362 COMPLETED
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
Jounce Therapeutics, Inc.
NCT03955471 TERMINATED
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
Tesaro, Inc.
NCT03455140 COMPLETED
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
University of Birmingham
NCT02341625 TERMINATED
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Bristol-Myers Squibb
NCT02141906 COMPLETED
A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin
University of Texas Southwestern Medical Center
NCT03325166 TERMINATED
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
OHSU Knight Cancer Institute
NCT04075604 COMPLETED
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Bristol-Myers Squibb
NCT03287947 TERMINATED
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Wake Forest University Health Sciences
NCT04447235 TERMINATED
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
Instituto do Cancer do Estado de São Paulo
NCT03130959 COMPLETED
A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies
Bristol-Myers Squibb
NCT05191017 WITHDRAWN
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
Nuvation Bio Inc.
NCT03524820 TERMINATED
Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
Hadassah Medical Organization
NCT02404441 COMPLETED
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Novartis Pharmaceuticals
NCT05263609 WITHDRAWN
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
NCT04001413 WITHDRAWN
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02700308 TERMINATED
A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases
Centre Leon Berard
NCT03843853 WITHDRAWN
Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT04315246 WITHDRAWN
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Y-mAbs Therapeutics
NCT04080843 COMPLETED
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
Zhejiang University
NCT03531827 TERMINATED
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
National Cancer Institute (NCI)
NCT02499952 TERMINATED
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Nasser Hanna, M.D.
NCT02582749 TERMINATED
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Ajjai Alva, MD
NCT03562897 COMPLETED
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Catalysis SL
NCT04895046 WITHDRAWN
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Walid Shaib, MD
NCT02303028 COMPLETED
Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours
The Hospital for Sick Children
NCT03245450 COMPLETED
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eisai Inc.
NCT04138875 WITHDRAWN
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Yale University
NCT03913741 COMPLETED
A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Genmab
NCT03199144 WITHDRAWN
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
Centre Francois Baclesse, Luxembourg
NCT03050060 TERMINATED
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
NCT02880371 TERMINATED
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Pfizer
NCT03144687 COMPLETED
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Incyte Corporation
NCT03170180 COMPLETED
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
NCT03392428 COMPLETED
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
NCT02736305 COMPLETED
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
National Cancer Centre, Singapore
NCT04475016 COMPLETED
TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer
Sun Yat-sen University
NCT02720185 TERMINATED
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
University of Wisconsin, Madison
NCT04176952 TERMINATED
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
Judith Dixon-Hughes
NCT05165849 WITHDRAWN
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
Zhejiang Genfleet Therapeutics Co., Ltd.
NCT04327986 TERMINATED
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
National Cancer Institute (NCI)
NCT04003623 TERMINATED
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Incyte Corporation
NCT03551795 COMPLETED
Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor
Xiaoyan Zhang
NCT02832167 COMPLETED
An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT04200404 COMPLETED
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
CStone Pharmaceuticals
NCT03410446 COMPLETED
Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
University Health Network, Toronto
NCT03075826 COMPLETED
A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Weill Medical College of Cornell University
NCT03469713 COMPLETED
Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
Gruppo Oncologico Italiano di Ricerca Clinica
NCT02850874 WITHDRAWN
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
NCT03294252 TERMINATED
Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers
Institut Cancerologie de l'Ouest
NCT03695510 COMPLETED
Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
National Taiwan University Hospital
NCT03787251 WITHDRAWN
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT02661542 COMPLETED
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT03684785 TERMINATED
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
NCT02859415 TERMINATED
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Cancer Institute (NCI)
NCT04125693 COMPLETED
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Bayer
NCT02349386 TERMINATED
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
BHR Pharma, LLC
NCT03334409 TERMINATED
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
NCT03292250 COMPLETED
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
NCT02614859 COMPLETED
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
Fox Chase Cancer Center
NCT04809012 WITHDRAWN
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
NCT02674061 COMPLETED
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Merck Sharp & Dohme LLC
NCT02978716 TERMINATED
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc.
NCT03067610 COMPLETED
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT02810418 COMPLETED
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
National Cancer Institute (NCI)
NCT03515551 TERMINATED
Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
Immunocore Ltd
NCT03180294 COMPLETED
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
NCT03454620 COMPLETED
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
Green Cross Corporation
NCT03347123 TERMINATED
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Incyte Corporation
NCT03792750 COMPLETED
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
NCT03352934 COMPLETED
Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy
Johannes Gutenberg University Mainz
NCT04015336 TERMINATED
E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
NCT04832438 WITHDRAWN
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Actuate Therapeutics Inc.
NCT03868423 WITHDRAWN
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Sameek Roychowdhury
NCT03875313 TERMINATED
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Calithera Biosciences, Inc
NCT02728258 COMPLETED
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NRG Oncology
NCT02460224 COMPLETED
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT03137537 TERMINATED
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
Dana-Farber Cancer Institute
NCT05181865 WITHDRAWN
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
Flame Biosciences
NCT03322384 COMPLETED
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
University of California, Davis
NCT02737475 COMPLETED
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
NCT03029611 TERMINATED
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
University of Washington
NCT02318277 COMPLETED
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
Incyte Corporation
NCT03132038 COMPLETED
Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
UNICANCER
NCT02874651 TERMINATED
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Sun Yat-sen University
NCT03220854 COMPLETED
SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx
Virginia Commonwealth University
NCT02963610 TERMINATED
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Fox Chase Cancer Center
NCT04757090 WITHDRAWN
89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111
Washington University School of Medicine
NCT03050814 TERMINATED
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Cancer Institute (NCI)
NCT02595372 COMPLETED
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
Kathy Miller
NCT04105062 WITHDRAWN
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Washington University School of Medicine
NCT02587598 TERMINATED
Study of INCB053914 in Subjects With Advanced Malignancies
Incyte Corporation
NCT03111732 COMPLETED
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Cancer Institute (NCI)
NCT02725268 COMPLETED
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
Millennium Pharmaceuticals, Inc.
NCT04165031 TERMINATED
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
NCT03520231 COMPLETED
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
NCT03123588 TERMINATED
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Incyte Corporation
NCT02756572 COMPLETED
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
University of Washington
NCT02561234 COMPLETED
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
Aeglea Biotherapeutics
NCT03245736 COMPLETED
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen Inc.
NCT03410914 COMPLETED
Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Sunnybrook Health Sciences Centre
NCT04381988 TERMINATED
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
Memorial Sloan Kettering Cancer Center
NCT03096808 COMPLETED
Adaptive Radiotherapy for Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT03276013 COMPLETED
Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer
Vall d'Hebron Institute of Oncology
NCT03738787 COMPLETED
Treatment of the Pancreatic Stump With Neoprene®-Based Glue After High-risk Pancreatoduodenectomy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT02565901 TERMINATED
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of Washington
NCT02907918 TERMINATED
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
Washington University School of Medicine
NCT03261947 COMPLETED
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT02992886 COMPLETED
Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly
Chinese Academy of Medical Sciences
NCT02423343 COMPLETED
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Eli Lilly and Company
NCT02599779 COMPLETED
A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
Sunnybrook Health Sciences Centre
NCT04430933 WITHDRAWN
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
NextCure, Inc.
NCT03394885 COMPLETED
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
Duke University
NCT02531737 COMPLETED
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
University Hospital, Limoges
NCT02521870 TERMINATED
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Dynavax Technologies Corporation
NCT02629523 COMPLETED
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA
Chonnam National University Hospital
NCT02769286 COMPLETED
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Chonnam National University Hospital
NCT04180384 COMPLETED
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Athenex, Inc.
NCT02869295 COMPLETED
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Nektar Therapeutics
NCT02765165 TERMINATED
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
NCT03098550 COMPLETED
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
Bristol-Myers Squibb
NCT02925000 COMPLETED
Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy
Taiwan Liposome Company
NCT03277352 TERMINATED
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Biosciences International Sàrl
NCT02124772 COMPLETED
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Novartis Pharmaceuticals
NCT03648879 COMPLETED
Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome
National Cancer Institute (NCI)
NCT03097588 COMPLETED
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
OHSU Knight Cancer Institute
NCT04655183 WITHDRAWN
Study of M4344 in Combination With Niraparib
EMD Serono Research & Development Institute, Inc.
NCT03142516 COMPLETED
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
Grupo Espanol Multidisciplinario del Cancer Digestivo
NCT02718144 COMPLETED
Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer
Pantarhei Oncology B.V.
NCT03451773 TERMINATED
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
National Cancer Institute (NCI)
NCT03113825 COMPLETED
Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Avelas Biosciences, Inc.
NCT02940223 TERMINATED
Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
NCT03052478 COMPLETED
Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Samsung Medical Center
NCT02941523 COMPLETED
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Noxopharm Limited
NCT02514252 TERMINATED
Sublingual Fentanyl for the Management of Breakthrough Pain
M.D. Anderson Cancer Center
NCT04464967 WITHDRAWN
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
NCT03264066 COMPLETED
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Hoffmann-La Roche
NCT02845908 COMPLETED
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
Fujian Cancer Hospital
NCT02394652 COMPLETED
The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial
University Health Network, Toronto
NCT03597009 TERMINATED
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
UNC Lineberger Comprehensive Cancer Center
NCT02311361 COMPLETED
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT03937791 TERMINATED
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
National Cancer Institute (NCI)
NCT02552121 COMPLETED
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Seagen Inc.
NCT03289819 COMPLETED
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
Institut fuer Frauengesundheit
NCT03955224 WITHDRAWN
Evaluation of Low-Level Laser Therapy Efficacy in Pain Management of Grade 2 Oral Mucositis Induced by Radiotherapy or Chemoradiotherapy: a Study in Patients With Upper Aerodigestive Tract Cancer
Institut Claudius Regaud
NCT02805660 TERMINATED
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mirati Therapeutics Inc.
NCT03876925 TERMINATED
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
Sunshine Lake Pharma Co., Ltd.
NCT02750514 TERMINATED
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
Bristol-Myers Squibb
NCT03666728 TERMINATED
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
NCT03729297 TERMINATED
Cabozantinib in Advanced Salivary Gland Cancer Patients
Radboud University Medical Center
NCT02633540 TERMINATED
Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function
Fox Chase Cancer Center
NCT04243954 COMPLETED
Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration
Fujian Cancer Hospital
NCT03600467 TERMINATED
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma
St Vincent's Hospital, Sydney
NCT02860819 COMPLETED
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer
National Cancer Institute, Slovakia
NCT02953782 COMPLETED
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
Gilead Sciences
NCT02697591 COMPLETED
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
Incyte Biosciences International Sàrl
NCT03638622 COMPLETED
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.
Massachusetts General Hospital
NCT02641691 COMPLETED
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Washington University School of Medicine
NCT03233412 COMPLETED
Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions
Barretos Cancer Hospital
NCT03368859 TERMINATED
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
NCT04536922 WITHDRAWN
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
National Cancer Institute (NCI)
NCT03066947 COMPLETED
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
BriaCell Therapeutics Corporation
NCT02725489 COMPLETED
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Mary Crowley Medical Research Center
NCT02470533 TERMINATED
Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Erasmus Medical Center
NCT02495103 TERMINATED
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
National Cancer Institute (NCI)
NCT03274011 COMPLETED
Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Fudan University
NCT03081884 COMPLETED
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
Emory University
NCT02587962 TERMINATED
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
NCT03742713 COMPLETED
Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer
Cristal Therapeutics
NCT03363776 TERMINATED
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
Bristol-Myers Squibb
NCT03170115 TERMINATED
Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer
Instituto Nacional de Cancer, Brazil
NCT03789175 COMPLETED
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome
National Heart, Lung, and Blood Institute (NHLBI)
NCT04437953 WITHDRAWN
Avatrombopag for Thrombocytopenia in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT03464968 COMPLETED
mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line
Seoul National University Bundang Hospital
NCT02780687 COMPLETED
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
Boehringer Ingelheim
NCT03312114 TERMINATED
Anti-PD-L1 and SAbR for Ovarian Cancer
University of Texas Southwestern Medical Center
NCT02788201 COMPLETED
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
NCT02605083 TERMINATED
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Effector Therapeutics
NCT02709889 TERMINATED
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
NCT04561817 WITHDRAWN
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Icahn School of Medicine at Mount Sinai
NCT04044950 WITHDRAWN
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
NCT03348826 WITHDRAWN
Study of Sodium Bicarbonate in Restoring Blocked Catheters
University Health Network, Toronto
NCT02315625 TERMINATED
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Cancer Institute (NCI)
NCT04539769 COMPLETED
Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes
Kyungpook National University Chilgok Hospital
NCT03097770 COMPLETED
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Chinese PLA General Hospital
NCT03351231 TERMINATED
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
Bristol-Myers Squibb
NCT02776137 COMPLETED
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NCT03187314 COMPLETED
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
Hangzhou Cancer Hospital
NCT02258464 TERMINATED
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
NCT03681951 TERMINATED
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
GlaxoSmithKline
NCT02402062 COMPLETED
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
NCT02386501 COMPLETED
Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
Advaxis, Inc.
NCT02530424 COMPLETED
"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
Fondazione Michelangelo
NCT03572829 COMPLETED
Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
Chinese Academy of Medical Sciences
NCT02395627 TERMINATED
Reversing Therapy Resistance With Epigenetic-Immune Modification
University of California, San Francisco
NCT02462200 TERMINATED
Shave Margins in Breast Conservation Therapy
Washington University School of Medicine
NCT03575806 COMPLETED
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT02380677 TERMINATED
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
NewLink Genetics Corporation
NCT02403531 COMPLETED
Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer
Mian XI
NCT03480152 TERMINATED
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
National Cancer Institute (NCI)
NCT02842125 TERMINATED
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
MultiVir, Inc.
NCT04184518 WITHDRAWN
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Grupo Español Multidisciplinar de Melanoma
NCT04016116 WITHDRAWN
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
NYU Langone Health
NCT03361228 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Incyte Corporation
NCT04044378 WITHDRAWN
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Peking University People's Hospital
NCT03104335 WITHDRAWN
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Peking University People's Hospital
NCT03704077 WITHDRAWN
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Bristol-Myers Squibb
NCT02224599 TERMINATED
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Kiromic BioPharma Inc.
NCT02949947 TERMINATED
Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy
M.D. Anderson Cancer Center
NCT02452463 TERMINATED
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
NCT03002831 TERMINATED
Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer
Henan Cancer Hospital
NCT02366871 COMPLETED
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
University of Colorado, Denver
NCT02528110 COMPLETED
Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer
Wuhan University
NCT03124433 COMPLETED
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer
Singapore General Hospital
NCT02830139 COMPLETED
Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer
Wuhan University
NCT02789332 COMPLETED
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
GBG Forschungs GmbH
NCT02596711 COMPLETED
Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers
M.D. Anderson Cancer Center
NCT04162379 COMPLETED
Oral Prednisolone Effect on Cancer WHO Stepladder Analgesia Protocol
Mansoura University
NCT02705352 COMPLETED
5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Massachusetts Eye and Ear Infirmary
NCT03678090 WITHDRAWN
The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion.
Yale University
NCT04260009 WITHDRAWN
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Takeda
NCT02487849 WITHDRAWN
HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma
Krankenhaus Barmherzige Schwestern Linz
NCT02819011 COMPLETED
OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
Bijan Najafi, PhD
NCT02541604 TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Hoffmann-La Roche
NCT02807337 COMPLETED
Supersaturated Calcium Phosphate Oral Rinse (Caphosol®) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments
Tampere University Hospital
NCT04158700 WITHDRAWN
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
NCT02425683 TERMINATED
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
NCT01998542 COMPLETED
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
Mirror Biologics, Inc.
NCT03628079 TERMINATED
A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.
Repos Pharma
NCT03532087 WITHDRAWN
Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
Borstkanker Onderzoek Groep
NCT03190616 COMPLETED
Apatinib in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
NCT02684071 TERMINATED
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
NCT03191968 COMPLETED
Prostate Cancer Survivors and Exercise and Behavioral Counseling
University of Illinois at Urbana-Champaign
NCT03300843 TERMINATED
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Cancer Institute (NCI)
NCT03114631 COMPLETED
Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer
The Republican Research and Practical Center for Epidemiology and Microbiology
NCT02397486 COMPLETED
The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients
Ain Shams University
NCT02451007 COMPLETED
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
PharmaMar
NCT03891472 COMPLETED
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
Medical University of Silesia
NCT03697824 WITHDRAWN
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
NCT02530515 COMPLETED
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02406170 COMPLETED
Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT03035591 COMPLETED
ODM-207 in Patients With Advance Solid Tumours
Orion Corporation, Orion Pharma
NCT02709993 WITHDRAWN
Consolidation Therapy in Patients With Hematologic Malignancies
Kiromic BioPharma Inc.
NCT02485470 TERMINATED
Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy
University of Michigan Rogel Cancer Center
NCT02950103 TERMINATED
Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients
Secretaria de Estado da Saúde
NCT02929862 COMPLETED
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Lycera Corp.
NCT03007836 COMPLETED
High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer
Fuda Cancer Hospital, Guangzhou
NCT02843802 COMPLETED
Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer
Fuda Cancer Hospital, Guangzhou
NCT02885727 WITHDRAWN
Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)
University of Maryland, Baltimore
NCT02843607 COMPLETED
Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer
Fuda Cancer Hospital, Guangzhou
NCT02849327 COMPLETED
Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer
Fuda Cancer Hospital, Guangzhou
NCT02849314 COMPLETED
Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer
Fuda Cancer Hospital, Guangzhou
NCT02849379 COMPLETED
Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer
Fuda Cancer Hospital, Guangzhou
NCT03008330 COMPLETED
High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer
Fuda Cancer Hospital, Guangzhou
NCT02338752 COMPLETED
Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT02747537 WITHDRAWN
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Washington University School of Medicine
NCT03147976 WITHDRAWN
QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors
NantPharma, LLC
NCT02864316 TERMINATED
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02352831 TERMINATED
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Washington University School of Medicine
NCT02999672 COMPLETED
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
Hoffmann-La Roche
NCT03507166 COMPLETED
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
RemeGen Co., Ltd.
NCT02999295 COMPLETED
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
National Cancer Center, Japan
NCT03204994 TERMINATED
Fluorescence Targeted Pelvic Lymph Node Mapping
Oxford University Hospitals NHS Trust
NCT03065023 TERMINATED
Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)
Merck Sharp & Dohme LLC
NCT03778879 WITHDRAWN
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Alan Katz
NCT02973672 COMPLETED
Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
Surgimab
NCT03207139 COMPLETED
Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer
Chang Gung Memorial Hospital
NCT02773329 COMPLETED
Using Game-based Exercise to Improve Balance in Cancer Patients
Baylor College of Medicine
NCT02306850 COMPLETED
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
St. Louis University
NCT03697239 WITHDRAWN
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Hitendra Patel
NCT03128281 WITHDRAWN
Pneumoperitoneum Management With Low vs. Higher Pressure
M.D. Anderson Cancer Center
NCT03908333 WITHDRAWN
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Medical College of Wisconsin
NCT02839681 TERMINATED
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
National Cancer Institute (NCI)
NCT03061708 TERMINATED
Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy
Samsung Medical Center
NCT03166176 WITHDRAWN
Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy
Samsung Medical Center
NCT03166904 WITHDRAWN
Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy
Samsung Medical Center
NCT03082833 TERMINATED
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
Samsung Medical Center
NCT02889718 COMPLETED
Anesthesia Feasibility Study With the CONCERT-CL® Station
Institut Cancerologie de l'Ouest
NCT02501213 TERMINATED
Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)
Centre Oscar Lambret
NCT03911921 COMPLETED
RSYR for Fatigue Reduction in Cancer Survivors
Peking University Cancer Hospital & Institute
NCT03282643 COMPLETED
Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients
Capital Medical University
NCT02946021 COMPLETED
Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema
Tactile Medical
NCT03109301 WITHDRAWN
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
National Cancer Institute (NCI)
NCT02575807 TERMINATED
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
Aduro Biotech, Inc.
NCT02950025 TERMINATED
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
Washington University School of Medicine
NCT02504892 TERMINATED
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
National Cancer Institute (NCI)
NCT02301143 COMPLETED
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
Celgene
NCT02423811 COMPLETED
Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy
National Cheng-Kung University Hospital
NCT03403777 COMPLETED
Avelumab in Refractory Testicular Germ Cell Cancer.
National Cancer Institute, Slovakia
NCT02509585 TERMINATED
A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
Cardinal Health 414, LLC
NCT02606994 TERMINATED
Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis
Oral Defense, LLC
NCT02580448 COMPLETED
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
Innocrin Pharmaceutical
NCT02275403 COMPLETED
Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma
The Christie NHS Foundation Trust
NCT02303041 TERMINATED
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Anne Chang
NCT02299635 TERMINATED
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Pfizer
NCT02633800 TERMINATED
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
NCT03002623 TERMINATED
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Cancer Institute (NCI)
NCT02374099 TERMINATED
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Celgene
NCT02269943 COMPLETED
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
NCT02560038 TERMINATED
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
NCT02465502 COMPLETED
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Bayer
NCT02669914 TERMINATED
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Washington University School of Medicine
NCT02472977 TERMINATED
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Bristol-Myers Squibb
NCT03223662 TERMINATED
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
National Cancer Institute (NCI)
NCT02375048 TERMINATED
Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI
Istituto Clinico Humanitas
NCT03029416 WITHDRAWN
Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension
Ronald McGarry
NCT03220009 WITHDRAWN
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
NCT02352844 COMPLETED
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Washington University School of Medicine
NCT02334007 COMPLETED
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
McMaster University
NCT02705703 WITHDRAWN
Consolidation Therapy in Patients With Metastatic Solid Malignancies
Kiromic BioPharma Inc.
NCT02223312 WITHDRAWN
Therapy for Progressive and/or Refractory Hematologic Malignancies
Kiromic BioPharma Inc.
NCT02846766 WITHDRAWN
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
Teresa Helsten, MD
NCT02747797 WITHDRAWN
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
Teresa Helsten, MD
NCT03207542 WITHDRAWN
Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
NCT02345460 TERMINATED
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Case Comprehensive Cancer Center
NCT02423954 TERMINATED
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Western Regional Medical Center
NCT02558868 COMPLETED
Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer
Zhejiang University
NCT03123744 WITHDRAWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
Razelle Kurzrock, MD
NCT03282214 COMPLETED
A Self-Management Energy Conservation Program for Cancer-Related Fatigue
University of Michigan
NCT03004105 WITHDRAWN
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
NCT02606123 TERMINATED
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
ESSA Pharmaceuticals
NCT02558959 COMPLETED
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
Zhejiang University
NCT02806648 COMPLETED
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
Grupo Espanol de Tumores Neuroendocrinos
NCT02479490 TERMINATED
PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT02473094 TERMINATED
Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer
University of Campinas, Brazil
NCT02499861 COMPLETED
Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies
St. Justine's Hospital
NCT02298595 WITHDRAWN
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Julie E. Bauman, MD, MPH
NCT02958163 TERMINATED
Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT02278783 TERMINATED
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
University of Utah
NCT02732327 TERMINATED
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
Forest Laboratories
NCT02417753 TERMINATED
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
National Cancer Institute (NCI)
NCT02766842 WITHDRAWN
Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)
Johns Hopkins University
NCT02808624 COMPLETED
L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients
Cairo University
NCT03120403 COMPLETED
Safety and Efficacy of Intrathecal Morphine in Children
Alaa Ali Mohamed Elzohry
NCT02406794 COMPLETED
Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors
University of Malaga
NCT02857608 WITHDRAWN
A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
Cardinal Health 414, LLC
NCT02685306 WITHDRAWN
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals
NCT02930876 COMPLETED
Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients
King's College London
NCT02449538 COMPLETED
Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
Samsung Medical Center
NCT02429622 COMPLETED
Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma
Chinese Academy of Medical Sciences
NCT03005015 WITHDRAWN
Lenvatinib in Second Line Endometrial Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT02647684 COMPLETED
Triple P for Parents of Children With a Diagnosis of Cancer
University of Manchester
NCT02562729 COMPLETED
Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer
Shanghai Gynecologic Oncology Group
NCT02600299 COMPLETED
Effectiveness of a Psycho-educational Group (PEG) Intervention on Supportive Care and Survivorship Issues in Early-stage Breast Cancer Survivors Who Have Received Systemic Treatment
National University of Singapore
NCT02539017 WITHDRAWN
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
NCT02656849 WITHDRAWN
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors
Dana-Farber Cancer Institute
NCT01445691 WITHDRAWN
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Constantinos Hadjipanayis
NCT02501278 WITHDRAWN
A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT02333474 COMPLETED
Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT02338778 COMPLETED
Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT02338804 COMPLETED
Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient
Fuda Cancer Hospital, Guangzhou
NCT02396433 WITHDRAWN
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
The University of Texas Health Science Center at San Antonio
NCT04533750 ACTIVE NOT RECRUITING
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
National Cancer Institute (NCI)
NCT04958239 ACTIVE NOT RECRUITING
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
NCT05538130 RECRUITING
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT04222413 RECRUITING
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT05172245 RECRUITING
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
NCT07156227 NOT YET RECRUITING
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT06868433 RECRUITING
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
NCT06803680 RECRUITING
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeiGene
NCT06904066 RECRUITING
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Cancer Institute (NCI)
NCT06091930 RECRUITING
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
NCT02298959 ACTIVE NOT RECRUITING
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT06251544 NOT YET RECRUITING
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Baylor College of Medicine
NCT03313778 ACTIVE NOT RECRUITING
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
ModernaTX, Inc.
NCT04704661 RECRUITING
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
NCT06982222 NOT YET RECRUITING
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
National Cancer Institute (NCI)
NCT06321484 RECRUITING
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
NCT07447856 RECRUITING
A Study Testing Topical Pain-Relieving Herbal Plasters in People Who Are Using Opioids for Their Pain
Memorial Sloan Kettering Cancer Center
NCT04514484 ACTIVE NOT RECRUITING
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
NCT07297160 NOT YET RECRUITING
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
Baylor College of Medicine
NCT02503722 ACTIVE NOT RECRUITING
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT07387068 RECRUITING
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
NCT04491942 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
NCT06625775 RECRUITING
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06589596 RECRUITING
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
NCT05981703 RECRUITING
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
NCT07046559 RECRUITING
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Eli Lilly and Company
NCT06147037 RECRUITING
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT05003895 RECRUITING
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Cancer Institute (NCI)
NCT06537310 ACTIVE NOT RECRUITING
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT05873686 RECRUITING
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
NCT06573294 RECRUITING
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Genmab
NCT07362888 NOT YET RECRUITING
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Adcendo ApS
NCT07321106 RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
NCT03207672 ACTIVE NOT RECRUITING
Study of E7389 Liposomal Formulation in Participants With Solid Tumor
Eisai Co., Ltd.
NCT07446816 RECRUITING
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
NCT07304128 RECRUITING
A Study of PLB-002 in Advanced Solid Tumors
Primelink BioTherapeitics(ShenZhen) Limited
NCT06057038 ACTIVE NOT RECRUITING
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
NCT06994806 RECRUITING
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT05155332 RECRUITING
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT06715124 ACTIVE NOT RECRUITING
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Quanta Therapeutics
NCT07360314 RECRUITING
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT07441694 NOT YET RECRUITING
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT07346846 NOT YET RECRUITING
A Study of BGM-2121 in Patients With Advanced Solid Tumors
BioGate Precision Medicine Corp.
NCT06884618 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Hoffmann-La Roche
NCT04855435 RECRUITING
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
NCT07046923 RECRUITING
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
NCT04473781 RECRUITING
Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT06612645 RECRUITING
Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
Chulalongkorn University
NCT06657144 RECRUITING
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT06663319 RECRUITING
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
NCT02721459 ACTIVE NOT RECRUITING
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT07269080 RECRUITING
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
University of Illinois at Chicago
NCT07064122 RECRUITING
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
AstraZeneca
NCT07213791 RECRUITING
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
NCT07114601 RECRUITING
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly and Company
NCT05914376 ACTIVE NOT RECRUITING
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
Hangzhou Converd Co., Ltd.
NCT04735978 ACTIVE NOT RECRUITING
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune Inc.
NCT05853367 RECRUITING
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Merck Sharp & Dohme LLC
NCT07413328 NOT YET RECRUITING
HWS116 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
NCT06389123 RECRUITING
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
University of California, Davis
NCT07382817 RECRUITING
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
M.D. Anderson Cancer Center
NCT06659341 RECRUITING
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Bayer
NCT04336241 ACTIVE NOT RECRUITING
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune Inc.
NCT07438782 NOT YET RECRUITING
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT06759649 RECRUITING
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Compugen Ltd
NCT03830320 RECRUITING
Positron Emission Tomography (PET) Imaging of Thrombosis
Massachusetts General Hospital
NCT05536141 RECRUITING
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Arcus Biosciences, Inc.
NCT06120075 ACTIVE NOT RECRUITING
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT05907304 ACTIVE NOT RECRUITING
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Erasca, Inc.
NCT04855656 RECRUITING
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Debiopharm International SA
NCT03833700 ACTIVE NOT RECRUITING
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Eisai Co., Ltd.
NCT06402201 RECRUITING
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
CDR-Life AG
NCT04288089 ACTIVE NOT RECRUITING
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Eisai Inc.
NCT04963153 ACTIVE NOT RECRUITING
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
NCT07008118 RECRUITING
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT05109975 ACTIVE NOT RECRUITING
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Debiopharm International SA
NCT07361562 RECRUITING
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Cogent Biosciences, Inc.
NCT05891171 ACTIVE NOT RECRUITING
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences, Inc.
NCT03448042 ACTIVE NOT RECRUITING
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
NCT07176975 NOT YET RECRUITING
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
NCT05557045 RECRUITING
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Jazz Pharmaceuticals
NCT07128680 RECRUITING
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
NCT06313593 RECRUITING
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT07279428 RECRUITING
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07382544 RECRUITING
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
M.D. Anderson Cancer Center
NCT06521554 RECRUITING
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Nuvalent Inc.
NCT06447662 RECRUITING
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
NCT06818812 ACTIVE NOT RECRUITING
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
NCT03203525 ACTIVE NOT RECRUITING
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
NCT07434609 NOT YET RECRUITING
Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Nanolattix Biotechnology Co., Ltd.
NCT06104488 RECRUITING
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
NCT04572295 ACTIVE NOT RECRUITING
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Eisai Co., Ltd.
NCT06799065 RECRUITING
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Accent Therapeutics
NCT04250155 ACTIVE NOT RECRUITING
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT05753722 RECRUITING
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Incendia Therapeutics
NCT05537740 ACTIVE NOT RECRUITING
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
NCT05208762 RECRUITING
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07190469 RECRUITING
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
ProteinQure Inc.
NCT07038369 ACTIVE NOT RECRUITING
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
NCT07161414 RECRUITING
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
AstraZeneca
NCT06422520 ACTIVE NOT RECRUITING
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT06596473 RECRUITING
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
NCT07226349 RECRUITING
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
NCT07426757 NOT YET RECRUITING
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Pfizer
NCT07247110 RECRUITING
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
NCT07222267 RECRUITING
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
BeOne Medicines
NCT07181681 RECRUITING
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
NCT07094204 RECRUITING
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
NCT06878248 RECRUITING
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Calibr, a division of Scripps Research
NCT07424547 RECRUITING
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
NCT06120283 RECRUITING
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeiGene
NCT07423117 NOT YET RECRUITING
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
IntoCell, Inc
NCT04661384 ACTIVE NOT RECRUITING
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
City of Hope Medical Center
NCT06233942 RECRUITING
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
NCT06648434 RECRUITING
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
NCT06625593 RECRUITING
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
NCT04649385 ACTIVE NOT RECRUITING
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT05527184 ACTIVE NOT RECRUITING
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
NCT06585488 RECRUITING
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeiGene
NCT03366116 RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT06959706 RECRUITING
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
NCT06598800 RECRUITING
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeiGene
NCT04893434 RECRUITING
Novel Imaging Technique to Assess Gynecologic Cancer
Memorial Sloan Kettering Cancer Center
NCT04847063 RECRUITING
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
National Cancer Institute (NCI)
NCT06515613 RECRUITING
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
NCT03968406 RECRUITING
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
NCT05396833 ACTIVE NOT RECRUITING
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono Research & Development Institute, Inc.
NCT07334119 RECRUITING
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
NCT03252938 ACTIVE NOT RECRUITING
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT07166601 RECRUITING
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT06496568 RECRUITING
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Hoffmann-La Roche
NCT05719558 RECRUITING
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Global Development, Inc.
NCT04485013 RECRUITING
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
NCT06641908 RECRUITING
Anti-GD2 ADC M3554 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT05382364 ACTIVE NOT RECRUITING
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
Pfizer
NCT07337525 RECRUITING
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Pilatus Biosciences Inc
NCT06524570 RECRUITING
Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy
UMC Utrecht
NCT07197554 RECRUITING
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
NCT05567185 ACTIVE NOT RECRUITING
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Janssen Pharmaceutical K.K.
NCT07414836 NOT YET RECRUITING
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
NCT06892379 RECRUITING
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT04973163 ACTIVE NOT RECRUITING
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Boehringer Ingelheim
NCT05581004 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT06804824 RECRUITING
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
NCT03911388 RECRUITING
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
NCT05954312 RECRUITING
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
NCT06651229 RECRUITING
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Janssen Research & Development, LLC
NCT06885697 RECRUITING
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06248411 RECRUITING
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
NCT06253520 RECRUITING
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Cancer Institute (NCI)
NCT06004245 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
NCT07238075 RECRUITING
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
Adcytherix SAS
NCT07123103 RECRUITING
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT04928677 RECRUITING
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
Memorial Sloan Kettering Cancer Center
NCT06150157 RECRUITING
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
NCT06566079 RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
NCT07066657 RECRUITING
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ArriVent BioPharma, Inc.
NCT05879978 ACTIVE NOT RECRUITING
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Boehringer Ingelheim
NCT06487858 ACTIVE NOT RECRUITING
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
BeOne Medicines
NCT07197671 RECRUITING
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
University of Wisconsin, Madison
NCT07148050 RECRUITING
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Seattle Children's Hospital
NCT06618001 RECRUITING
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Janssen Research & Development, LLC
NCT06778863 RECRUITING
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clasp Therapeutics, Inc.
NCT06779851 ACTIVE NOT RECRUITING
A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors
Bright Peak Therapeutics Inc
NCT06311578 RECRUITING
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
NCT07408258 NOT YET RECRUITING
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
OncoC4, Inc.
NCT04606381 ACTIVE NOT RECRUITING
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
Janssen Research & Development, LLC
NCT05818683 RECRUITING
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development, LLC
NCT07223125 RECRUITING
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Janssen Research & Development, LLC
NCT07107230 RECRUITING
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Janssen Research & Development, LLC
NCT06973863 RECRUITING
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
PharmaEngine
NCT05103683 RECRUITING
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
NCT07407985 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT05067283 RECRUITING
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Merck Sharp & Dohme LLC
NCT04197934 ACTIVE NOT RECRUITING
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
NCT04449874 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
NCT07407504 NOT YET RECRUITING
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT07374848 RECRUITING
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
Zai Lab (Shanghai) Co., Ltd.
NCT06943677 RECRUITING
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT07094113 RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
NCT05176483 RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT07329894 RECRUITING
Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
Beijing GoBroad Hospital
NCT04503278 RECRUITING
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
BioNTech Cell & Gene Therapies GmbH
NCT06997029 RECRUITING
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
NCT06623396 RECRUITING
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT06440005 RECRUITING
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex, Inc.
NCT06238479 RECRUITING
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06586957 RECRUITING
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
NCT07252479 RECRUITING
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Adlai Nortye Biopharma Co., Ltd.
NCT04617522 RECRUITING
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Gilead Sciences
NCT06750185 RECRUITING
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
BioNTech SE
NCT07404332 NOT YET RECRUITING
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
Mohammed Milhem
NCT07403721 NOT YET RECRUITING
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
NCT07402915 RECRUITING
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
AstraZeneca
NCT07036133 RECRUITING
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
Acrotech Biopharma Inc.
NCT07015697 RECRUITING
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Daiichi Sankyo
NCT07195916 RECRUITING
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
NCT06561685 RECRUITING
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT07258836 RECRUITING
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Eli Lilly and Company
NCT05082259 RECRUITING
ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
Institute of Cancer Research, United Kingdom
NCT06179160 RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
NCT06178614 RECRUITING
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
NCT05936359 RECRUITING
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT06917079 RECRUITING
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT05947474 ACTIVE NOT RECRUITING
ORB-011 In Patients With Advanced Solid Tumors
Orionis Biosciences Inc
NCT05238922 RECRUITING
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
NCT05239143 ACTIVE NOT RECRUITING
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
NCT06031441 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT06619587 RECRUITING
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Genentech, Inc.
NCT07395258 NOT YET RECRUITING
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT04044859 ACTIVE NOT RECRUITING
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM CT, LLC
NCT05479812 ACTIVE NOT RECRUITING
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Werewolf Therapeutics, Inc.
NCT07055854 RECRUITING
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
Oregon State University
NCT05620017 RECRUITING
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
NCT07080242 RECRUITING
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
SystImmune Inc.
NCT05787587 RECRUITING
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT03740256 RECRUITING
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT07391644 NOT YET RECRUITING
A Study of JSKN027 in Patients With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT05838768 ACTIVE NOT RECRUITING
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Novartis Pharmaceuticals
NCT06507306 RECRUITING
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT06480552 RECRUITING
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
NCT06568614 RECRUITING
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
BeOne Medicines
NCT06650163 RECRUITING
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Jonsson Comprehensive Cancer Center
NCT07390838 RECRUITING
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
NCT04459273 ACTIVE NOT RECRUITING
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Jonsson Comprehensive Cancer Center
NCT06880549 ACTIVE NOT RECRUITING
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
ModernaTX, Inc.
NCT06655246 RECRUITING
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
NCT06487624 RECRUITING
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
FBD Biologics Limited
NCT07349537 RECRUITING
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines, Inc.
NCT05892718 RECRUITING
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
FBD Biologics Limited
NCT03120624 ACTIVE NOT RECRUITING
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
Mayo Clinic
NCT06244485 RECRUITING
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Daiichi Sankyo
NCT07292818 RECRUITING
Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
UNC Lineberger Comprehensive Cancer Center
NCT05352750 ACTIVE NOT RECRUITING
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
Sonnet BioTherapeutics
NCT06469281 RECRUITING
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
NCT06293898 RECRUITING
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
NCT07383506 NOT YET RECRUITING
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Cogent Biosciences, Inc.
NCT05791448 RECRUITING
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
University of Southern California
NCT06364696 ACTIVE NOT RECRUITING
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Astellas Pharma Inc
NCT06911489 RECRUITING
Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients
Chengdu New Radiomedicine Technology Co. LTD.
NCT07215637 RECRUITING
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
NCT07381829 RECRUITING
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
HC Biopharma Inc.
NCT07380334 NOT YET RECRUITING
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT05877599 RECRUITING
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
NCT06717750 RECRUITING
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
NCT06809114 RECRUITING
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Axcynsis Therapeutics Pte Ltd
NCT04389281 RECRUITING
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Immunolight, LLC
NCT04391049 ACTIVE NOT RECRUITING
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
NCT06308263 ACTIVE NOT RECRUITING
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NCT07377591 RECRUITING
A Study of HDM2006 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT07217171 RECRUITING
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
NCT07371104 NOT YET RECRUITING
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Daewoong Pharmaceutical Co. LTD.
NCT04170153 ACTIVE NOT RECRUITING
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono Research & Development Institute, Inc.
NCT06644300 RECRUITING
Study of BM230 in Patients With Advanced Solid Tumors
Suzhou Biomissile Pharmaceuticals Co., Ltd.
NCT04241835 RECRUITING
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Epizyme, Inc.
NCT06792552 RECRUITING
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
NCT05983432 RECRUITING
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
NCT06218914 RECRUITING
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
NCT04150042 RECRUITING
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology, Inc.
NCT06266299 RECRUITING
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co., Ltd.
NCT07372625 NOT YET RECRUITING
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
PMV Pharmaceuticals, Inc
NCT07269145 RECRUITING
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06484985 RECRUITING
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Axter Therapeutics (Beijing) Co., Ltd
NCT06993116 ACTIVE NOT RECRUITING
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
Guangdong Hengrui Pharmaceutical Co., Ltd
NCT06287918 NOT YET RECRUITING
A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
3H (Suzhou) Pharmaceuticals Co., Ltd.
NCT05753501 RECRUITING
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
NCT07368127 NOT YET RECRUITING
A Study of TPD3310 in Patients With Advanced Malignant Tumors
TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
NCT07218913 RECRUITING
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
NCT07363967 RECRUITING
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors
Beijing StoneWise Technology Co., Ltd
NCT07162038 RECRUITING
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT07363369 NOT YET RECRUITING
Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
West China Hospital
NCT06150183 ACTIVE NOT RECRUITING
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
BioNTech SE
NCT05174637 ACTIVE NOT RECRUITING
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT05827614 ACTIVE NOT RECRUITING
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Boundless Bio, Inc.
NCT06821048 RECRUITING
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
Weijia Fang, MD
NCT06465069 RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT07358806 RECRUITING
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.
NCT07361107 RECRUITING
Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)
Northwell Health
NCT07042100 RECRUITING
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
NCT05914545 RECRUITING
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT07358884 NOT YET RECRUITING
First in Human Study of QLS5316 in Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT05983133 ACTIVE NOT RECRUITING
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05653869 ACTIVE NOT RECRUITING
A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions
Applied Pharmaceutical Science, Inc.
NCT07317505 RECRUITING
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
NCT06612840 RECRUITING
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07348653 NOT YET RECRUITING
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
NCT06609187 RECRUITING
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07356856 NOT YET RECRUITING
Efficacy and Safety of Microtransplantation for Advanced and Relapsed Solid Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
NCT05187182 RECRUITING
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
NCT07356453 RECRUITING
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
FoRx Therapeutics AG
NCT06503783 RECRUITING
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06770569 RECRUITING
Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
NCT05519449 RECRUITING
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Janux Therapeutics
NCT07351903 RECRUITING
A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT05835687 RECRUITING
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT06736379 RECRUITING
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
NCT06974110 RECRUITING
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT07284186 RECRUITING
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
NCT06927570 RECRUITING
A Study of HS-20122 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT07345637 NOT YET RECRUITING
Phase I Study of FXS887 in the Treatment of Solid Tumors
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT06932952 ACTIVE NOT RECRUITING
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V.
NCT07186452 RECRUITING
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06302426 RECRUITING
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
NCT07231458 RECRUITING
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Abalos Therapeutics GmbH
NCT07294872 NOT YET RECRUITING
A Study of TIL in Advanced Solid Tumors (CZ)
Shanghai Juncell Therapeutics
NCT06751329 RECRUITING
A Study of DM002 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT06302621 RECRUITING
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
NCT07275242 RECRUITING
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06704724 ACTIVE NOT RECRUITING
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
NCT06859762 RECRUITING
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT05092373 RECRUITING
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
NCT07292038 RECRUITING
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors
NucMito Pharmaceuticals Co. Ltd.
NCT06400472 RECRUITING
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
NCT06234423 RECRUITING
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
OnCusp Therapeutics, Inc.
NCT05614739 RECRUITING
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company
NCT02715284 ACTIVE NOT RECRUITING
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Tesaro, Inc.
NCT07229313 RECRUITING
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
NCT07197645 RECRUITING
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
Telix Pharmaceuticals (Innovations) Pty Limited
NCT06607185 RECRUITING
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT05156866 ACTIVE NOT RECRUITING
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
NCT06466187 ACTIVE NOT RECRUITING
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07181473 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
NCT06667141 RECRUITING
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Acrivon Therapeutics
NCT03875287 ACTIVE NOT RECRUITING
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07333820 NOT YET RECRUITING
Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201
Yonsei University
NCT06806046 ACTIVE NOT RECRUITING
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NCT04111458 ACTIVE NOT RECRUITING
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
Boehringer Ingelheim
NCT06816108 RECRUITING
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Ono Pharmaceutical Co. Ltd
NCT04673448 ACTIVE NOT RECRUITING
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
NCT07159828 ACTIVE NOT RECRUITING
A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors
Axion Bio, Inc
NCT06856499 RECRUITING
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
NCT02988960 ACTIVE NOT RECRUITING
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
AbbVie
NCT05902520 ACTIVE NOT RECRUITING
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
AgonOx, Inc.
NCT04235777 RECRUITING
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Cancer Institute (NCI)
NCT07131189 ACTIVE NOT RECRUITING
A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd
NCT05017012 ACTIVE NOT RECRUITING
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
Merck Sharp & Dohme LLC
NCT06964009 RECRUITING
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Elizabeth Stover, MD, PhD
NCT03843359 ACTIVE NOT RECRUITING
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT05614258 ACTIVE NOT RECRUITING
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
Adagene Inc
NCT06977126 RECRUITING
Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers
University Health Network, Toronto
NCT06990464 RECRUITING
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
NCT05308732 ACTIVE NOT RECRUITING
Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy
Instituto Nacional de Cancer, Brazil
NCT06512116 RECRUITING
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
Shanghai Institute Of Biological Products
NCT07232407 RECRUITING
A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06298058 RECRUITING
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Shanghai Institute Of Biological Products
NCT07277270 RECRUITING
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT06985368 RECRUITING
A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
NCT06235437 RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Ascendo Biotechnology Co., Ltd.
NCT06781983 RECRUITING
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
NCT06999187 RECRUITING
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT05544929 ACTIVE NOT RECRUITING
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT03955978 ACTIVE NOT RECRUITING
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
NCT07274852 RECRUITING
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT03602157 ACTIVE NOT RECRUITING
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
NCT07319364 RECRUITING
A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT03912064 ACTIVE NOT RECRUITING
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
NCT05346484 ACTIVE NOT RECRUITING
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
Imugene Limited
NCT05614102 ACTIVE NOT RECRUITING
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Bayer
NCT07077434 RECRUITING
A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT05571839 ACTIVE NOT RECRUITING
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT07252414 RECRUITING
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT07310134 RECRUITING
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
NCT07029399 RECRUITING
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
NCT06026410 RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology, Inc.
NCT06384352 RECRUITING
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07232524 RECRUITING
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06350006 RECRUITING
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06368921 RECRUITING
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
NCT05957081 RECRUITING
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
PharmAbcine
NCT06908434 RECRUITING
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT07100210 RECRUITING
A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity
Xingchen Peng
NCT06882135 RECRUITING
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
NCT06257264 RECRUITING
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT05007782 RECRUITING
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Gilead Sciences
NCT06952010 RECRUITING
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
NCT05075993 ACTIVE NOT RECRUITING
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
M.D. Anderson Cancer Center
NCT07230977 RECRUITING
GenSci139 in Patients With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT06328673 ACTIVE NOT RECRUITING
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
D2M Biotherapeutics Inc.
NCT06022029 RECRUITING
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
OncoNano Medicine, Inc.
NCT07251166 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT04913285 ACTIVE NOT RECRUITING
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Pierre Fabre Medicament
NCT05306132 RECRUITING
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
NCT06545942 RECRUITING
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT07292402 RECRUITING
JSKN022 in Subjects With Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT04777994 RECRUITING
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Calico Life Sciences LLC
NCT07300150 RECRUITING
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PAQ Therapeutics, Inc.
NCT07256756 NOT YET RECRUITING
A Study of GC203 TIL in Advanced Solid Tumors (NF)
Shanghai Juncell Therapeutics
NCT06131398 ACTIVE NOT RECRUITING
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Amgen
NCT07260708 RECRUITING
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
NCT06298357 ACTIVE NOT RECRUITING
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
University of Alabama at Birmingham
NCT06421935 ACTIVE NOT RECRUITING
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
EMD Serono Research & Development Institute, Inc.
NCT05802056 RECRUITING
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Mayo Clinic
NCT07141706 RECRUITING
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
DualityBio Inc.
NCT05276973 ACTIVE NOT RECRUITING
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
NCT05277051 RECRUITING
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT06065371 RECRUITING
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
NCT05270213 RECRUITING
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Riboscience, LLC.
NCT07128914 RECRUITING
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
GeneSail Biotech (Shanghai) Co., Ltd.
NCT06049212 ACTIVE NOT RECRUITING
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Merck Sharp & Dohme LLC
NCT06797336 RECRUITING
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
PAQ Therapeutics, Inc.
NCT05836324 RECRUITING
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT06551142 RECRUITING
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
GlaxoSmithKline
NCT03922555 RECRUITING
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Massachusetts General Hospital
NCT06269978 RECRUITING
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Arjun Mittra
NCT06727812 RECRUITING
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
NCT04541082 RECRUITING
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT06063317 ACTIVE NOT RECRUITING
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
Imugene Limited
NCT03006172 ACTIVE NOT RECRUITING
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
NCT07291050 NOT YET RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT07275073 RECRUITING
JMT106 Injection in the Treatment of Advanced Solid Tumors
Shanghai JMT-Bio Inc.
NCT07288957 RECRUITING
A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors
Abbisko Therapeutics Co, Ltd
NCT06724016 RECRUITING
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT06349837 RECRUITING
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
NCT05856981 RECRUITING
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
NCT06441331 RECRUITING
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
ITM Solucin GmbH
NCT05471856 RECRUITING
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
NCT06132113 RECRUITING
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
NCT05220046 ACTIVE NOT RECRUITING
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
NCT06832982 RECRUITING
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
Shanghai Pushi Medical Science Co. Ltd
NCT06799533 ACTIVE NOT RECRUITING
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Pfizer
NCT06108050 RECRUITING
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Jazz Pharmaceuticals
NCT07285395 RECRUITING
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
NCT05159700 ACTIVE NOT RECRUITING
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Zhuhai Yufan Biotechnologies Co., Ltd
NCT06131840 RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05539430 ACTIVE NOT RECRUITING
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Legend Biotech USA Inc
NCT04898543 ACTIVE NOT RECRUITING
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
NCT06414460 RECRUITING
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
NCT06375187 RECRUITING
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Shanghai Juncell Therapeutics
NCT06724042 NOT YET RECRUITING
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
NCT06835569 RECRUITING
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
NCT07257640 RECRUITING
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
Zhejiang University
NCT07274085 RECRUITING
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT04329494 RECRUITING
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
NCT07275853 NOT YET RECRUITING
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
TCRx Therapeutics Co.Ltd
NCT06241456 RECRUITING
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT04389632 RECRUITING
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05338658 RECRUITING
Study of PAT in Patients With Solid Tumor Cancers
Masonic Cancer Center, University of Minnesota
NCT07090499 RECRUITING
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT06736327 RECRUITING
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05521984 RECRUITING
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
NCT07269899 RECRUITING
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Sun Yat-sen University
NCT07231120 RECRUITING
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia
Jiangsu Nutai Biologics Co., Ltd
NCT07087197 RECRUITING
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06107868 ACTIVE NOT RECRUITING
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
University Health Network, Toronto
NCT06428331 RECRUITING
A Study of SKB518 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06115642 RECRUITING
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT07265921 RECRUITING
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT07134998 RECRUITING
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Jiangsu HengRui Medicine Co., Ltd.
NCT05245500 RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
NCT05394675 ACTIVE NOT RECRUITING
A Study of DS-9606a in Patients With Advanced Solid Tumors
Daiichi Sankyo
NCT05122546 ACTIVE NOT RECRUITING
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
NCT02627443 ACTIVE NOT RECRUITING
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT06826040 RECRUITING
SKB445 for Injection in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05483868 RECRUITING
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
NCT07260591 RECRUITING
VSV-02 Compassionate Use in Advanced Solid Tumors
The First Affiliated Hospital of Xinxiang Medical College
NCT02869217 ACTIVE NOT RECRUITING
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
NCT05859074 RECRUITING
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT07260513 ACTIVE NOT RECRUITING
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor.
Suzhou Genhouse Bio Co., Ltd.
NCT06001788 RECRUITING
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
NCT07021898 RECRUITING
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Erasca, Inc.
NCT05013216 RECRUITING
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07262164 NOT YET RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
Shanghai Virogin Biotech Co., Ltd.
NCT07260305 RECRUITING
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
NCT06912087 RECRUITING
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
NCT07259889 RECRUITING
Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors
Guangzhou Xiling Biotechnology Co., Ltd.
NCT07257497 NOT YET RECRUITING
Safety and Efficacy of Combining a Vitamin B6-Limited Diet With Immunotherapy in Solid Tumor Patients: A Clinical Study Protocol
West China Hospital
NCT07208136 RECRUITING
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Jemincare
NCT07252661 NOT YET RECRUITING
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
NCT06533059 RECRUITING
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
NCT06215846 ENROLLING BY INVITATION
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
NCT07207707 RECRUITING
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT04250545 ACTIVE NOT RECRUITING
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05901285 RECRUITING
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Vaxiion Therapeutics
NCT05547321 RECRUITING
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
NCT06662760 RECRUITING
Clinical Trial of TQB3002 in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT07106827 RECRUITING
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
West China Hospital
NCT06238401 RECRUITING
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
NCT06391918 ACTIVE NOT RECRUITING
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
GenVivo, Inc.
NCT05117476 ACTIVE NOT RECRUITING
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Cullinan Therapeutics Inc.
NCT07081984 RECRUITING
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Therorna
NCT05631899 ACTIVE NOT RECRUITING
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
NCT07232420 RECRUITING
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT04388852 ACTIVE NOT RECRUITING
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
NCT07021066 RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune Inc.
NCT04483778 ACTIVE NOT RECRUITING
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT03618381 ACTIVE NOT RECRUITING
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT06915753 RECRUITING
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Tyra Biosciences, Inc
NCT06328738 ACTIVE NOT RECRUITING
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
NCT07123415 RECRUITING
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Aptabio Therapeutics, Inc.
NCT04520711 ACTIVE NOT RECRUITING
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
NCT07237464 RECRUITING
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants
Shenzhen Kexing Pharmaceutical Co., Ltd.
NCT06897735 NOT YET RECRUITING
Exploratory Study of Inhaled Afatinib Dimaleate PK Profile
Petrov, Andrey
NCT04999384 RECRUITING
First in Human, Dose Escalation Study of AN4005
Adlai Nortye Biopharma Co., Ltd.
NCT05608148 RECRUITING
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Kyushu University
NCT06874335 RECRUITING
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Biohaven Therapeutics Ltd.
NCT06258408 RECRUITING
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
Broadenbio Ltd., Co.
NCT05489237 RECRUITING
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRx Inc. - A GSK Company
NCT05973487 ACTIVE NOT RECRUITING
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics, Inc.
NCT05629689 RECRUITING
A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies
GE Healthcare
NCT06143007 ACTIVE NOT RECRUITING
A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
Broadenbio Ltd., Co.
NCT07229898 RECRUITING
A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
Henan Genuine Biotech Co., Ltd.
NCT06618651 RECRUITING
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07142980 RECRUITING
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.
NCT07231081 RECRUITING
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
Tcelltech Inc.
NCT05367635 RECRUITING
A Study of SKB315 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT02595879 ACTIVE NOT RECRUITING
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
National Cancer Institute (NCI)
NCT05661461 RECRUITING
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Aadi Bioscience, Inc.
NCT06597721 RECRUITING
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
NCT06342986 RECRUITING
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT03582475 ACTIVE NOT RECRUITING
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
NCT04794699 RECRUITING
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
IDEAYA Biosciences
NCT05085548 ACTIVE NOT RECRUITING
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ProDa BioTech, LLC
NCT03093909 RECRUITING
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
NCT05458219 RECRUITING
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT06326411 RECRUITING
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Nested Therapeutics, Inc
NCT06006273 RECRUITING
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
NCT02321501 ACTIVE NOT RECRUITING
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT07139990 RECRUITING
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
University of Texas Southwestern Medical Center
NCT06858813 RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
AbbVie
NCT06675136 RECRUITING
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
City of Hope Medical Center
NCT06504368 RECRUITING
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT07098299 RECRUITING
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
Barbara Ann Karmanos Cancer Institute
NCT04620603 ACTIVE NOT RECRUITING
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Case Comprehensive Cancer Center
NCT06291987 RECRUITING
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
University of Chicago
NCT05162755 ACTIVE NOT RECRUITING
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
Institut de Recherches Internationales Servier
NCT04084067 RECRUITING
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
NCT07224568 NOT YET RECRUITING
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
Seattle Children's Hospital
NCT06714617 ACTIVE NOT RECRUITING
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune Inc.
NCT03114462 RECRUITING
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
M.D. Anderson Cancer Center
NCT06034002 RECRUITING
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
NCT05029882 ACTIVE NOT RECRUITING
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
NCT03484299 RECRUITING
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
University of Louisville
NCT02993146 ACTIVE NOT RECRUITING
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
NCT05274048 RECRUITING
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
NCT05327946 ACTIVE NOT RECRUITING
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Boehringer Ingelheim
NCT05963867 RECRUITING
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Boehringer Ingelheim
NCT02817633 ACTIVE NOT RECRUITING
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
NCT04446351 ACTIVE NOT RECRUITING
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT07218003 RECRUITING
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
NCT04897321 RECRUITING
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
NCT02668770 ACTIVE NOT RECRUITING
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
NCT04185883 ACTIVE NOT RECRUITING
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
NCT04169763 RECRUITING
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT06544655 RECRUITING
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT06084416 ACTIVE NOT RECRUITING
A Study of Sovilnesib in Subjects With Ovarian Cancer
Volastra Therapeutics, Inc.
NCT02937272 ACTIVE NOT RECRUITING
A Study of LY3200882 in Participants With Solid Tumors
Eli Lilly and Company
NCT05599984 ACTIVE NOT RECRUITING
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
NCT05661201 RECRUITING
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Georgetown University
NCT05627063 ACTIVE NOT RECRUITING
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
Abbisko Therapeutics Co, Ltd
NCT03889795 ACTIVE NOT RECRUITING
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
Danae Hamouda, MD
NCT06188208 ACTIVE NOT RECRUITING
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
NCT05768932 RECRUITING
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen, Inc.
NCT06576037 RECRUITING
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
NCT07216833 NOT YET RECRUITING
Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Kyunghee Burkitt, DO, PhD
NCT06801002 RECRUITING
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Jabez Bioscience, Inc
NCT05497778 ACTIVE NOT RECRUITING
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
NCT03435952 ACTIVE NOT RECRUITING
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
M.D. Anderson Cancer Center
NCT04050709 ACTIVE NOT RECRUITING
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
ImmunityBio, Inc.
NCT03634267 ACTIVE NOT RECRUITING
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
M.D. Anderson Cancer Center
NCT02626312 ACTIVE NOT RECRUITING
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
NCT06130254 RECRUITING
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
NCT05039801 RECRUITING
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT03162627 ACTIVE NOT RECRUITING
Selumetinib and Olaparib in Solid Tumors
M.D. Anderson Cancer Center
NCT06066424 RECRUITING
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
NCT05948826 ACTIVE NOT RECRUITING
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
NCT06752681 RECRUITING
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT06788509 ENROLLING BY INVITATION
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
NCT06403436 RECRUITING
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
TOLREMO therapeutics AG
NCT02589522 ACTIVE NOT RECRUITING
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT04058756 ACTIVE NOT RECRUITING
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis Pharmaceuticals
NCT07207681 NOT YET RECRUITING
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
The First Hospital of Jilin University
NCT06990698 RECRUITING
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
Zhuhai Fapon Biopharma Co., Ltd.
NCT07179692 RECRUITING
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT03993873 ACTIVE NOT RECRUITING
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
Turning Point Therapeutics, Inc.
NCT07200479 NOT YET RECRUITING
A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
NCT04295863 RECRUITING
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
University of Chicago
NCT06933524 NOT YET RECRUITING
Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors
Autotelicbio
NCT06136884 RECRUITING
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A2A Pharmaceuticals Inc.
NCT06126666 RECRUITING
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
NCT04887935 RECRUITING
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Washington University School of Medicine
NCT05423977 ENROLLING BY INVITATION
Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
NCT07170592 NOT YET RECRUITING
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
NCT07196579 NOT YET RECRUITING
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
TCRx Therapeutics Co.Ltd
NCT06088472 RECRUITING
TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Grit Biotechnology
NCT04794972 RECRUITING
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05470348 RECRUITING
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT04606472 ACTIVE NOT RECRUITING
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06241898 RECRUITING
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
NCT05461768 RECRUITING
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05631964 RECRUITING
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05393427 ACTIVE NOT RECRUITING
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05385692 ACTIVE NOT RECRUITING
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05194982 RECRUITING
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06953453 RECRUITING
A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors
Lee's Pharmaceutical Limited
NCT03191682 ACTIVE NOT RECRUITING
A First-in-Human Study of PRL3-ZUMAB
National University Hospital, Singapore
NCT07189949 NOT YET RECRUITING
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.
NCT05163028 ACTIVE NOT RECRUITING
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
HUYABIO International, LLC.
NCT07190833 NOT YET RECRUITING
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
NCT05485974 ACTIVE NOT RECRUITING
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
HUYABIO International, LLC.
NCT04337177 RECRUITING
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
NCT04722523 RECRUITING
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT05216432 RECRUITING
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Relay Therapeutics, Inc.
NCT06210815 RECRUITING
A Study of HLX42 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT06674538 ENROLLING BY INVITATION
Clinical Trial to Treat Stage IV Cancer Patients
Moonshot Antibodies
NCT07177937 NOT YET RECRUITING
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
NCT06636435 RECRUITING
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Chiome Bioscience Inc.
NCT06469008 RECRUITING
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06533332 RECRUITING
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
NCT06493864 RECRUITING
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06475131 RECRUITING
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06500052 RECRUITING
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT02381561 ACTIVE NOT RECRUITING
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
National Cancer Institute (NCI)
NCT06926283 RECRUITING
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
NCT06549478 RECRUITING
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
City of Hope Medical Center
NCT05204147 RECRUITING
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
City of Hope Medical Center
NCT06347068 RECRUITING
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
NCT04064359 RECRUITING
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Oxford BioTherapeutics Ltd
NCT06577987 RECRUITING
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT05055609 RECRUITING
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
Trethera
NCT06979674 RECRUITING
Study of ESG406 in Adults With Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
NCT05357651 RECRUITING
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
L & L Bio Co., Ltd., Ningbo, China
NCT05259709 RECRUITING
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
Regeneron Pharmaceuticals
NCT06983743 RECRUITING
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Erasca, Inc.
NCT02637934 RECRUITING
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Abramson Cancer Center at Penn Medicine
NCT07165132 NOT YET RECRUITING
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
NCT06014502 RECRUITING
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis
NCT06082960 ACTIVE NOT RECRUITING
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
NCT05653882 ACTIVE NOT RECRUITING
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics, Inc.
NCT06783569 RECRUITING
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
JiaRay Group
NCT06239467 RECRUITING
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
OnKure, Inc.
NCT07163325 RECRUITING
EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
Epics Therapeutics
NCT07100847 RECRUITING
Periprostatic Neurolysis in Prostate Cancer
University of Texas Southwestern Medical Center
NCT07110090 RECRUITING
Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05378425 RECRUITING
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Nectin Therapeutics Ltd
NCT05107674 RECRUITING
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
NCT05359445 RECRUITING
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Immatics Biotechnologies GmbH
NCT02496208 ACTIVE NOT RECRUITING
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
NCT06563375 RECRUITING
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
M.D. Anderson Cancer Center
NCT05533463 ACTIVE NOT RECRUITING
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Jiangsu HengRui Medicine Co., Ltd.
NCT06739291 RECRUITING
A Study of SIGX1094R in Patients With Advanced Solid Tumors
Signet Therapeutics
NCT05932862 RECRUITING
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
NCT07156253 RECRUITING
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
NCT04047251 ACTIVE NOT RECRUITING
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT07086768 NOT YET RECRUITING
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
Lei Zheng
NCT06398418 RECRUITING
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Rise Therapeutics LLC
NCT05411133 RECRUITING
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
Arbele Pty Ltd
NCT05241834 ACTIVE NOT RECRUITING
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Eli Lilly and Company
NCT06694480 RECRUITING
Study of FID-022 in Participants With Advanced Solid Tumors
Fulgent Pharma LLC.
NCT06873659 RECRUITING
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen Inc.
NCT07132541 RECRUITING
Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate)
Minia University
NCT07075185 RECRUITING
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Kelonia Therapeutics, Inc.
NCT05701488 RECRUITING
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Jiping Wang, MD, PhD
NCT05076760 RECRUITING
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen, Inc.
NCT06040541 RECRUITING
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
NCT03611595 RECRUITING
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Peter Zage
NCT06806982 RECRUITING
A Study of VRN101099 in Patients With HER2-Positive Solid Tumors
Voronoi, Inc
NCT07144085 NOT YET RECRUITING
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
Yi Tian
NCT05735366 ACTIVE NOT RECRUITING
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
Chugai Pharmaceutical
NCT05836896 RECRUITING
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Technische Universität Dresden
NCT05752552 ACTIVE NOT RECRUITING
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
DeuterOncology
NCT07139067 RECRUITING
Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors
Peking University
NCT07056556 RECRUITING
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT07136558 NOT YET RECRUITING
Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
NCT05835609 RECRUITING
PM534 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar
NCT07135128 RECRUITING
A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors
Xiaorong Sun
NCT05782361 RECRUITING
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Institute of Cancer Research, United Kingdom
NCT06487455 RECRUITING
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
Shanghai Pharmaceuticals Holding Co., Ltd
NCT06036121 ACTIVE NOT RECRUITING
A Study of ADRX-0706 in Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT04429542 RECRUITING
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT05906862 RECRUITING
AMT-253 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics (Australia) Pty Ltd
NCT05717348 ACTIVE NOT RECRUITING
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
Elpiscience (Suzhou) Biopharma, Ltd.
NCT06547957 ACTIVE NOT RECRUITING
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
iTeos Therapeutics
NCT04890613 RECRUITING
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Senhwa Biosciences, Inc.
NCT07119996 NOT YET RECRUITING
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT05718219 ACTIVE NOT RECRUITING
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT07118176 RECRUITING
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
NCT07117214 NOT YET RECRUITING
A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
Novartis Pharmaceuticals
NCT07118709 NOT YET RECRUITING
A Study of KC1086 in Patients With Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
NCT03893955 ACTIVE NOT RECRUITING
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT05279300 RECRUITING
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
NCT05836948 RECRUITING
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT07110883 RECRUITING
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT05226507 ACTIVE NOT RECRUITING
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Nuvectis Pharma, Inc.
NCT07100249 RECRUITING
A Study of HDM2012 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT06375564 RECRUITING
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
The First Affiliated Hospital of Xiamen University
NCT05906537 ACTIVE NOT RECRUITING
SKB410 for Injection in Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
NCT07110363 NOT YET RECRUITING
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
Biotroy Therapeutics
NCT07107178 NOT YET RECRUITING
A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma
Biotroy Therapeutics
NCT06960395 RECRUITING
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology, Inc.
NCT04778839 RECRUITING
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
NCT05740202 ACTIVE NOT RECRUITING
A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT04046133 ACTIVE NOT RECRUITING
Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus
Cardiff University
NCT07101549 NOT YET RECRUITING
Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18)
changjianhua
NCT03872947 ACTIVE NOT RECRUITING
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
NCT07072325 NOT YET RECRUITING
Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers
West China Hospital
NCT07100925 NOT YET RECRUITING
A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma
Ankyra Therapeutics, Inc
NCT06463340 RECRUITING
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Schrödinger, Inc.
NCT07098052 RECRUITING
A Study of HDM2020 in Patients With Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT04572451 RECRUITING
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Yana Najjar
NCT05735496 ACTIVE NOT RECRUITING
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT05635643 RECRUITING
Study of CHS-114 in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT06756035 RECRUITING
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
NCT02498912 ACTIVE NOT RECRUITING
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT05879627 ACTIVE NOT RECRUITING
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Bio-Thera Solutions
NCT05617755 ACTIVE NOT RECRUITING
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc.
NCT05341349 ACTIVE NOT RECRUITING
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
NCT07092748 RECRUITING
A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors
Zhejiang Hisun Pharmaceutical Co. Ltd.
NCT06220838 RECRUITING
Study SC-101 in Subjects With Advanced Malignancies
Tianjin ConjuStar Biologics Co., Ltd.
NCT06710158 RECRUITING
Study of SC-102 in Patients With Advanced Solid Tumors
Tianjin ConjuStar Biologics Co., Ltd.
NCT07088588 NOT YET RECRUITING
Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
NCT06761937 RECRUITING
Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients
Erasmus Medical Center
NCT05217693 RECRUITING
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
NCT06644755 RECRUITING
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT06992713 RECRUITING
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
NCT07071090 RECRUITING
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Heronova Pharmaceuticals
NCT03772561 RECRUITING
Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
National University Hospital, Singapore
NCT05701709 RECRUITING
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06666270 RECRUITING
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
NCT06826313 RECRUITING
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
NCT06171750 RECRUITING
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ankyra Therapeutics, Inc
NCT06963814 RECRUITING
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
HC Biopharma Inc.
NCT06929663 RECRUITING
A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors
Akeso
NCT05881525 RECRUITING
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
TCRCure Biopharma Ltd.
NCT04189614 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
AbbVie
NCT04457232 ACTIVE NOT RECRUITING
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
Jonsson Comprehensive Cancer Center
NCT06128148 RECRUITING
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Guangzhou JOYO Pharma Co., Ltd
NCT04511845 ACTIVE NOT RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Chugai Pharmaceutical
NCT07060014 NOT YET RECRUITING
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
The Methodist Hospital Research Institute
NCT06993870 RECRUITING
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.
NCT04046575 ACTIVE NOT RECRUITING
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Washington University School of Medicine
NCT06720987 RECRUITING
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences Inc.
NCT05857969 RECRUITING
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Florida International University
NCT06719362 RECRUITING
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
NCT02974738 ACTIVE NOT RECRUITING
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02474368 ACTIVE NOT RECRUITING
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
Dana-Farber Cancer Institute
NCT05103631 RECRUITING
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
NCT03336606 ACTIVE NOT RECRUITING
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
NCT04470024 RECRUITING
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
Providence Health & Services
NCT07057349 NOT YET RECRUITING
CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
Cytosite Biopharma Inc.
NCT04460937 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
NCT07054307 NOT YET RECRUITING
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma
Jiyan Liu
NCT06980454 ACTIVE NOT RECRUITING
Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
Shanghai Henlius Biotech
NCT07053735 NOT YET RECRUITING
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
Peking University First Hospital
NCT07053904 ENROLLING BY INVITATION
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
PharmaEssentia
NCT02112565 ACTIVE NOT RECRUITING
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
City of Hope Medical Center
NCT06548217 ACTIVE NOT RECRUITING
A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
NCT07050459 RECRUITING
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT06132828 RECRUITING
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
Zhejiang Doer Biologics Co., Ltd.
NCT04721015 ACTIVE NOT RECRUITING
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
AbbVie
NCT07045428 NOT YET RECRUITING
68Ga-GP-01 Injection in Solid Tumors Participants
GrandPharma (China) Co., Ltd.
NCT07040943 RECRUITING
Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
West China Hospital
NCT06410131 RECRUITING
Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16
Sound Biopharmaceuticals Ltd.
NCT06415487 RECRUITING
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Acepodia Biotech, Inc.
NCT05277766 RECRUITING
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
University Hospital, Ghent
NCT04740424 RECRUITING
FS222 First in Human Study in Patients With Advanced Malignancies
invoX Pharma Limited
NCT07045454 RECRUITING
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
Minghui Pharmaceutical (Hangzhou) Ltd
NCT06163391 RECRUITING
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
SOTIO Biotech AG
NCT04827810 RECRUITING
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
Fox Chase Cancer Center
NCT06240728 RECRUITING
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
NextPoint Therapeutics, Inc.
NCT05276310 RECRUITING
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
NCT04648202 ACTIVE NOT RECRUITING
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
invoX Pharma Limited
NCT04521686 ACTIVE NOT RECRUITING
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT06076291 ACTIVE NOT RECRUITING
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
NCT04603001 ACTIVE NOT RECRUITING
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT07038044 NOT YET RECRUITING
Safety and Efficacy of an Arginine-Restricted Diet in Patients With Solid Tumors
West China Hospital
NCT05785754 RECRUITING
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
NCT05354323 ACTIVE NOT RECRUITING
NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
NEC OncoImmunity AS
NCT05935098 ACTIVE NOT RECRUITING
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
BeiGene
NCT03264664 ACTIVE NOT RECRUITING
Study of E7386 in Participants With Selected Advanced Neoplasms
Eisai Inc.
NCT06431594 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT04997993 RECRUITING
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
Deborah Doroshow
NCT06601218 RECRUITING
Impact of Daily Oral Cannabis Doses in Patients With Cancer
Shanna Babalonis, PhD
NCT07028047 NOT YET RECRUITING
Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study
Sun Yat-sen University
NCT05329103 RECRUITING
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Peel Therapeutics Inc
NCT07021534 RECRUITING
Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial
Zhejiang University
NCT06349811 RECRUITING
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06046066 RECRUITING
A Phase 1 Study of NM6603 in Advanced Solid Tumors
NucMito Pharmaceuticals Co. Ltd.
NCT04823897 RECRUITING
A Study of CCI-001 in Patients With Recurrent and/or Metastatic Solid Tumours
PharmaMatrix Holdings Ltd
NCT07016997 RECRUITING
A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.
Chiome Bioscience Inc.
NCT07014878 NOT YET RECRUITING
A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors
Beijing DCTY Biotech Co.,Ltd.
NCT06883149 RECRUITING
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
Chinese PLA General Hospital
NCT04412616 RECRUITING
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
Changchun Intellicrown Pharmaceutical Co. LTD
NCT06028373 RECRUITING
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited
NCT05205109 RECRUITING
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
Antengene Therapeutics Limited
NCT02608385 ACTIVE NOT RECRUITING
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
NCT07004296 RECRUITING
A Study of HDM2005 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT06063681 RECRUITING
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Stingray Therapeutics
NCT06110195 ACTIVE NOT RECRUITING
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
NCT06963281 RECRUITING
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
NCT06878612 RECRUITING
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
Xingchen Peng
NCT05718895 RECRUITING
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Antengene Biologics Limited
NCT06253195 ACTIVE NOT RECRUITING
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
BeiGene
NCT05740956 RECRUITING
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT03155061 ACTIVE NOT RECRUITING
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
NCT06898255 RECRUITING
A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia
Genfleet Therapeutics (Shanghai) Inc.
NCT07001592 RECRUITING
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT06927297 RECRUITING
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
West China Hospital
NCT05518253 RECRUITING
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Weijia Fang, MD
NCT06998173 NOT YET RECRUITING
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
Danatlas Pharmaceuticals Co., Ltd
NCT06954077 RECRUITING
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT04866641 RECRUITING
Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors
Taivex Therapeutics Corporation
NCT05704985 ACTIVE NOT RECRUITING
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT04221204 ACTIVE NOT RECRUITING
A Monotherapy in Subjects With Advanced Solid Tumors
3D Medicines (Beijing) Co., Ltd.
NCT06644573 NOT YET RECRUITING
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
Nyree Penn
NCT03821935 ACTIVE NOT RECRUITING
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT06902350 RECRUITING
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
NCT06337084 RECRUITING
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Monopar Therapeutics
NCT04616534 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
National Cancer Institute (NCI)
NCT04192344 RECRUITING
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Abbisko Therapeutics Co, Ltd
NCT04354246 ACTIVE NOT RECRUITING
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
NCT06912152 RECRUITING
MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors
Zhejiang University
NCT06246968 RECRUITING
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05048368 NOT YET RECRUITING
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
Sunshine Lake Pharma Co., Ltd.
NCT05678010 ACTIVE NOT RECRUITING
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT03440450 ACTIVE NOT RECRUITING
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT06532565 RECRUITING
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Gilead Sciences
NCT04137536 ACTIVE NOT RECRUITING
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT02663297 ACTIVE NOT RECRUITING
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
NCT06673329 RECRUITING
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06958679 RECRUITING
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06970795 RECRUITING
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
NCT06968572 RECRUITING
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
Haisco Pharmaceutical Group Co., Ltd.
NCT06307925 RECRUITING
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
HC Biopharma Inc.
NCT06966583 NOT YET RECRUITING
NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC
Sichuan University
NCT05765851 ACTIVE NOT RECRUITING
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT06963398 NOT YET RECRUITING
A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT06963502 NOT YET RECRUITING
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT06962254 RECRUITING
Imatinib and Trametinib for KRAS-mutated Solid Tumor
China Medical University Hospital
NCT04502602 ACTIVE NOT RECRUITING
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
Virginia Commonwealth University
NCT06954558 RECRUITING
A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
NCT06934616 NOT YET RECRUITING
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
Genor Biopharma Co., Ltd.
NCT05598151 RECRUITING
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT06747390 RECRUITING
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Ryan Carey
NCT05167071 ACTIVE NOT RECRUITING
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Harbour BioMed (Guangzhou) Co. Ltd.
NCT06907628 RECRUITING
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06944457 RECRUITING
Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
Pharosgen Co.,Ltd
NCT06188624 RECRUITING
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT05967533 RECRUITING
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT06932094 NOT YET RECRUITING
Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06307795 RECRUITING
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
NCT06936735 NOT YET RECRUITING
Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT05919537 ACTIVE NOT RECRUITING
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Hummingbird Bioscience
NCT06235983 ACTIVE NOT RECRUITING
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT05509790 ACTIVE NOT RECRUITING
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
Eli Lilly and Company
NCT05749432 RECRUITING
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
Ganzhou Hemay Pharmaceutical Co., Ltd
NCT02204098 ACTIVE NOT RECRUITING
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
Washington University School of Medicine
NCT06925659 NOT YET RECRUITING
A Study of QLM2011 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical (Hainan) Co., Ltd.
NCT06475937 RECRUITING
A Study of DM001 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT04868773 ACTIVE NOT RECRUITING
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
NCT05473624 RECRUITING
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06462365 RECRUITING
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
NCT06094556 RECRUITING
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT03696030 ACTIVE NOT RECRUITING
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
City of Hope Medical Center
NCT06462716 ACTIVE NOT RECRUITING
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
NCT06508138 ENROLLING BY INVITATION
Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06716138 RECRUITING
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
NCT05969314 ACTIVE NOT RECRUITING
To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer
Tata Memorial Hospital
NCT06672523 RECRUITING
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
Bristol-Myers Squibb
NCT06258304 RECRUITING
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
GigaGen, Inc.
NCT06710379 RECRUITING
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT04685473 ACTIVE NOT RECRUITING
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
NCT06621563 RECRUITING
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06096974 RECRUITING
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Shanghai YingLi Pharmaceutical Co. Ltd.
NCT04419532 ACTIVE NOT RECRUITING
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo Co., Ltd.
NCT05495295 RECRUITING
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Phost'In Therapeutics
NCT06913218 NOT YET RECRUITING
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
Akeso
NCT05544240 RECRUITING
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Williams Cancer Foundation
NCT04751786 ACTIVE NOT RECRUITING
Dose Escalation Study of Immunomodulatory Nanoparticles
Radboud University Medical Center
NCT05868226 RECRUITING
PRE-I-SPY Phase I/Ib Oncology Platform Program
QuantumLeap Healthcare Collaborative
NCT06446713 RECRUITING
PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer
University Medical Center Groningen
NCT06885645 NOT YET RECRUITING
First-In-Human Study in Participants With Advanced Solid Tumors
Chengdu Kanghong Biotech Co., Ltd.
NCT05477849 RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
Shanghai Virogin Biotech Co., Ltd.
NCT03478462 ACTIVE NOT RECRUITING
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Cellectar Biosciences, Inc.
NCT06796699 RECRUITING
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT06716619 RECRUITING
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
NCT06897228 RECRUITING
PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors
Shenzhen Celconta Life Science Co., Ltd.
NCT04877717 ACTIVE NOT RECRUITING
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT06687941 RECRUITING
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Aptamer Sciences, Inc.
NCT06816992 RECRUITING
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
NCT06587295 RECRUITING
Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy
National Cancer Centre, Singapore
NCT04328844 ACTIVE NOT RECRUITING
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
NCT05828459 RECRUITING
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Onward Therapeutics
NCT06883539 RECRUITING
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
LaunXP Biomedical Co., Ltd.
NCT06718621 RECRUITING
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT06158139 RECRUITING
Autologous CAR-T Cells Targeting B7-H3 in PDAC
UNC Lineberger Comprehensive Cancer Center
NCT06541639 RECRUITING
EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors
Peking University
NCT06108479 RECRUITING
Study of DF6215 in Patients with Advanced Solid Tumors
Dragonfly Therapeutics
NCT06132503 RECRUITING
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Lantern Pharma Inc.
NCT04998422 RECRUITING
A Study of HG381 Administered to Patients With Advanced Solid Tumors
HitGen Inc.
NCT06220864 RECRUITING
SNV1521 in Participants with Advanced Solid Tumors
Synnovation Therapeutics, Inc.
NCT06046742 RECRUITING
A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors
Guangzhou Virotech Pharmaceutical Co., Ltd.
NCT06726369 RECRUITING
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT06707610 RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
NCT06872580 NOT YET RECRUITING
A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT06167317 RECRUITING
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Gilead Sciences
NCT06595329 RECRUITING
Comparison Between Epidural Analgesia and Intrathecal Opioid Analgesia for Pain Management in Open Nephrectomy
University Hospital of Split
NCT04196257 RECRUITING
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings, Inc.
NCT05285358 RECRUITING
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
NCT05907980 RECRUITING
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Chugai Pharmaceutical
NCT06069570 RECRUITING
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Kiromic BioPharma Inc.
NCT05036291 RECRUITING
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Ningbo Newbay Technology Development Co., Ltd
NCT06352359 RECRUITING
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4, Inc.
NCT06443489 RECRUITING
A Trial of SHR-4849 in Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06005740 RECRUITING
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
TORL Biotherapeutics, LLC
NCT05607498 RECRUITING
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
NCT06035744 RECRUITING
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Cullinan Therapeutics Inc.
NCT03594422 RECRUITING
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Ascentage Pharma Group Inc.
NCT06687070 RECRUITING
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Ascentage Pharma Group Inc.
NCT05701306 RECRUITING
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Ascentage Pharma Group Inc.
NCT06394414 RECRUITING
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06484816 RECRUITING
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Shenzhen TargetRx, Inc.
NCT06571422 RECRUITING
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT06328439 RECRUITING
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
NCT06831539 RECRUITING
Impact of PEG Bowel Preparation on Gut Microbiome Composition Recovery
Centre hospitalier de l'Université de Montréal (CHUM)
NCT05430360 RECRUITING
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors
Grit Biotechnology
NCT04643574 ACTIVE NOT RECRUITING
NeoTIL in Advanced Solid Tumors
Centre Hospitalier Universitaire Vaudois
NCT05580991 ACTIVE NOT RECRUITING
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
Canwell Biotech Limited
NCT04670679 ACTIVE NOT RECRUITING
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Erasca, Inc.
NCT06051760 RECRUITING
NV-001 in the Treatment of Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06773091 RECRUITING
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
Shanghai NK Cell Technology Co., LTD
NCT06801470 RECRUITING
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
CD (Suzhou) Biopharma Co., Ltd.
NCT06074497 ACTIVE NOT RECRUITING
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.
Kangabio AUSTRALIA LTD PTY
NCT05430373 RECRUITING
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Grit Biotechnology
NCT04762641 RECRUITING
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
ABL Bio, Inc.
NCT03860272 ACTIVE NOT RECRUITING
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
NCT04701645 RECRUITING
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT05858736 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
OncoC4, Inc.
NCT04872166 RECRUITING
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Edgewood Oncology Inc.
NCT04423029 RECRUITING
A Study of DF6002 Alone and in Combination With Nivolumab
Dragonfly Therapeutics
NCT06800196 NOT YET RECRUITING
A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations
KinoTeck Therapeutics Co., Ltd
NCT06224855 RECRUITING
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Hangzhou DAC Biotechnology Co., Ltd.
NCT05341557 RECRUITING
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Betta Pharmaceuticals Co., Ltd.
NCT06349408 RECRUITING
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT03791112 ACTIVE NOT RECRUITING
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
NCT05789602 RECRUITING
A Study of BPI-460372 in Advanced Solid Tumor Patients
Betta Pharmaceuticals Co., Ltd.
NCT06772415 RECRUITING
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT06418061 RECRUITING
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT06299124 ACTIVE NOT RECRUITING
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
Regor Pharmaceuticals Inc.
NCT06781125 NOT YET RECRUITING
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
NCT06782425 RECRUITING
Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T)
Shenzhen Celconta Life Science Co., Ltd.
NCT06779045 NOT YET RECRUITING
A Study of AK-1286 in Patients With Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
NCT06770764 RECRUITING
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
Trutino Biosciences Inc.
NCT05957536 RECRUITING
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
D3 Bio (Wuxi) Co., Ltd
NCT06764836 RECRUITING
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT06763159 RECRUITING
A Study of HS-20124 in Patients with Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06686745 RECRUITING
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT06760117 RECRUITING
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
Sun Yat-sen University
NCT04900818 RECRUITING
Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT06755242 NOT YET RECRUITING
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT05238792 RECRUITING
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients with High Risk Solid Tumors
Children's National Research Institute
NCT06752447 NOT YET RECRUITING
A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors
Shandong New Time Pharmaceutical Co., LTD
NCT06748872 NOT YET RECRUITING
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
Medigene AG
NCT06404905 RECRUITING
Clinical Trial of BT02 in Patients With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05954091 NOT YET RECRUITING
OH2 Administered by Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
NCT02789228 ACTIVE NOT RECRUITING
Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors
Children's National Research Institute
NCT06742593 NOT YET RECRUITING
Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
Suzhou Maximum Bio-tech Co., Ltd.
NCT04660929 ACTIVE NOT RECRUITING
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
NCT05694715 RECRUITING
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
NCT05076396 RECRUITING
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
PharmaMar
NCT04576091 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
NCT06730659 RECRUITING
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
NCT06728189 RECRUITING
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors
Peking University Cancer Hospital & Institute
NCT06726564 RECRUITING
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
NCT04104607 RECRUITING
The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma
University Hospital Tuebingen
NCT06723964 ACTIVE NOT RECRUITING
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
AP Biosciences Inc.
NCT06426680 RECRUITING
A Study of the ILB-3101 in Patients with Advanced Solid Tumors
Innolake Biopharm
NCT04928508 RECRUITING
Advanced or Recurrent Solid Tumors Treated With SHetA2
University of Oklahoma
NCT04443088 ACTIVE NOT RECRUITING
An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors
Shenzhen Ionova Life Sciences Co., Ltd.
NCT06302062 RECRUITING
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
NCT06710821 NOT YET RECRUITING
Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors
Yizhuo Zhang
NCT04516447 RECRUITING
A Study of ZN-c3 in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT05349890 ACTIVE NOT RECRUITING
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
Providence Health & Services
NCT05302037 RECRUITING
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
CytoMed Therapeutics Pte Ltd
NCT03842085 RECRUITING
Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
Beijing Mabworks Biotech Co., Ltd.
NCT06084286 RECRUITING
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Sichuan University
NCT06158477 RECRUITING
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Chengdu JOYO pharma Co., Ltd.
NCT06026254 ACTIVE NOT RECRUITING
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
ImmuneSensor Therapeutics Inc.
NCT06169579 ENROLLING BY INVITATION
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Shenzhen NewDEL Biotech, Co., Ltd
NCT05382325 ACTIVE NOT RECRUITING
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Merck Sharp & Dohme LLC
NCT05463952 ACTIVE NOT RECRUITING
A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
Pfizer
NCT03568058 ACTIVE NOT RECRUITING
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Ezra Cohen
NCT05278546 ACTIVE NOT RECRUITING
A Study of ILB2109 in Patients With Advanced Solid Malignancies
Innolake Biopharm
NCT05156203 RECRUITING
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
Taivex Therapeutics Corporation
NCT05650242 RECRUITING
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
Shandong Boan Biotechnology Co., Ltd
NCT03907527 ACTIVE NOT RECRUITING
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Precigen, Inc
NCT06190886 RECRUITING
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Proviva Therapeutics, Inc.
NCT05983523 RECRUITING
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
PharmaEngine
NCT05462717 ACTIVE NOT RECRUITING
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
NCT06652529 NOT YET RECRUITING
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
Aromics Therapeutics
NCT04130542 ACTIVE NOT RECRUITING
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
NCT04635995 ACTIVE NOT RECRUITING
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
NCT04261413 RECRUITING
Phase Ia/Ib Study of RS-0139 in Patients with a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
NCT05772455 RECRUITING
A Study of XZB-0004 in Patients With Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
NCT04511871 ACTIVE NOT RECRUITING
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Shanghai PerHum Therapeutics Co., Ltd.
NCT05548634 ACTIVE NOT RECRUITING
A Study of TAVO412 in Patients with Cancer
Tavotek Biotherapeutics
NCT05159440 ACTIVE NOT RECRUITING
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
TORL Biotherapeutics, LLC
NCT06649656 NOT YET RECRUITING
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
NCT04387916 RECRUITING
A Study of KC1036 in Patients with Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
NCT04093466 RECRUITING
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
NCT06196762 RECRUITING
Phase I of XKH002 Injection in Patients
Zhejiang Kanova Biopharmaceutical Co., LTD
NCT02521844 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
NCT06160752 RECRUITING
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Tyra Biosciences, Inc
NCT03603951 ACTIVE NOT RECRUITING
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Jiangsu HengRui Medicine Co., Ltd.
NCT06621615 NOT YET RECRUITING
Clinical Study of CVL006 Injection in Advanced Solid Tumors
Convalife (Shanghai) Co., Ltd.
NCT03546426 ACTIVE NOT RECRUITING
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT06614751 NOT YET RECRUITING
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
Danatlas Pharmaceuticals Co., Ltd
NCT06615193 RECRUITING
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT06614686 RECRUITING
U87 CAR-T in Patients With Advanced Head and Neck Tumors
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NCT06234397 RECRUITING
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
NCT06259552 RECRUITING
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co., Ltd.
NCT06598735 NOT YET RECRUITING
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT06594874 NOT YET RECRUITING
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT04811703 RECRUITING
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer
Hospices Civils de Lyon
NCT03891706 RECRUITING
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
NCT05773937 RECRUITING
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
NCT06389526 NOT YET RECRUITING
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Coherus Oncology, Inc.
NCT06592417 RECRUITING
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT01883297 ACTIVE NOT RECRUITING
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University Health Network, Toronto
NCT06582017 RECRUITING
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
NCT04928612 RECRUITING
A Study of CBP-1018 in Patients With Advanced Solid Tumors
Coherent Biopharma (Suzhou) Co., Ltd.
NCT04931823 ACTIVE NOT RECRUITING
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
NCT04740398 RECRUITING
A Study of CBP-1008 in Patients With Advanced Solid Tumor
Coherent Biopharma (Suzhou) Co., Ltd.
NCT06404281 RECRUITING
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
Changzhou No.2 People's Hospital
NCT06558175 NOT YET RECRUITING
Reirradiation Dose Escalation in Thoracic Cancers
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT05351502 RECRUITING
A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors
Beyond Air Inc.
NCT06553846 NOT YET RECRUITING
A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors
Fudan University
NCT05244551 RECRUITING
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Abbisko Therapeutics Co, Ltd
NCT06549751 NOT YET RECRUITING
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Marker Therapeutics, Inc.
NCT06548672 RECRUITING
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
Biocity Biopharmaceutics Co., Ltd.
NCT06544720 RECRUITING
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
The Affiliated Hospital of Qingdao University
NCT06452160 RECRUITING
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences Inc.
NCT05266612 RECRUITING
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
Virogin Biotech Canada Ltd
NCT06536400 RECRUITING
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
Haisco Pharmaceutical Group Co., Ltd.
NCT06271252 RECRUITING
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd.
NCT05861895 RECRUITING
A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors
HighField Biopharmaceuticals Corporation
NCT06533605 NOT YET RECRUITING
Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
NCT05076552 ACTIVE NOT RECRUITING
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Tachyon Therapeutics, Inc.
NCT06257680 RECRUITING
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
Aeonvital Biomedicine
NCT05474859 NOT YET RECRUITING
Subjects With Advanced or Metastatic Solid Tumor Malignancies
Xenthera, Inc.
NCT06530082 NOT YET RECRUITING
A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06528249 NOT YET RECRUITING
Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies
Zhejiang Provincial People's Hospital
NCT06386705 RECRUITING
TSN084 Treating Patients With Advanced Malignant Tumors
Tyligand Bioscience (Shanghai) Limited
NCT06256055 RECRUITING
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
NCT05639153 RECRUITING
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
Zhejiang Doer Biologics Co., Ltd.
NCT05878691 ACTIVE NOT RECRUITING
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Glenmark Specialty S.A.
NCT05731752 ACTIVE NOT RECRUITING
Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
NCT06332170 RECRUITING
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT06336707 RECRUITING
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT05979155 RECRUITING
A Study of NWY001 in Subjects With Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
NCT06501183 RECRUITING
Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors
Shanghai Pudong Hospital
NCT05620862 ACTIVE NOT RECRUITING
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
Sun Yat-sen University
NCT05010694 ACTIVE NOT RECRUITING
GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results
Suzhou Genhouse Bio Co., Ltd.
NCT06329206 RECRUITING
A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
NCT05948865 RECRUITING
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
NCT06413953 RECRUITING
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06477614 RECRUITING
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT05830045 RECRUITING
A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT04952272 RECRUITING
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT06196294 RECRUITING
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
NCT06195384 RECRUITING
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT06195293 RECRUITING
Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT04842812 RECRUITING
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT05410717 RECRUITING
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT03778814 RECRUITING
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
NCT06473948 NOT YET RECRUITING
To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
Jemincare
NCT05300438 ACTIVE NOT RECRUITING
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.
Tyligand Bioscience (Shanghai) Limited
NCT03198052 RECRUITING
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
NCT05779917 RECRUITING
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
NCT03530397 ACTIVE NOT RECRUITING
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT05819684 RECRUITING
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06445517 RECRUITING
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
InSilico Medicine Hong Kong Limited
NCT06399419 RECRUITING
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Osel, Inc.
NCT06433726 RECRUITING
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
NCT06421610 RECRUITING
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
Odense University Hospital
NCT05564858 RECRUITING
A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NCT06415903 NOT YET RECRUITING
A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06415500 NOT YET RECRUITING
A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites
Anhui Provincial Hospital
NCT06418113 RECRUITING
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
Hospital San Carlos, Madrid
NCT05650580 RECRUITING
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Tarapeutics Science Inc.
NCT06410092 RECRUITING
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
Sound Biopharmaceuticals Ltd.
NCT06403735 RECRUITING
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
NCT05868174 RECRUITING
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Limited
NCT06086522 RECRUITING
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Qualigen Theraputics, Inc.
NCT06394622 RECRUITING
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Fudan University
NCT05909241 RECRUITING
A Study of BA1202 in Patients With Advanced Solid Tumors
Shandong Boan Biotechnology Co., Ltd
NCT06383507 NOT YET RECRUITING
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Zhejiang University
NCT05989724 RECRUITING
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen Inc.
NCT05700084 RECRUITING
Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
NCT06374173 RECRUITING
A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
Hefei TG ImmunoPharma Co., Ltd.
NCT06368960 RECRUITING
BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors
InnoBM Pharmaceuticals Co., Ltd.
NCT06358053 NOT YET RECRUITING
CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
Corregene Biotechnology Co., Ltd
NCT06348290 NOT YET RECRUITING
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
Jemincare
NCT05263479 RECRUITING
A Study of HS-20089 in Patients With Advanced Solid Tumors
Shanghai Hansoh Biomedical Co., Ltd
NCT06247657 RECRUITING
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours
Shanghai Best-Link Bioscience, LLC
NCT06342336 RECRUITING
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Qingdao Sino-Cell Biomedicine Co., Ltd.
NCT05394168 ACTIVE NOT RECRUITING
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
NCT03560882 ACTIVE NOT RECRUITING
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Joaquina Baranda
NCT06223256 RECRUITING
A Study of NBL-028 in Patients With Advanced Solid Tumors
NovaRock Biotherapeutics, Ltd
NCT05037149 ACTIVE NOT RECRUITING
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Sirnaomics
NCT06240546 RECRUITING
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
Luye Pharma Group Ltd.
NCT05798026 RECRUITING
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Eutilex
NCT04965077 RECRUITING
Treatment of Advanced and Metastatic Solid Tumors With MIL97
Beijing Mabworks Biotech Co., Ltd.
NCT05103046 RECRUITING
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
NCT05894421 RECRUITING
TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06307249 RECRUITING
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Lebanese University
NCT04695327 RECRUITING
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy
TILT Biotherapeutics Ltd.
NCT05877664 RECRUITING
Study of ZG0895.HCl in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06101082 RECRUITING
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
China Medical University, China
NCT04766320 RECRUITING
Study on TIL for the Treatment of r/r Gynecologic Tumors
Shanghai 10th People's Hospital
NCT06205082 ENROLLING BY INVITATION
A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor
LittDD Medicines Ltd
NCT06277804 NOT YET RECRUITING
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor
Letolab
NCT04282044 RECRUITING
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04137900 RECRUITING
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
NCT06037317 RECRUITING
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors
Shouyao Holdings (Beijing) Co. LTD
NCT06225856 RECRUITING
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
Shanghai Yuyao Biotech Co., Ltd.
NCT05605119 RECRUITING
First in Human, Dose Escalation, Dose Expansion Study of AUR105
Aurigene Discovery Technologies Limited
NCT05607199 RECRUITING
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Aurigene Discovery Technologies Limited
NCT06215950 RECRUITING
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Chongqing Precision Biotech Co., Ltd
NCT06211647 RECRUITING
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Ruimin Wang
NCT06209385 RECRUITING
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT02792465 ACTIVE NOT RECRUITING
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
University Health Network, Toronto
NCT05582590 NOT YET RECRUITING
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
NexImmune Inc.
NCT06197139 RECRUITING
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Xinlu Wang
NCT06193993 ACTIVE NOT RECRUITING
Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients
National University Hospital, Singapore
NCT06170294 RECRUITING
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
Peking University
NCT06166472 NOT YET RECRUITING
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
Akeso
NCT05940896 RECRUITING
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
RemeGen Co., Ltd.
NCT06134531 NOT YET RECRUITING
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
Nanfang Hospital, Southern Medical University
NCT06134960 NOT YET RECRUITING
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
Peking University
NCT06131216 NOT YET RECRUITING
Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06126406 RECRUITING
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT06121557 RECRUITING
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06010875 RECRUITING
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT06121570 RECRUITING
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06010862 RECRUITING
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT05866692 RECRUITING
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
TYK Medicines, Inc
NCT05895825 RECRUITING
A Study of EOC237 in Patients With Advanced Solid Tumor
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
NCT06093698 NOT YET RECRUITING
An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
ITabMed Co., Ltd.
NCT05621486 ACTIVE NOT RECRUITING
A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors
Shanghai East Hospital
NCT06072989 RECRUITING
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors
Shanghai East Hospital
NCT06054932 RECRUITING
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
Beijing Likang Life Science and Tech Co., Ltd.
NCT06043466 RECRUITING
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT06026800 RECRUITING
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms
Sir Run Run Shaw Hospital
NCT06026774 RECRUITING
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Sir Run Run Shaw Hospital
NCT06019702 RECRUITING
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
Sir Run Run Shaw Hospital
NCT06027346 RECRUITING
A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours
Shijiazhuang Yiling Pharmaceutical Co. Ltd
NCT05631886 RECRUITING
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
NCT05982080 RECRUITING
A Study to Investigate FP002 in Subjects With Advanced Malignancies
Guangdong Fapon Biopharma Inc.
NCT05767684 RECRUITING
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
NCT05990621 RECRUITING
Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms
Changhai Hospital
NCT05788107 NOT YET RECRUITING
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
NCT05886374 RECRUITING
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
Hutchmed
NCT05940116 NOT YET RECRUITING
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NCT05933668 NOT YET RECRUITING
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor
Peking University
NCT05924906 NOT YET RECRUITING
A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors
Suzhou Neologics Bioscience Co., Ltd.
NCT05911464 RECRUITING
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT05823285 RECRUITING
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
NCT05232409 RECRUITING
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Valley Health System
NCT05361954 NOT YET RECRUITING
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
NCT05804864 NOT YET RECRUITING
A Study of KM501 in Patients With Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05783089 NOT YET RECRUITING
MSLN-targeted CAR-T Cells in Solid Tumors.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05781048 NOT YET RECRUITING
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT05766527 NOT YET RECRUITING
A Study of KM602 in Patients With Advanced Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05095441 NOT YET RECRUITING
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
ImmVira Pharma Co. Ltd
NCT05528055 RECRUITING
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT02477878 ACTIVE NOT RECRUITING
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT05392699 RECRUITING
ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05320874 NOT YET RECRUITING
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
Xuanzhu Biopharmaceutical Co., Ltd.
NCT05172310 RECRUITING
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
Karolinska University Hospital
NCT03420963 TERMINATED
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
NCT06894771 COMPLETED
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Merck Sharp & Dohme LLC
NCT06287463 TERMINATED
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Deciphera Pharmaceuticals, LLC
NCT02379416 COMPLETED
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
National Cancer Institute (NCI)
NCT06625515 TERMINATED
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
NCT06546553 TERMINATED
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
NCT03388619 COMPLETED
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Cancer Institute (NCI)
NCT05381909 TERMINATED
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeiGene
NCT05233436 TERMINATED
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Pfizer
NCT05578092 TERMINATED
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
NCT03964233 COMPLETED
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
NCT05638334 TERMINATED
Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
Institut de Recherches Internationales Servier
NCT05800964 COMPLETED
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen
NCT04397276 COMPLETED
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
NCT02423057 COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT03065062 SUSPENDED
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
NCT02909777 COMPLETED
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Dana-Farber Cancer Institute
NCT06056024 COMPLETED
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
Boehringer Ingelheim
NCT06331559 TERMINATED
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT06540066 TERMINATED
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeiGene
NCT05478486 COMPLETED
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
Godavari Biorefineries Limited
NCT05372367 COMPLETED
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Boehringer Ingelheim
NCT06560645 TERMINATED
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
NCT04640480 COMPLETED
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
NCT02952248 COMPLETED
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
NCT04991480 COMPLETED
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
NCT03156114 COMPLETED
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Boehringer Ingelheim
NCT04544995 TERMINATED
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
NCT02408861 TERMINATED
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02856425 COMPLETED
Trial Of Pembrolizumab And Nintedanib
Gustave Roussy, Cancer Campus, Grand Paris
NCT06299761 TERMINATED
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
Boundless Bio, Inc.
NCT06560632 TERMINATED
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
Repare Therapeutics
NCT04587479 COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT03780725 TERMINATED
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
Boehringer Ingelheim
NCT05209295 TERMINATED
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Bristol-Myers Squibb
NCT05194072 TERMINATED
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT03510104 COMPLETED
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Meryx, Inc.
NCT02948426 TERMINATED
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT04501276 COMPLETED
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Adagene Inc
NCT06741072 SUSPENDED
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Ohio State University Comprehensive Cancer Center
NCT06130722 COMPLETED
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
Suzhou Forlong Biotechnology Co., Ltd
NCT06476548 COMPLETED
Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors
H. Lee Moffitt Cancer Center and Research Institute
NCT03905148 COMPLETED
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
BeiGene
NCT05378737 COMPLETED
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
Bio-Thera Solutions
NCT05678998 COMPLETED
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
NCT04617314 COMPLETED
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
NCT05864573 COMPLETED
Study of ZGGS15 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06337630 TERMINATED
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
Institut Curie
NCT04648254 COMPLETED
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Qurient Co., Ltd.
NCT04045496 COMPLETED
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT05025358 COMPLETED
A Study of LP-118 in Patients With Advanced Tumors
Guangzhou Lupeng Pharmaceutical Company LTD.
NCT05012618 TERMINATED
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Chugai Pharmaceutical
NCT06626256 WITHDRAWN
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
NCT06846099 COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Risen (Suzhou) Pharma Tech Co., Ltd.
NCT05483933 COMPLETED
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
NCT03955640 TERMINATED
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
Thomas Jefferson University
NCT04936178 COMPLETED
A Study of NB003 in Patients With Advanced Malignancies
Ningbo Newbay Technology Development Co., Ltd
NCT05047536 TERMINATED
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
NCT03258593 COMPLETED
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Cancer Institute (NCI)
NCT03388632 COMPLETED
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Cancer Institute (NCI)
NCT05240898 COMPLETED
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
NCT05287399 COMPLETED
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Ascletis Pharmaceuticals Co., Ltd.
NCT03573310 COMPLETED
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Janssen Research & Development, LLC
NCT06509906 TERMINATED
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono Research & Development Institute, Inc.
NCT03245892 COMPLETED
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT06049576 SUSPENDED
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
NCT05165433 COMPLETED
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
Akamis Bio
NCT04580446 COMPLETED
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
University of Texas Southwestern Medical Center
NCT06438783 TERMINATED
TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NCT05417750 COMPLETED
A Phase I Study of GC101 TIL in Advanced Solid Tumors
Shanghai Juncell Therapeutics
NCT03595059 COMPLETED
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
NCT05155722 COMPLETED
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors
Bio-Thera Solutions
NCT03260504 TERMINATED
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
NCT05105971 COMPLETED
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Bio-Thera Solutions
NCT03968653 TERMINATED
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
Debiopharm International SA
NCT05147350 TERMINATED
Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
Debiopharm International SA
NCT03177291 COMPLETED
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
NCT05147272 TERMINATED
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Debiopharm International SA
NCT05549804 COMPLETED
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05387928 COMPLETED
A Study of KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT04303858 COMPLETED
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT05252416 TERMINATED
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
NCT03449381 COMPLETED
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT03307785 COMPLETED
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
NCT05586321 COMPLETED
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
Genmab
NCT03109080 COMPLETED
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)
Institut Curie
NCT06001580 COMPLETED
A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.
NCT05668585 COMPLETED
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
C4 Therapeutics, Inc.
NCT06289894 TERMINATED
A Study of BRY805 in Participants With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.
NCT05014139 TERMINATED
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Astellas Pharma Global Development, Inc.
NCT05938296 SUSPENDED
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
NCT02936102 TERMINATED
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT05980416 TERMINATED
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT03468426 COMPLETED
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
Boehringer Ingelheim
NCT04374877 COMPLETED
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT05252390 TERMINATED
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
NCT05322408 COMPLETED
HCW9218 in Select Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT05111353 COMPLETED
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine
NCT04017819 SUSPENDED
Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4
Stanford University
NCT03396445 COMPLETED
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
Merck Sharp & Dohme LLC
NCT03770494 TERMINATED
A Study of LY3405105 in Participants With Advanced Cancer
Eli Lilly and Company
NCT03564821 COMPLETED
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT06171178 TERMINATED
A Study of ASP1012 in Adults With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03010176 COMPLETED
Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Merck Sharp & Dohme LLC
NCT04824443 COMPLETED
Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19
Memorial Sloan Kettering Cancer Center
NCT06158958 TERMINATED
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
AbbVie
NCT04568902 COMPLETED
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Eisai Co., Ltd.
NCT04543188 TERMINATED
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
NCT02597036 TERMINATED
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT06523803 TERMINATED
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
Zymeworks BC Inc.
NCT03144661 TERMINATED
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
NCT05646797 TERMINATED
A Study of ASP2074 in Adults With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT02680795 COMPLETED
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Acrotech Biopharma Inc.
NCT05858164 COMPLETED
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Bayer
NCT05859464 TERMINATED
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Zai Lab (Hong Kong), Ltd.
NCT05082610 COMPLETED
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Hummingbird Bioscience
NCT04272034 TERMINATED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT05639751 COMPLETED
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Prelude Therapeutics
NCT06336148 TERMINATED
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
NCT05025085 COMPLETED
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Agenus Inc.
NCT02512926 COMPLETED
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Stanford University
NCT04982926 TERMINATED
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
NCT04117958 TERMINATED
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Amgen
NCT02964013 COMPLETED
Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)
Merck Sharp & Dohme LLC
NCT05293496 COMPLETED
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
NCT05514444 COMPLETED
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
Merck Sharp & Dohme LLC
NCT03522142 TERMINATED
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Incyte Corporation
NCT05317078 TERMINATED
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Amgen
NCT03564691 COMPLETED
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Merck Sharp & Dohme LLC
NCT03972150 COMPLETED
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
NCT05976334 TERMINATED
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
NCT05300048 COMPLETED
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Faeth Therapeutics
NCT04631029 COMPLETED
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
National Cancer Institute (NCI)
NCT04215978 COMPLETED
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT02674152 COMPLETED
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
NCT06296056 COMPLETED
Phase I Trial of Combined Immune Cell Therapy for Metastatic Stage IV Solid Tumors (SDH-Combi)
Seoul Hospital
NCT06098651 COMPLETED
A Study of DCR-STAT3 in Adults With Solid Tumors
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT06264921 TERMINATED
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
NCT04417465 COMPLETED
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
AbbVie
NCT05501821 COMPLETED
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
Kling Biotherapeutics B.V.
NCT04674748 TERMINATED
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
Incyte Biosciences Japan GK
NCT05385705 TERMINATED
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Vall d'Hebron Institute of Oncology
NCT05200364 TERMINATED
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Sutro Biopharma, Inc.
NCT06285097 TERMINATED
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
NCT06182579 TERMINATED
Phase I Study of RiMO-401 With Radiation in Advanced Tumors
Coordination Pharmaceuticals, Inc.
NCT05391048 COMPLETED
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
Impact Therapeutics, Inc.
NCT05109832 COMPLETED
A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects
Impact Therapeutics, Inc.
NCT05072106 COMPLETED
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
NCT04242147 TERMINATED
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Kadmon, a Sanofi Company
NCT05673460 COMPLETED
A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
Merck Sharp & Dohme LLC
NCT05390944 COMPLETED
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
NCT05904496 TERMINATED
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeiGene
NCT03944499 COMPLETED
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT04446260 COMPLETED
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT04344795 COMPLETED
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Tempest Therapeutics
NCT05707676 TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
L & L Bio Co., Ltd., Ningbo, China
NCT04249843 TERMINATED
Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors
MapKure, LLC
NCT05826275 COMPLETED
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
Toragen, Inc.
NCT03036228 COMPLETED
MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
Thomas Helleday Foundation
NCT05723640 COMPLETED
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
Yantai LNC Biotechnology Singapore PTE. LTD.
NCT06471712 COMPLETED
Clinical Study of 18F-LNC1007 Injection PET/CT
Yantai LNC Biotechnology Singapore PTE. LTD.
NCT04879849 COMPLETED
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Takeda
NCT04418167 SUSPENDED
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
NCT06463782 COMPLETED
Clinical Study of 68Ga-LNC1007 Injection PET/CT
Yantai LNC Biotechnology Singapore PTE. LTD.
NCT05063318 COMPLETED
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
NCT05114668 COMPLETED
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Kazia Therapeutics Limited
NCT03900442 COMPLETED
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
Prescient Therapeutics, Ltd.
NCT05490043 TERMINATED
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene (Hangzhou) Biologics Co., Ltd.
NCT04772989 COMPLETED
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT03114319 TERMINATED
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT05582850 COMPLETED
DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours
Domain Therapeutics SA
NCT06074705 TERMINATED
A Study of DS-1471a In Subjects With Advanced Solid Tumors
Daiichi Sankyo Co., Ltd.
NCT04970992 COMPLETED
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Da Zen Theranostics Inc
NCT04169321 COMPLETED
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
Cytosite Biopharma Inc.
NCT07138378 COMPLETED
A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.
Xspray Pharma AB
NCT05494918 COMPLETED
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
Alphamab (Australia) Co Pty Ltd.
NCT04047862 COMPLETED
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
NCT02185690 COMPLETED
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
University Health Network, Toronto
NCT02784795 TERMINATED
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT03748186 COMPLETED
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Sutro Biopharma, Inc.
NCT03708328 COMPLETED
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT04147234 COMPLETED
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Boehringer Ingelheim
NCT05388877 TERMINATED
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Mayo Clinic
NCT06263582 COMPLETED
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
UNC Lineberger Comprehensive Cancer Center
NCT06165614 COMPLETED
Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya
UNC Lineberger Comprehensive Cancer Center
NCT03739931 COMPLETED
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
ModernaTX, Inc.
NCT05708924 TERMINATED
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT07121829 TERMINATED
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT06877533 TERMINATED
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
iTeos Belgium SA
NCT06372236 COMPLETED
UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors
Peking University
NCT05997342 COMPLETED
A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04487236 COMPLETED
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
Suzhou Zanrong Pharma Limited
NCT03762447 COMPLETED
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT02836600 COMPLETED
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT05717140 WITHDRAWN
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Mayo Clinic
NCT06231550 COMPLETED
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
FindCure Biosciences (ZhongShan) Co., Ltd.
NCT02776917 COMPLETED
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
Barbara Parker, MD
NCT02903914 COMPLETED
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
NCT06039384 TERMINATED
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Incyte Corporation
NCT02628574 COMPLETED
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
Leap Therapeutics, Inc.
NCT06048367 COMPLETED
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
NCT03059823 COMPLETED
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
Incyte Corporation
NCT03013218 COMPLETED
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
NCT04610736 COMPLETED
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Orphelia Pharma
NCT04306900 COMPLETED
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
NCT03307629 COMPLETED
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Noxopharm Limited
NCT05391022 COMPLETED
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Constellation Pharmaceuticals
NCT04051827 COMPLETED
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Millennium Pharmaceuticals, Inc.
NCT05162469 COMPLETED
A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05983146 WITHDRAWN
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
NCT04257110 COMPLETED
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
NCT03034304 TERMINATED
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
NCT03249792 TERMINATED
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Merck Sharp & Dohme LLC
NCT03654547 COMPLETED
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
TransThera Sciences (Nanjing), Inc.
NCT06886659 COMPLETED
A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)
Incepta Pharmaceuticals Ltd
NCT06255665 COMPLETED
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
Janssen Research & Development, LLC
NCT03199586 COMPLETED
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
NCT04501770 COMPLETED
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
Wuhan YZY Biopharma Co., Ltd.
NCT05444530 COMPLETED
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Janssen Research & Development, LLC
NCT05028556 COMPLETED
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
Wuhan YZY Biopharma Co., Ltd.
NCT04239092 TERMINATED
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
NCT04501744 COMPLETED
A Study of M701 (EpCAM and CD3) in Malignant Ascites
Wuhan YZY Biopharma Co., Ltd.
NCT06235541 WITHDRAWN
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors
Genome & Company
NCT06161558 WITHDRAWN
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT06443710 COMPLETED
Technetium [99mTc]-H7ND in Patients With Gastrointestinal Malignancies and Healthy Volunteers
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
NCT04116320 TERMINATED
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
Craig L Slingluff, Jr
NCT05387265 TERMINATED
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
CytomX Therapeutics
NCT04242199 COMPLETED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT05323045 COMPLETED
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
Byondis B.V.
NCT05839600 TERMINATED
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Boehringer Ingelheim
NCT03153280 TERMINATED
Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer
Cancer Trials Ireland
NCT03289962 COMPLETED
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
NCT05153330 TERMINATED
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
NCT05487235 COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT05383703 COMPLETED
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
Moon (Guangzhou) Biotechnology Co., Ltd.
NCT03884556 COMPLETED
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
NCT05274451 TERMINATED
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
NCT06416436 WITHDRAWN
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
NCT05958199 SUSPENDED
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
NCT03990233 COMPLETED
A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
OSE Immunotherapeutics
NCT04991129 TERMINATED
The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer
Suzhou Junjing BioSciences Co., Ltd.
NCT06630247 TERMINATED
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03918278 COMPLETED
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
Merck Sharp & Dohme LLC
NCT03239145 COMPLETED
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
NCT03099174 COMPLETED
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
NCT04613492 TERMINATED
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
AstraZeneca
NCT06007482 COMPLETED
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma Australia Pty. Ltd.
NCT04991506 COMPLETED
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
NCT04730843 COMPLETED
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
NCT04975958 COMPLETED
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
NCT07030439 COMPLETED
A Bioequivalence Study to Compare Senaparib Manufactured at 2 Sites in Healthy Subjects in Fasting State
Impact Therapeutics, Inc.
NCT05594043 COMPLETED
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)
Merck Sharp & Dohme LLC
NCT04278859 COMPLETED
Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
NCT06719973 WITHDRAWN
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
EMD Serono Research & Development Institute, Inc.
NCT05788484 COMPLETED
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT03881488 COMPLETED
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
NCT07019194 COMPLETED
An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition
Impact Therapeutics, Inc.
NCT06381050 COMPLETED
The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT05625412 COMPLETED
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT04986865 TERMINATED
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited
NCT02517918 COMPLETED
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
Institut Bergonié
NCT02836795 COMPLETED
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT02419495 TERMINATED
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT06535009 TERMINATED
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
Ono Pharmaceutical Co. Ltd
NCT03277482 TERMINATED
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Dana-Farber Cancer Institute
NCT02720068 COMPLETED
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
Merck Sharp & Dohme LLC
NCT05192174 TERMINATED
Study of NIB101 in Participants With Advanced Solid Tumors
Noile-Immune Biotech, Inc
NCT04972981 COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
NCT05389462 TERMINATED
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
ADC Therapeutics S.A.
NCT06344351 COMPLETED
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT03508570 COMPLETED
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
M.D. Anderson Cancer Center
NCT04642365 TERMINATED
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Hoffmann-La Roche
NCT04927663 TERMINATED
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
Rahul Aggarwal
NCT04121286 COMPLETED
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
Allist Pharmaceuticals, Inc.
NCT05759949 COMPLETED
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Relay Therapeutics, Inc.
NCT02318771 COMPLETED
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05075564 COMPLETED
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma, Ltd.
NCT05571969 SUSPENDED
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Allarity Therapeutics
NCT05242822 TERMINATED
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Kinnate Biopharma
NCT02507583 COMPLETED
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
david andrews
NCT04261439 TERMINATED
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis Pharmaceuticals
NCT05494762 TERMINATED
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
BeiGene
NCT05757492 TERMINATED
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT04291079 COMPLETED
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Scholar Rock, Inc.
NCT05840510 TERMINATED
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Mirati Therapeutics Inc.
NCT03260322 COMPLETED
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Astellas Pharma Global Development, Inc.
NCT04301011 TERMINATED
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Turnstone Biologics, Corp.
NCT05396300 COMPLETED
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
Weijia Fang, MD
NCT02598726 COMPLETED
Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer
Mayo Clinic
NCT03954067 COMPLETED
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03544905 COMPLETED
Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
Haihe Biopharma Co., Ltd.
NCT06194877 TERMINATED
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLC
NCT02875223 TERMINATED
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
NCT04836195 COMPLETED
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
Pacylex Pharmaceuticals
NCT04209465 TERMINATED
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Black Diamond Therapeutics, Inc.
NCT04886622 COMPLETED
A Study of DT2216 in Relapsed/Refractory Malignancies
Dialectic Therapeutics, Inc
NCT04774952 COMPLETED
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
NCT06345001 COMPLETED
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Bayer
NCT04485416 SUSPENDED
Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors
University of California, Davis
NCT03724890 COMPLETED
Study of Avelumab-M3814 Combinations
EMD Serono Research & Development Institute, Inc.
NCT04943900 COMPLETED
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Bristol-Myers Squibb
NCT03975387 TERMINATED
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Taiho Oncology, Inc.
NCT05940844 WITHDRAWN
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
NCT05620472 COMPLETED
Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1
Tomsk National Research Medical Center of the Russian Academy of Sciences
NCT05904236 TERMINATED
Safety and Tolerability of Intravenous Administration of ICVB-1042
IconOVir Bio
NCT05737706 TERMINATED
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Mirati Therapeutics Inc.
NCT04330664 COMPLETED
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Mirati Therapeutics Inc.
NCT02454010 COMPLETED
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT03597581 COMPLETED
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Inspirna, Inc.
NCT03894618 COMPLETED
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
NCT05828303 WITHDRAWN
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
NCT04108481 TERMINATED
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
University of Iowa
NCT04553692 TERMINATED
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
NCT03585764 TERMINATED
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Pennsylvania
NCT05584111 COMPLETED
Oral Administration of STC-15 in Subjects With Advanced Malignancies
STORM Therapeutics LTD
NCT04137289 COMPLETED
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Boehringer Ingelheim
NCT05043714 COMPLETED
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
Akamis Bio
NCT04053283 COMPLETED
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
Akamis Bio
NCT03195699 COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT05463432 COMPLETED
A Study of HR19024 in Subjects With Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT05225584 COMPLETED
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
Kymera Therapeutics, Inc.
NCT06597786 WITHDRAWN
A Study of Exercise Therapy in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT04586270 TERMINATED
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
NCT06873542 COMPLETED
A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
Heronova Pharmaceuticals
NCT03165955 COMPLETED
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Health Hope Pharma
NCT05023928 COMPLETED
Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
Sichuan University
NCT02783300 COMPLETED
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
GlaxoSmithKline
NCT04882917 COMPLETED
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
EMD Serono Research & Development Institute, Inc.
NCT04105335 COMPLETED
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
Mina Alpha Limited
NCT05940571 COMPLETED
First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors
Medibiofarma S.L.
NCT04608045 COMPLETED
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
NCT03261011 COMPLETED
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
Akesobio Australia Pty Ltd
NCT03352531 COMPLETED
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
Akesobio Australia Pty Ltd
NCT04047290 COMPLETED
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Akesobio Australia Pty Ltd
NCT04572152 COMPLETED
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
Akeso
NCT03073395 COMPLETED
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Five Eleven Pharma, Inc.
NCT04537715 COMPLETED
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Epizyme, Inc.
NCT03956680 COMPLETED
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
Bristol-Myers Squibb
NCT05087992 COMPLETED
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
Boehringer Ingelheim
NCT06365918 WITHDRAWN
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
M.D. Anderson Cancer Center
NCT02966548 COMPLETED
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04249947 TERMINATED
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
NCT05943041 COMPLETED
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
GILongevity
NCT03654716 COMPLETED
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Dana-Farber Cancer Institute
NCT04805307 COMPLETED
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
Keymed Biosciences Co.Ltd
NCT05178888 COMPLETED
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Mirati Therapeutics Inc.
NCT02667873 COMPLETED
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
Stemline Therapeutics, Inc.
NCT04862780 TERMINATED
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
NCT04999202 TERMINATED
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Bayer
NCT05241873 TERMINATED
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
NCT05631574 TERMINATED
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Biomea Fusion Inc.
NCT04023669 COMPLETED
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
St. Jude Children's Research Hospital
NCT03628677 COMPLETED
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT03404791 COMPLETED
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
Janssen Research & Development, LLC
NCT03247309 COMPLETED
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
Immatics US, Inc.
NCT04406623 COMPLETED
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer
Shattuck Labs, Inc.
NCT05098405 TERMINATED
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Molecular Partners AG
NCT03447470 COMPLETED
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Redx Pharma Ltd
NCT03821233 COMPLETED
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Zymeworks BC Inc.
NCT06258330 COMPLETED
Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors
Aummune Ltd.
NCT05601219 TERMINATED
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
Adanate, Inc
NCT03948763 TERMINATED
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Merck Sharp & Dohme LLC
NCT05775406 COMPLETED
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
Kymera Therapeutics, Inc.
NCT05613036 COMPLETED
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body
Boehringer Ingelheim
NCT06302140 TERMINATED
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
Viracta Therapeutics, Inc.
NCT03667716 COMPLETED
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Compugen Ltd
NCT06681870 WITHDRAWN
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03936959 TERMINATED
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Eli Lilly and Company
NCT04121676 COMPLETED
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
Agenus Inc.
NCT02751528 TERMINATED
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NantBioScience, Inc.
NCT03854227 TERMINATED
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
NCT05382936 TERMINATED
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Stemline Therapeutics, Inc.
NCT06012708 COMPLETED
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713
New Cancer Cure-Bio Co.,Ltd.
NCT03329937 COMPLETED
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
Tesaro, Inc.
NCT04234113 TERMINATED
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
SOTIO Biotech AG
NCT06560138 WITHDRAWN
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
Atridia Pty Ltd.
NCT04727554 COMPLETED
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Amgen
NCT05176509 COMPLETED
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT04052971 COMPLETED
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
Abion Inc
NCT05169697 COMPLETED
A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT02630823 COMPLETED
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
NCT06228846 COMPLETED
An Phase I Study of YY001 in Patients with Advanced Solid Tumors
Shanghai Yuyao Biotech Co., Ltd.
NCT05904730 COMPLETED
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Lynkcell Europe
NCT05394818 COMPLETED
The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT05116709 COMPLETED
Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors
Bio-Thera Solutions
NCT02723955 COMPLETED
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
NCT05279690 COMPLETED
Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors
Icahn School of Medicine at Mount Sinai
NCT05414136 COMPLETED
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006
Bio-Thera Solutions
NCT03150810 COMPLETED
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
NCT05781360 TERMINATED
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
NCT04404569 TERMINATED
Continued Treatment for Participants Enrolled in Studies of BXQ-350
Bexion Pharmaceuticals, Inc.
NCT04975256 TERMINATED
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Mirati Therapeutics Inc.
NCT03518554 COMPLETED
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
NCT04908176 COMPLETED
A Drug-drug Interaction Study of Avapritinib and Midazolam
Blueprint Medicines Corporation
NCT05375084 TERMINATED
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Navire Pharma Inc., a BridgeBio company
NCT04310592 TERMINATED
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Celularity Incorporated
NCT05480865 TERMINATED
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
Navire Pharma Inc., a BridgeBio company
NCT03922204 COMPLETED
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
Merus B.V.
NCT06619951 COMPLETED
A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
Jiangsu vcare pharmaceutical technology co., LTD
NCT05751837 COMPLETED
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal
Patrick Wagner, MD, FACS
NCT03030417 COMPLETED
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
National Cancer Institute (NCI)
NCT04672434 COMPLETED
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
NCT05831995 TERMINATED
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
ABM Therapeutics Corporation
NCT04319757 COMPLETED
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
NCT05018273 COMPLETED
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
Nykode Therapeutics ASA
NCT03387917 TERMINATED
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Swiss Cancer Institute
NCT05501912 TERMINATED
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
ABM Therapeutics Shanghai Company Limited
NCT02892123 COMPLETED
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
NCT05736224 COMPLETED
Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Yale University
NCT04526509 TERMINATED
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Adaptimmune
NCT02702492 TERMINATED
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
Karyopharm Therapeutics Inc
NCT05198349 TERMINATED
First in Human Study of M1069 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT02143401 COMPLETED
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT05246111 COMPLETED
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NCT05357820 COMPLETED
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
Nuvation Bio Inc.
NCT02972034 TERMINATED
Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
Merck Sharp & Dohme LLC
NCT05357911 COMPLETED
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
Nuvation Bio Inc.
NCT03027128 COMPLETED
QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
ImmunityBio, Inc.
NCT05990920 COMPLETED
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
NKGen Biotech, Inc.
NCT03166631 TERMINATED
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
Boehringer Ingelheim
NCT03834662 COMPLETED
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
Bristol-Myers Squibb
NCT02699515 COMPLETED
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
Merck KGaA, Darmstadt, Germany
NCT05228015 TERMINATED
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Ikena Oncology
NCT02619253 COMPLETED
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Nabil Adra
NCT04145297 COMPLETED
Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
University of Utah
NCT05712889 COMPLETED
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
NCT02635672 COMPLETED
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
NCT06048705 TERMINATED
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Adaptimmune
NCT03945253 COMPLETED
Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors
Astellas Pharma Inc
NCT05943990 TERMINATED
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Adaptimmune
NCT04855929 COMPLETED
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
Anaveon AG
NCT03833427 TERMINATED
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
Merck Sharp & Dohme LLC
NCT06448364 TERMINATED
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
Pfizer
NCT04504669 COMPLETED
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
AstraZeneca
NCT02456883 COMPLETED
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03666143 COMPLETED
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT04795713 TERMINATED
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Molecular Templates, Inc.
NCT03565445 COMPLETED
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Astellas Pharma Global Development, Inc.
NCT03799003 TERMINATED
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Astellas Pharma Global Development, Inc.
NCT04094506 COMPLETED
Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors
Astellas Pharma Inc
NCT03457532 COMPLETED
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Haihe Biopharma Co., Ltd.
NCT04525014 TERMINATED
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
EpicentRx, Inc.
NCT02383368 COMPLETED
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
Astellas Pharma Global Development, Inc.
NCT05231733 WITHDRAWN
Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors
SparX Biotech(Jiangsu) Co., Ltd.
NCT04096638 COMPLETED
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
invoX Pharma Limited
NCT03215511 COMPLETED
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
Bayer
NCT05076591 SUSPENDED
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
NCT04870840 COMPLETED
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
M.D. Anderson Cancer Center
NCT02265536 COMPLETED
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Eli Lilly and Company
NCT03960060 TERMINATED
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
Shanghai PerHum Therapeutics Co., Ltd.
NCT03994211 COMPLETED
Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
BeiGene
NCT03809624 TERMINATED
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Inhibrx Biosciences, Inc
NCT03641586 COMPLETED
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
BeiGene
NCT05814536 TERMINATED
IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor
AnHeart Therapeutics Inc.
NCT04270864 TERMINATED
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
Gustave Roussy, Cancer Campus, Grand Paris
NCT05043298 COMPLETED
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT02516813 COMPLETED
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
EMD Serono Research & Development Institute, Inc.
NCT04908046 COMPLETED
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
Hutchmed
NCT06161493 WITHDRAWN
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Haider Mahdi
NCT03087591 COMPLETED
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
Wake Forest University Health Sciences
NCT04021277 TERMINATED
PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin
EXACT Therapeutics AS
NCT04861987 COMPLETED
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
Processa Pharmaceuticals
NCT03466268 COMPLETED
Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Haihe Biopharma Co., Ltd.
NCT03220347 TERMINATED
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Celgene
NCT06631625 COMPLETED
Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries.
Alexandria University
NCT03507491 COMPLETED
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
NCT02480374 COMPLETED
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Imunon
NCT03936465 COMPLETED
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Dana-Farber Cancer Institute
NCT03946800 COMPLETED
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT04659629 COMPLETED
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Neurogene Inc.
NCT02791334 COMPLETED
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Eli Lilly and Company
NCT04147819 COMPLETED
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein
Bayer
NCT03864042 COMPLETED
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
NCT05298592 COMPLETED
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
Bristol-Myers Squibb
NCT03251378 COMPLETED
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchison Medipharma Limited
NCT04672460 COMPLETED
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04713891 COMPLETED
A Study of KF-0210 in Advanced Solid Tumors Patients
Keythera Pharmaceuticals (Australia) Pty Ltd
NCT04130763 COMPLETED
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1
Peking University
NCT03447314 COMPLETED
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
GlaxoSmithKline
NCT02944864 TERMINATED
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT02994953 TERMINATED
A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)
EMD Serono Research & Development Institute, Inc.
NCT03028766 COMPLETED
WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer
University of Birmingham
NCT04182516 TERMINATED
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
NCT04965818 TERMINATED
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Taiho Oncology, Inc.
NCT04087018 COMPLETED
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
Arcus Biosciences, Inc.
NCT05117177 COMPLETED
New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer
iTeos Therapeutics
NCT03783403 TERMINATED
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Celgene
NCT03604783 TERMINATED
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT05002868 COMPLETED
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
Rhizen Pharmaceuticals SA
NCT04742556 COMPLETED
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
Boehringer Ingelheim
NCT04335253 COMPLETED
First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
iTeos Therapeutics
NCT03523819 COMPLETED
A Study of CS1002 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
NCT02903771 COMPLETED
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Kazia Therapeutics Limited
NCT03516123 COMPLETED
A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors
CStone Pharmaceuticals
NCT03744403 COMPLETED
A Study of CS1001 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
NCT03873883 COMPLETED
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
iTeos Therapeutics
NCT03814005 COMPLETED
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
NCT02301104 COMPLETED
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Taiho Oncology, Inc.
NCT02301117 COMPLETED
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
NCT03410927 TERMINATED
A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
Taiho Oncology, Inc.
NCT04366648 COMPLETED
Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor
JenKem Technology Co., Ltd.
NCT04770246 TERMINATED
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
Taiho Oncology, Inc.
NCT05065710 COMPLETED
A Study of ZL-1211 in Patients With Advanced Solid Tumor
Zai Biopharmaceutical (Suzhou) Co., Ltd.
NCT04747470 TERMINATED
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
NCT06372574 WITHDRAWN
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
Genentech, Inc.
NCT03284723 TERMINATED
PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
Pfizer
NCT05088070 COMPLETED
Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd
NCT06529445 COMPLETED
Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects
Jiangsu vcare pharmaceutical technology co., LTD
NCT02964507 TERMINATED
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
GlaxoSmithKline
NCT06004921 COMPLETED
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
Arcus Biosciences, Inc.
NCT05996445 TERMINATED
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
NCT03187288 COMPLETED
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
University Health Network, Toronto
NCT03343054 COMPLETED
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Pfizer
NCT04349969 COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
Akesobio Australia Pty Ltd
NCT02520778 COMPLETED
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05569512 TERMINATED
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Malika Kapadia
NCT03355066 TERMINATED
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
NCT02595866 COMPLETED
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
NCT03192345 COMPLETED
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
NCT02714374 TERMINATED
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
Andrew Lowy
NCT06297642 TERMINATED
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT06044142 COMPLETED
Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment
Riyadh Elm University
NCT05764915 TERMINATED
A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
Regor Pharmaceuticals Inc.
NCT05101109 COMPLETED
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
ABL Bio, Inc.
NCT06172309 COMPLETED
A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
Nanjing Chia-tai Tianqing Pharmaceutical
NCT03154294 COMPLETED
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
NCT03435250 TERMINATED
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Institut de Recherches Internationales Servier
NCT03329001 COMPLETED
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
Tesaro, Inc.
NCT04675528 COMPLETED
Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study
Daehwa Pharmaceutical Co., Ltd.
NCT05702424 COMPLETED
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
IGM Biosciences, Inc.
NCT04305249 TERMINATED
Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
Antengene Therapeutics Limited
NCT03667482 COMPLETED
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
NCT03641547 COMPLETED
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
University of Oxford
NCT05933070 TERMINATED
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
Inmune Bio, Inc.
NCT05338346 TERMINATED
A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
Antengene Discovery Limited
NCT05039931 WITHDRAWN
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
NCT03956056 TERMINATED
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
NCT02857998 COMPLETED
A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Hutchison Medipharma Limited
NCT04410224 COMPLETED
Study of ASN004 in Patients With Advanced Solid Tumors
Kirilys Therapeutics Inc.
NCT05769959 TERMINATED
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Hoffmann-La Roche
NCT03752398 COMPLETED
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Xencor, Inc.
NCT04505839 COMPLETED
First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
ST Pharm Co., Ltd.
NCT03829111 COMPLETED
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
City of Hope Medical Center
NCT03934814 COMPLETED
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
I-Mab Biopharma US Limited
NCT05578820 COMPLETED
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
NCT04641871 COMPLETED
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
NCT05594875 COMPLETED
A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors
Atridia Pty Ltd.
NCT05621525 TERMINATED
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
LianBio LLC
NCT03451825 TERMINATED
Phase I/II Study of Avelumab in Pediatric Cancer Participants
EMD Serono Research & Development Institute, Inc.
NCT03301896 TERMINATED
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis Pharmaceuticals
NCT05731934 COMPLETED
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
NCT03621982 TERMINATED
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
NCT04638491 COMPLETED
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Luye Pharma Group Ltd.
NCT03872206 COMPLETED
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05054348 COMPLETED
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
Immune-Onc Therapeutics
NCT05309187 COMPLETED
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
Immune-Onc Therapeutics
NCT03434262 COMPLETED
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
NCT02552953 COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Cyclacel Pharmaceuticals, Inc.
NCT04357587 COMPLETED
Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer
Case Comprehensive Cancer Center
NCT02834611 COMPLETED
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Keystone Nano, Inc
NCT05631327 TERMINATED
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
Jazz Pharmaceuticals
NCT03199040 TERMINATED
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Washington University School of Medicine
NCT03666273 COMPLETED
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
Bayer
NCT04400383 COMPLETED
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
CARsgen Therapeutics Co., Ltd.
NCT05508100 COMPLETED
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
Immune-Onc Therapeutics
NCT04190628 TERMINATED
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
NCT03238027 COMPLETED
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Syndax Pharmaceuticals
NCT02858869 COMPLETED
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
NCT02663518 TERMINATED
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
NCT04887194 COMPLETED
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
NCT02517398 COMPLETED
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT05309512 TERMINATED
Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT03874897 COMPLETED
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
NCT04873895 TERMINATED
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
Abramson Cancer Center at Penn Medicine
NCT02867007 COMPLETED
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin, Inc.
NCT03650348 COMPLETED
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
NCT05152212 COMPLETED
Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
Lyvgen Biopharma Holdings Limited
NCT04694781 COMPLETED
Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
NCT04349280 TERMINATED
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
GlaxoSmithKline
NCT05678283 WITHDRAWN
A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT05518201 COMPLETED
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Shanghai Bovax Biotechnology Co., Ltd.
NCT04059588 COMPLETED
A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin
Rockefeller University
NCT05001516 COMPLETED
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
Turning Point Therapeutics, Inc.
NCT06372223 COMPLETED
A Food Effect Study of SPH5030 Tablets.
Shanghai Pharmaceuticals Holding Co., Ltd
NCT02516553 COMPLETED
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
Boehringer Ingelheim
NCT04306224 COMPLETED
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
ImmuneOncia Therapeutics Inc.
NCT05061537 TERMINATED
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
NCT03250832 COMPLETED
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
Tesaro, Inc.
NCT04040699 COMPLETED
KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor
Peking University
NCT04557306 COMPLETED
Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
CHABiotech CO., Ltd
NCT03490669 COMPLETED
Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
AstraZeneca
NCT04148937 COMPLETED
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
NCT03206021 COMPLETED
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
The Hospital for Sick Children
NCT06219499 WITHDRAWN
Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841
OncoC4, Inc.
NCT04095273 COMPLETED
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Bayer
NCT06137651 WITHDRAWN
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Northwestern University
NCT04901806 TERMINATED
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors
Pyramid Biosciences
NCT03329950 COMPLETED
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
NCT05128539 TERMINATED
A Study Explore JS001+JS002 in Patients With Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
NCT03010982 COMPLETED
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Epizyme, Inc.
NCT04682431 TERMINATED
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
NCT03590054 COMPLETED
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Rahul Aggarwal
NCT04586335 TERMINATED
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
NCT04200963 COMPLETED
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT05472506 WITHDRAWN
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Ikena Oncology
NCT04761601 TERMINATED
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
NCT05547906 COMPLETED
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
MetaFines
NCT04914351 COMPLETED
HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
Shanghai HyaMab Biotech Co.,Ltd.
NCT05231746 COMPLETED
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
STCube, Inc.
NCT05121948 TERMINATED
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
HiberCell, Inc.
NCT04834778 COMPLETED
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
HiberCell, Inc.
NCT04144140 TERMINATED
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Eisai Inc.
NCT04069026 COMPLETED
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer
Bayer
NCT05496595 TERMINATED
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
NCT03604445 TERMINATED
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
Boehringer Ingelheim
NCT03705351 TERMINATED
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
NCT04158583 TERMINATED
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT05051241 COMPLETED
A Study of GFH018 in Patients With Advanced Solid Tumors
Zhejiang Genfleet Therapeutics Co., Ltd.
NCT04920383 TERMINATED
ALPN-202 With PD-1 Inhibition in Advanced Malignancies
Alpine Immune Sciences, Inc.
NCT03343301 COMPLETED
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
Five Prime Therapeutics, Inc.
NCT06198556 COMPLETED
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT05277402 COMPLETED
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
NCT04892043 TERMINATED
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
NCT03523390 COMPLETED
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
NCT05078593 COMPLETED
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
NCT03728179 COMPLETED
RACIN in Patients With Advanced TIL-negative Solid Tumors
Centre Hospitalier Universitaire Vaudois
NCT05248074 COMPLETED
To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers
Abion Inc
NCT03345784 TERMINATED
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
National Cancer Institute (NCI)
NCT05498480 COMPLETED
Study of Relatlimab in Combination With Nivolumab in Chinese Participants
Bristol-Myers Squibb
NCT03516214 COMPLETED
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
University of Cologne
NCT05408871 TERMINATED
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
Yale University
NCT04341311 TERMINATED
Phase I Study of Marizomib + Panobinostat for Children With DIPG
Dana-Farber Cancer Institute
NCT03964259 COMPLETED
Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia
Virginia Commonwealth University
NCT05641324 TERMINATED
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Anaveon AG
NCT04842630 TERMINATED
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT04921878 COMPLETED
A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT04675996 TERMINATED
First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors
InteRNA
NCT05400265 COMPLETED
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
Shanghai Henlius Biotech
NCT03209401 TERMINATED
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Georgetown University
NCT04857138 COMPLETED
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT03255070 COMPLETED
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx, Inc.
NCT04862767 COMPLETED
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Autotelicbio
NCT03012230 COMPLETED
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
Mayo Clinic
NCT04564417 TERMINATED
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors
Pierre Fabre Medicament
NCT05099536 WITHDRAWN
3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
3D Medicines (Beijing) Co., Ltd.
NCT04609579 TERMINATED
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
NCT02828098 COMPLETED
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Highlight Therapeutics
NCT04025216 TERMINATED
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Kite, A Gilead Company
NCT05848843 WITHDRAWN
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
NCT02564900 COMPLETED
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo Co., Ltd.
NCT02457845 COMPLETED
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
Gregory K. Friedman, MD
NCT05002140 COMPLETED
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
XRad Therapeutics Inc
NCT04235101 COMPLETED
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
Byondis B.V.
NCT06165809 WITHDRAWN
A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04483505 COMPLETED
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
Fundacion CRIS de Investigación para Vencer el Cáncer
NCT03912831 TERMINATED
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Gilead Sciences
NCT05930457 COMPLETED
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
The First Affiliated Hospital of Guangzhou Medical University
NCT03565367 COMPLETED
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
Daniel M. Spielman
NCT04267939 TERMINATED
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Bayer
NCT04096716 TERMINATED
Mapping Draining Lymph Nodes in CNS Malignancies
Washington University School of Medicine
NCT03454451 COMPLETED
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
NCT03219268 COMPLETED
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
NCT05814835 COMPLETED
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
Chinese PLA General Hospital
NCT02482168 COMPLETED
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
NCT04944888 COMPLETED
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Chinese PLA General Hospital
NCT04272944 COMPLETED
A Study of MSB2311 in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT03463473 COMPLETED
A Phase I Study of MSB2311 in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT03928314 TERMINATED
Study of ORIC-101 in Combination With Anticancer Therapy
ORIC Pharmaceuticals
NCT02571036 COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
NCT05490381 WITHDRAWN
Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
University of Washington
NCT03525392 TERMINATED
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
NCT05800249 COMPLETED
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
Shanghai HyaMab Biotech Co.,Ltd.
NCT05159518 COMPLETED
A Study of PRT2527 in Participants With Advanced Solid Tumors
Prelude Therapeutics
NCT05861778 COMPLETED
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
NCT04457778 COMPLETED
First in Human Study of M6223
EMD Serono Research & Development Institute, Inc.
NCT04513067 TERMINATED
A Safety Study of YQ23 in Advanced Solid Tumors Patients
New Beta Innovation Limited
NCT03229278 COMPLETED
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
NCT03131765 COMPLETED
Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors
Yisheng Biopharma (Singapore) Pte. Ltd.
NCT03861403 TERMINATED
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
NCT04892875 WITHDRAWN
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
Jennifer Choe
NCT04147247 COMPLETED
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
Boehringer Ingelheim
NCT05791474 WITHDRAWN
ATI-2231 in Advanced Solid Tumor Malignancies
Washington University School of Medicine
NCT05644626 WITHDRAWN
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
BeiGene
NCT03225105 TERMINATED
M3541 in Combination With Radiotherapy in Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT04393506 COMPLETED
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Shanghai Jiao Tong University School of Medicine
NCT04473716 COMPLETED
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Shanghai Jiao Tong University School of Medicine
NCT02693080 COMPLETED
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
Stanford University
NCT03954704 TERMINATED
Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors
Gilead Sciences
NCT04830501 COMPLETED
Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT05017623 COMPLETED
A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT04602117 WITHDRAWN
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
NCT03810742 COMPLETED
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
NCT03416816 TERMINATED
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
NCT03715504 COMPLETED
Study of TP-3654 in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT02483247 COMPLETED
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
NCT03429218 COMPLETED
First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT02729298 COMPLETED
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT02467361 COMPLETED
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Sumitomo Pharma America, Inc.
NCT05369221 COMPLETED
Feasibility of ReSpace™ Hydrogel to Establish a Stable Cervical-rectal Space
Peking Union Medical College Hospital
NCT02834780 COMPLETED
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
H3 Biomedicine Inc.
NCT03941262 COMPLETED
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
NKGen Biotech, Inc.
NCT04630522 COMPLETED
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
Shanghai JMT-Bio Inc.
NCT02432326 COMPLETED
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT05905341 WITHDRAWN
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
NCT05221385 TERMINATED
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT03304210 COMPLETED
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
University Hospital, Ghent
NCT04337853 COMPLETED
Radiotherapy of Tongue Cancer Using an Intraoral Stent
Oslo University Hospital
NCT03240861 TERMINATED
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
Jonsson Comprehensive Cancer Center
NCT04247126 COMPLETED
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
NCT04475523 COMPLETED
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
Curis, Inc.
NCT02644460 COMPLETED
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
Emory University
NCT04162327 COMPLETED
A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
NCT04958434 TERMINATED
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT05600582 WITHDRAWN
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Codagenix, Inc
NCT03099109 COMPLETED
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
Eli Lilly and Company
NCT04404140 TERMINATED
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hoffmann-La Roche
NCT02718911 COMPLETED
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT03690154 TERMINATED
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NCT03188965 COMPLETED
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Bayer
NCT05073484 TERMINATED
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients
Bio-Thera Solutions
NCT05120375 TERMINATED
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China
Bio-Thera Solutions
NCT02897375 COMPLETED
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
NCT04635631 COMPLETED
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
Pfizer
NCT03122106 TERMINATED
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Washington University School of Medicine
NCT03730337 COMPLETED
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
NCT05828277 WITHDRAWN
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
NCT03859752 SUSPENDED
TR1801-ADC in Patients With Tumors That Express c-Met
Open Innovation Partners, Inc.
NCT05921916 COMPLETED
Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers
Medibiofarma S.L.
NCT04865159 TERMINATED
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Kura Oncology, Inc.
NCT04551885 TERMINATED
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT05069935 TERMINATED
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT05698888 TERMINATED
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
Virtuoso BINco, Inc.
NCT04729205 TERMINATED
Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies
Lipomedix Pharmaceuticals Inc.
NCT04357756 COMPLETED
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT03714958 COMPLETED
Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type
Centre Leon Berard
NCT03452332 COMPLETED
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
M.D. Anderson Cancer Center
NCT03109041 COMPLETED
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
CivaTech Oncology
NCT05040932 COMPLETED
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
Eucure (Beijing) Biopharma Co., Ltd
NCT04912466 COMPLETED
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
NCT05470933 TERMINATED
A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors
Suzhou Junjing BioSciences Co., Ltd.
NCT02536183 TERMINATED
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
AeRang Kim
NCT03139370 TERMINATED
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Kite, A Gilead Company
NCT04293094 COMPLETED
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
Volastra Therapeutics, Inc.
NCT04116710 COMPLETED
A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors
Heat Biologics
NCT04257617 COMPLETED
A Trial of ZL-1201 in Subjects With Advanced Cancer
Zai Lab (Shanghai) Co., Ltd.
NCT02959619 COMPLETED
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
Betta Pharmaceuticals Co., Ltd.
NCT03990454 COMPLETED
Safety Study of SLC-391 in Subjects With Solid Tumors
SignalChem Lifesciences Corporation
NCT05119998 COMPLETED
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
NCT04467853 TERMINATED
A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors
Shanghai East Hospital
NCT03808870 COMPLETED
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer
NatureWise Biotech & Medicals Corporation
NCT04131426 COMPLETED
Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia
University of Rochester
NCT04601402 COMPLETED
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
NCT02459301 COMPLETED
A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
Canadian Cancer Trials Group
NCT05129280 TERMINATED
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
Hoffmann-La Roche
NCT04214093 TERMINATED
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
AstraZeneca
NCT04034238 COMPLETED
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
National Cancer Institute (NCI)
NCT03745989 COMPLETED
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
Merck Sharp & Dohme LLC
NCT04585841 COMPLETED
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
University of Copenhagen
NCT04456140 COMPLETED
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Mayo Clinic
NCT04541225 TERMINATED
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
NCT02503774 COMPLETED
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
MedImmune LLC
NCT03927573 TERMINATED
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
AvenCell Europe GmbH
NCT04695847 COMPLETED
M1231 in Participants With Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT04601285 TERMINATED
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT03790488 COMPLETED
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
Jounce Therapeutics, Inc.
NCT03028103 COMPLETED
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Epizyme, Inc.
NCT04914117 COMPLETED
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
RemeGen Co., Ltd.
NCT05153408 TERMINATED
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
NCT04440943 COMPLETED
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT03333031 TERMINATED
A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies
Herbert Lyerly
NCT03521037 COMPLETED
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
pharmaand GmbH
NCT02986100 COMPLETED
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
pharmaand GmbH
NCT03499444 COMPLETED
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
pharmaand GmbH
NCT03733951 COMPLETED
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT05046808 COMPLETED
Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT04989829 COMPLETED
Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03954366 COMPLETED
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
pharmaand GmbH
NCT04348916 TERMINATED
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Oncorus, Inc.
NCT03871855 TERMINATED
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT04186637 TERMINATED
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
Alpine Immune Sciences, Inc.
NCT02583269 COMPLETED
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Wake Forest University Health Sciences
NCT05877651 COMPLETED
MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
HRYZ Biotech Co.
NCT03311412 COMPLETED
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT04849273 TERMINATED
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Turning Point Therapeutics, Inc.
NCT05199519 COMPLETED
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345
Innovent Biologics (Suzhou) Co. Ltd.
NCT03892018 TERMINATED
The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol
Athenex, Inc.
NCT03588039 TERMINATED
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Athenex, Inc.
NCT05336279 COMPLETED
Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition
Jiangsu HengRui Medicine Co., Ltd.
NCT02351765 COMPLETED
ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers
The Christie NHS Foundation Trust
NCT04341259 COMPLETED
A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.
Hoffmann-La Roche
NCT02761694 TERMINATED
Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT03310541 COMPLETED
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
NCT04184869 COMPLETED
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Acrotech Biopharma Inc.
NCT05236049 COMPLETED
Use of an Allograft Set-up (SclerFIX) as Replacement of Sclera Graft for Support of Enucleation Implant
TBF Genie Tissulaire
NCT03841110 COMPLETED
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT03884517 TERMINATED
Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
Bio-Thera Solutions
NCT04088604 COMPLETED
Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
Luye Pharma Group Ltd.
NCT04686383 COMPLETED
Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors
Calgent Biotechnology Co., Ltd
NCT04144842 COMPLETED
Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017
Alligator Bioscience AB
NCT03802955 COMPLETED
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Adagene (Suzhou) Limited
NCT04650451 SUSPENDED
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Bellicum Pharmaceuticals
NCT04893551 TERMINATED
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
BerGenBio ASA
NCT04135261 COMPLETED
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
NCT03507699 COMPLETED
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
Sheba Medical Center
NCT03730142 COMPLETED
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Shanghai Jiatan Pharmatech Co., Ltd
NCT04084951 COMPLETED
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
NCT03618953 TERMINATED
This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers
Turnstone Biologics, Corp.
NCT03758781 COMPLETED
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03713905 COMPLETED
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
Guangzhou Gloria Biosciences Co., Ltd.
NCT02737787 COMPLETED
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT03396211 COMPLETED
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
NCT04112498 COMPLETED
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Bristol-Myers Squibb
NCT04089449 COMPLETED
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Prelude Therapeutics
NCT04381325 TERMINATED
A Study of MSB0254 Injection in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
NCT02890368 TERMINATED
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
NCT04630769 COMPLETED
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Masonic Cancer Center, University of Minnesota
NCT03849469 COMPLETED
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Xencor, Inc.
NCT04746612 TERMINATED
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
Haihe Biopharma Co., Ltd.
NCT03426254 WITHDRAWN
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
Center Trials & Treatment
NCT03886831 COMPLETED
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
NCT04991740 COMPLETED
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
NCT05388279 TERMINATED
A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT05264038 COMPLETED
A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514
Oncocross Australia Pty Ltd.
NCT05187858 COMPLETED
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Lupin Ltd.
NCT02278250 COMPLETED
First in Human Study of M4344 in Participants With Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT04060511 COMPLETED
A Study of HS-10342 in Patients With Advanced Solid Tumor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT02452268 TERMINATED
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Novartis Pharmaceuticals
NCT05531708 WITHDRAWN
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
Shanghai Pudong Hospital
NCT04911881 COMPLETED
A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT04911894 COMPLETED
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT03545971 COMPLETED
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
NCT02721589 COMPLETED
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03689192 COMPLETED
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Herlev Hospital
NCT04196283 COMPLETED
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
AbbVie
NCT04557384 TERMINATED
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
Eli Lilly and Company
NCT02742935 COMPLETED
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03758001 COMPLETED
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT03889275 COMPLETED
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
MedImmune LLC
NCT03589651 COMPLETED
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Incyte Corporation
NCT03431948 COMPLETED
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
University of Chicago
NCT03901950 COMPLETED
Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
Evopoint Biosciences Inc.
NCT04542291 COMPLETED
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Washington University School of Medicine
NCT04683354 COMPLETED
Study of HL-085 in Patients With Advanced Solid Tumor Tumors
Kechow Pharma, Inc.
NCT05347979 COMPLETED
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
Corcept Therapeutics
NCT03359733 WITHDRAWN
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
Calithera Biosciences, Inc
NCT03370302 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies
Calithera Biosciences, Inc
NCT02834247 TERMINATED
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
NCT03338881 WITHDRAWN
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
Calithera Biosciences, Inc
NCT05230290 COMPLETED
Clinical Study of KD6001 in Advanced Solid Tumours
Shanghai Kanda Biotechnology Co., Ltd.
NCT02959905 COMPLETED
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
BGI, China
NCT04835714 TERMINATED
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
Boehringer Ingelheim
NCT05381935 WITHDRAWN
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma, Ltd.
NCT04252339 COMPLETED
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT04202705 COMPLETED
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875
Byondis B.V.
NCT03420742 COMPLETED
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
NCT05060276 WITHDRAWN
Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
NCT04430842 COMPLETED
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
NCT04797468 WITHDRAWN
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
Shanghai Henlius Biotech
NCT02825940 COMPLETED
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT02998736 COMPLETED
Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy
Ottawa Hospital Research Institute
NCT05472220 WITHDRAWN
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
Pamela Munster
NCT04316169 WITHDRAWN
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
NCT04049903 COMPLETED
Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors
Molecular Partners AG
NCT04659096 COMPLETED
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
Ionis Pharmaceuticals, Inc.
NCT02607813 TERMINATED
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Novartis Pharmaceuticals
NCT03906643 WITHDRAWN
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies
Herbert Lyerly
NCT04097769 COMPLETED
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
Waterstone Hanxbio Pty Ltd
NCT04699929 COMPLETED
A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
NCT04678921 COMPLETED
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
I-Mab Biopharma US Limited
NCT04080024 COMPLETED
A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer
Spago Nanomedical AB
NCT03082209 COMPLETED
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
AbbVie
NCT03051477 COMPLETED
Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03815682 TERMINATED
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Repertoire Immune Medicines
NCT03517488 COMPLETED
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor, Inc.
NCT05132803 WITHDRAWN
TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03809767 COMPLETED
A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
CStone Pharmaceuticals
NCT05528120 COMPLETED
Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
Jiangsu vcare pharmaceutical technology co., LTD
NCT04336124 COMPLETED
Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients
TaiRx, Inc.
NCT03386942 COMPLETED
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
Eisai Inc.
NCT02627274 COMPLETED
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Hoffmann-La Roche
NCT02857270 COMPLETED
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
NCT03349073 COMPLETED
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
NCT03934359 COMPLETED
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
Shanghai De Novo Pharmatech Co., Ltd.
NCT03195764 TERMINATED
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Taivex Therapeutics Corporation
NCT04322552 COMPLETED
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03926013 COMPLETED
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
NCT03856541 COMPLETED
A Study of SHR-A1403 in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT04457180 COMPLETED
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT02437370 COMPLETED
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
University of California, Davis
NCT02937116 COMPLETED
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT02829099 COMPLETED
A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors
Janssen Research & Development, LLC
NCT04049617 TERMINATED
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Gilead Sciences
NCT03883919 COMPLETED
Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
Washington University School of Medicine
NCT04861948 TERMINATED
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
NCT05469490 WITHDRAWN
Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
Luke, Jason, MD
NCT03335540 COMPLETED
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
Bristol-Myers Squibb
NCT02943733 TERMINATED
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
University of Wisconsin, Madison
NCT03129776 TERMINATED
Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer
Sunnybrook Health Sciences Centre
NCT03616574 COMPLETED
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Holy Stone Healthcare Co., Ltd
NCT05262842 WITHDRAWN
JS001+IMP4297 in Patients With Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
NCT03894540 TERMINATED
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Ipsen
NCT04272203 TERMINATED
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
AbbVie
NCT05440006 COMPLETED
A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT03056833 COMPLETED
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Ronald Buckanovich
NCT05008913 TERMINATED
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
AstraZeneca
NCT04554667 COMPLETED
Heavy Lifting Strength Training in Head and Neck Cancer Survivors
University of Alberta
NCT04878484 WITHDRAWN
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
Athenex, Inc.
NCT03182673 TERMINATED
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT02706392 TERMINATED
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
NCT05520372 COMPLETED
Autologous Immune Enhancement Therapy (AIET) for Cancer Patients
Vinmec Research Institute of Stem Cell and Gene Technology
NCT02862457 COMPLETED
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
Merck Sharp & Dohme LLC
NCT03970382 SUSPENDED
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
NCT03088527 COMPLETED
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
Stemline Therapeutics, Inc.
NCT03782467 COMPLETED
Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015
Alligator Bioscience AB
NCT02278965 COMPLETED
Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
Katherine D. Crew
NCT04261075 COMPLETED
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
MedImmune LLC
NCT04324372 COMPLETED
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
Sunshine Lake Pharma Co., Ltd.
NCT04108676 COMPLETED
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT04428086 COMPLETED
A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.
Jiangsu HengRui Medicine Co., Ltd.
NCT02926768 COMPLETED
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Checkpoint Therapeutics, Inc.
NCT02977195 COMPLETED
First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors
Centre Leon Berard
NCT02719691 COMPLETED
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
University of Colorado, Denver
NCT03517956 COMPLETED
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
Bayer
NCT02935907 COMPLETED
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
Ascentage Pharma Group Inc.
NCT03133247 COMPLETED
A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients
Atridia Pty Ltd.
NCT03080311 COMPLETED
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
Ascentage Pharma Group Inc.
NCT03642834 COMPLETED
Study of ICP-105 in Solid Tumors Patients
Beijing InnoCare Pharma Tech Co., Ltd.
NCT03502681 TERMINATED
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Monika Joshi, MD
NCT02535325 COMPLETED
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03102320 COMPLETED
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Bayer
NCT02602119 COMPLETED
Intraoperative Imaging of Pulmonary Nodules by OTL38
University of Pennsylvania
NCT03852511 COMPLETED
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
Akamis Bio
NCT02644291 COMPLETED
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02508532 COMPLETED
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
NCT02630199 COMPLETED
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Samsung Medical Center
NCT03023319 COMPLETED
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Nagla Abdel Karim
NCT03588650 COMPLETED
A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors
Shanghai Henlius Biotech
NCT04335604 COMPLETED
A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors
Onconic Therapeutics Inc.
NCT03270176 COMPLETED
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
Debiopharm International SA
NCT02833753 COMPLETED
Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
University of Massachusetts, Worcester
NCT05010096 WITHDRAWN
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT03312842 COMPLETED
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
NCT03444753 TERMINATED
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Bristol-Myers Squibb
NCT03666988 TERMINATED
First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
GlaxoSmithKline
NCT03525795 COMPLETED
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
Constellation Pharmaceuticals
NCT02801097 TERMINATED
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
EpicentRx, Inc.
NCT04653142 COMPLETED
A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
NCT03053466 COMPLETED
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Apollomics (Australia) Pty. Ltd.
NCT03916094 COMPLETED
Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
Shanghai Henlius Biotech
NCT03851146 COMPLETED
A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours
Peter MacCallum Cancer Centre, Australia
NCT03172936 TERMINATED
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Novartis Pharmaceuticals
NCT04009460 TERMINATED
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
Elpiscience Biopharma, Ltd.
NCT03071757 COMPLETED
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT02897778 COMPLETED
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02734433 COMPLETED
Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
Daiichi Sankyo Co., Ltd.
NCT02315066 COMPLETED
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
NCT03000257 COMPLETED
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
NCT03726294 COMPLETED
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
NatureWise Biotech & Medicals Corporation
NCT04035473 COMPLETED
A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Athenex, Inc.
NCT02354898 COMPLETED
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
Sumitomo Pharma Co., Ltd.
NCT03366428 COMPLETED
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
Daiichi Sankyo Co., Ltd.
NCT03162510 COMPLETED
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers
National Health Research Institutes, Taiwan
NCT03147768 COMPLETED
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
Laser Tissue Welding, Inc.
NCT03682744 WITHDRAWN
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Sorrento Therapeutics, Inc.
NCT02035358 COMPLETED
Immunotherapy Study for Metastatic Renal Cell Cancer
NewLink Genetics Corporation
NCT03924245 TERMINATED
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Vanderbilt-Ingram Cancer Center
NCT02364492 COMPLETED
A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse
Institut Pasteur
NCT02410512 COMPLETED
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT02324439 COMPLETED
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
Southern Illinois University
NCT03600090 COMPLETED
Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
NCT01553071 TERMINATED
Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
South Plains Oncology Consortium
NCT02646748 COMPLETED
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
NCT03579628 COMPLETED
AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors
Valerio Therapeutics
NCT01904123 COMPLETED
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
NCT03951116 COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors
Fochon Pharmaceuticals, Ltd.
NCT03138538 TERMINATED
M8891 First in Human in Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT03203876 COMPLETED
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
NCT02427581 WITHDRAWN
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Washington University School of Medicine
NCT02526017 COMPLETED
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics, Inc.
NCT02442414 COMPLETED
A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors
Sihuan Pharmaceutical Holdings Group Ltd.
NCT04168957 TERMINATED
An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
Athenex, Inc.
NCT03101488 COMPLETED
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT03739138 TERMINATED
Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)
Merck Sharp & Dohme LLC
NCT03910530 COMPLETED
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
Incyte Biosciences Japan GK
NCT03953742 COMPLETED
Study of CPI-200 in Patients With Advanced Tumors
Coordination Pharmaceuticals, Inc.
NCT03475251 COMPLETED
A Study of CS1003 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
NCT02493751 COMPLETED
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
Pfizer
NCT03987685 COMPLETED
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Athenex, Inc.
NCT02596503 COMPLETED
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
NCT02559024 TERMINATED
Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
Providence Health & Services
NCT02705963 COMPLETED
A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors
Novartis Pharmaceuticals
NCT04522557 COMPLETED
Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT02723864 COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT03248843 COMPLETED
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT03317743 COMPLETED
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Idience Co., Ltd.
NCT04811898 COMPLETED
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
NCT02947165 COMPLETED
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT03665129 TERMINATED
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
Innate Pharma
NCT03015324 COMPLETED
Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors
Peng Wang, MD PhD
NCT02909452 COMPLETED
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT03168438 TERMINATED
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
NCT03084926 COMPLETED
First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors
Molecular Partners AG
NCT03823989 COMPLETED
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
Lipomedix Pharmaceuticals Inc.
NCT04810208 TERMINATED
Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours
Lidds AB
NCT02675439 TERMINATED
Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Chinook Therapeutics, Inc. (formerly Aduro)
NCT04191928 COMPLETED
Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
Thomas Jefferson University
NCT02573259 COMPLETED
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Pfizer
NCT03400306 WITHDRAWN
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
AbbVie
NCT02660034 COMPLETED
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
BeiGene
NCT03348514 COMPLETED
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
NCT02716948 COMPLETED
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04973020 COMPLETED
A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers
Jiangsu HengRui Medicine Co., Ltd.
NCT02642809 COMPLETED
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Washington University School of Medicine
NCT02767921 TERMINATED
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
University of Southern California
NCT03319459 COMPLETED
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT02407990 COMPLETED
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
BeiGene
NCT03364049 COMPLETED
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
Merck Sharp & Dohme LLC
NCT03497429 COMPLETED
A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
Takeda
NCT03661632 COMPLETED
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
NCT03100045 COMPLETED
Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
Johns Hopkins University
NCT04508179 COMPLETED
A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects
7 Hills Pharma, LLC
NCT03752177 TERMINATED
A Study of LY3415244 in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT05086848 COMPLETED
A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
NCT05084456 WITHDRAWN
Oral Docetaxel in Patients With Normal or Impaired Liver Function
Modra Pharmaceuticals
NCT02914470 COMPLETED
Carboplatin-cyclophosphamide Combined With Atezolizumab
The Netherlands Cancer Institute
NCT03147378 COMPLETED
Food Effect Study of ModraDoc006 in Combination With Ritonavir
Modra Pharmaceuticals
NCT03895684 COMPLETED
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
Salarius Pharmaceuticals, LLC
NCT04585724 WITHDRAWN
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Emory University
NCT04418141 COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
Curon Biopharmaceutical (Australia) Co Pty Ltd
NCT03489343 COMPLETED
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT04252248 TERMINATED
Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage
University Hospital Heidelberg
NCT03006029 COMPLETED
Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
Theramab LLC
NCT03745807 COMPLETED
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT03607955 WITHDRAWN
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
Washington University School of Medicine
NCT03009292 COMPLETED
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
Eisai Co., Ltd.
NCT03403725 TERMINATED
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
Menarini Group
NCT04158349 TERMINATED
Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer
University of Utah
NCT03991494 COMPLETED
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
BeiGene
NCT04071262 COMPLETED
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
Eli Lilly and Company
NCT03051035 TERMINATED
First-in-Human Study of KO-947 in Non-Hematological Malignancies
Kura Oncology, Inc.
NCT02478866 COMPLETED
Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
Betta Pharmaceuticals Co., Ltd.
NCT04014257 COMPLETED
A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies
Handok Inc.
NCT02730481 COMPLETED
A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
Athenex, Inc.
NCT04111445 TERMINATED
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
NCT02777710 COMPLETED
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Centre Leon Berard
NCT02588612 COMPLETED
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
NCT03057145 COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Geoffrey Shapiro, MD, PhD
NCT02655822 COMPLETED
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Corvus Pharmaceuticals, Inc.
NCT03471286 TERMINATED
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04771390 COMPLETED
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
Bayer
NCT04584515 COMPLETED
IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
Impact Therapeutics, Inc.
NCT04351165 COMPLETED
BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects
Impact Therapeutics, Inc.
NCT04187456 COMPLETED
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body
AstraZeneca
NCT02564198 COMPLETED
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Eli Lilly and Company
NCT02367196 COMPLETED
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
Celgene
NCT03636750 COMPLETED
A Study of Injection HB002.1T in Subjects With Solid Tumor
Huabo Biopharm Co., Ltd.
NCT04312282 TERMINATED
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
Odonate Therapeutics, Inc.
NCT04178902 TERMINATED
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
AbbVie
NCT04258527 COMPLETED
Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
Innovent Biologics (Suzhou) Co. Ltd.
NCT02859857 COMPLETED
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
Bexion Pharmaceuticals, Inc.
NCT03967093 TERMINATED
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
Bexion Pharmaceuticals, Inc.
NCT02546531 COMPLETED
Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Washington University School of Medicine
NCT04427774 TERMINATED
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
NCT02908451 TERMINATED
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
AbGenomics B.V Taiwan Branch
NCT03360734 COMPLETED
Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors
Glycotope GmbH
NCT02715531 COMPLETED
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
NCT03292783 COMPLETED
This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001
ABL Bio, Inc.
NCT03077607 COMPLETED
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
NCT02232243 COMPLETED
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Peng Wang, MD PhD
NCT03804515 TERMINATED
A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
Spectrum Pharmaceuticals, Inc
NCT02292173 COMPLETED
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT02609230 COMPLETED
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Fox Chase Cancer Center
NCT02827968 COMPLETED
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT03359850 COMPLETED
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Tesaro, Inc.
NCT03006887 COMPLETED
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Co., Ltd.
NCT03481816 COMPLETED
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
National Cancer Institute (NCI)
NCT04498520 WITHDRAWN
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Pamela Munster
NCT02528357 COMPLETED
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
GlaxoSmithKline
NCT02499224 COMPLETED
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
CellabMED
NCT04419623 COMPLETED
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
Telios Pharma, Inc.
NCT02303990 COMPLETED
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
Abramson Cancer Center at Penn Medicine
NCT03009214 COMPLETED
A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
amcure GmbH
NCT03205176 COMPLETED
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AstraZeneca
NCT03234712 COMPLETED
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
AbbVie
NCT03706274 WITHDRAWN
PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
CytomX Therapeutics
NCT02817113 TERMINATED
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
Orient Europharma Co., Ltd.
NCT04868344 COMPLETED
A Study of MRG003 in Patients With Advanced Solid Tumors
Shanghai Miracogen Inc.
NCT03604679 COMPLETED
SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors
SymBio Pharmaceuticals
NCT03406364 COMPLETED
Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
Metagone Biotech Inc.
NCT02608229 TERMINATED
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Washington University School of Medicine
NCT03495323 COMPLETED
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
NCT04162301 TERMINATED
A Study of CS3002 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
NCT03507543 COMPLETED
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
NCT03449030 TERMINATED
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
Millennium Pharmaceuticals, Inc.
NCT03722186 SUSPENDED
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
NCT03992326 TERMINATED
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
Centre Hospitalier Universitaire Vaudois
NCT04281290 TERMINATED
Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)
University Medical Centre Ljubljana
NCT04025307 TERMINATED
Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours
Iqvia Pty Ltd
NCT03213964 COMPLETED
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
Masonic Cancer Center, University of Minnesota
NCT03515824 TERMINATED
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)
Merck Sharp & Dohme LLC
NCT03134638 TERMINATED
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Syros Pharmaceuticals
NCT03318445 COMPLETED
Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
Pamela Munster
NCT02897765 COMPLETED
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
BioNTech US Inc.
NCT02997176 COMPLETED
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Pfizer
NCT04338724 COMPLETED
A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
NCT02699749 COMPLETED
A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors
Millennium Pharmaceuticals, Inc.
NCT02740270 COMPLETED
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
Novartis Pharmaceuticals
NCT03489369 COMPLETED
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT04274907 TERMINATED
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
AbbVie
NCT02392793 COMPLETED
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
St. Jude Children's Research Hospital
NCT04488016 COMPLETED
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
AstraZeneca
NCT04675021 COMPLETED
Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects
AstraZeneca
NCT02866916 WITHDRAWN
Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)
Institut Claudius Regaud
NCT03760614 WITHDRAWN
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
Abramson Cancer Center at Penn Medicine
NCT02900157 COMPLETED
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
MedImmune LLC
NCT03736850 COMPLETED
Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
CStone Pharmaceuticals
NCT02721043 COMPLETED
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Nina Bhardwaj
NCT03708211 COMPLETED
A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT04275960 COMPLETED
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
Bayer
NCT02392611 COMPLETED
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Gilead Sciences
NCT02608125 TERMINATED
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
Principia Biopharma, a Sanofi Company
NCT03162562 TERMINATED
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
CanariaBio Inc.
NCT03096340 TERMINATED
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Intezyne Technologies, Inc.
NCT02703571 TERMINATED
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
Novartis Pharmaceuticals
NCT02925104 COMPLETED
A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT04109092 WITHDRAWN
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
Eisai Inc.
NCT02626234 COMPLETED
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis Pharmaceuticals
NCT02520752 COMPLETED
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis Pharmaceuticals
NCT02798978 COMPLETED
A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects
GlaxoSmithKline
NCT04195373 WITHDRAWN
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract
Themis Bioscience GmbH
NCT03790423 COMPLETED
18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
Rigshospitalet, Denmark
NCT03976050 TERMINATED
Phase I Study of HL-085 in Patients With Advanced Solid Tumors
Shanghai Kechow Pharma, Inc.
NCT02706535 COMPLETED
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
GlaxoSmithKline
NCT04006301 COMPLETED
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
Janssen Research & Development, LLC
NCT04142554 WITHDRAWN
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
UNC Lineberger Comprehensive Cancer Center
NCT04274933 TERMINATED
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
AbbVie
NCT02595918 TERMINATED
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
National Cancer Institute (NCI)
NCT02781805 TERMINATED
Pilot Study of Bisphosphonates for Breast Cancer
University of Wisconsin, Madison
NCT03443622 WITHDRAWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
SupremeCure Pharma Inc.
NCT03101280 COMPLETED
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Hoffmann-La Roche
NCT03226574 COMPLETED
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
NCT03512340 COMPLETED
Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
Surface Oncology
NCT03272256 COMPLETED
Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
ImmunoMet Therapeutics, Inc.
NCT03189030 TERMINATED
Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
Aduro Biotech, Inc.
NCT03553108 COMPLETED
A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.
AstraZeneca
NCT02476955 TERMINATED
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT02919696 COMPLETED
A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers
Eli Lilly and Company
NCT02355535 COMPLETED
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Vanquish Oncology, Inc.
NCT02429466 COMPLETED
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Nasser Hanna
NCT02622074 COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
Merck Sharp & Dohme LLC
NCT03384316 COMPLETED
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Cancer Institute (NCI)
NCT03961100 COMPLETED
A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
Genentech, Inc.
NCT03375086 COMPLETED
A Study of APX3330 in Patients With Advanced Solid Tumors
Apexian Pharmaceuticals, Inc.
NCT03030287 COMPLETED
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
OncoMed Pharmaceuticals, Inc.
NCT03539484 TERMINATED
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Hoffmann-La Roche
NCT02916095 COMPLETED
Kanitinib in Treating Patients With Advanced Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd.
NCT02323191 COMPLETED
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT02658214 COMPLETED
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
NCT03008018 COMPLETED
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours
Karus Therapeutics Limited
NCT02722954 COMPLETED
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT03119428 TERMINATED
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
OncoMed Pharmaceuticals, Inc.
NCT03295942 TERMINATED
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
OncoMed Pharmaceuticals, Inc.
NCT02482441 COMPLETED
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
OncoMed Pharmaceuticals, Inc.
NCT03118817 COMPLETED
Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers
Hanmi Pharmaceutical Company Limited
NCT02405065 COMPLETED
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573
Hanmi Pharmaceutical Company Limited
NCT04260360 WITHDRAWN
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
NanOlogy, LLC
NCT04013048 COMPLETED
Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
NCT02881138 COMPLETED
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
NCT03511222 TERMINATED
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Washington University School of Medicine
NCT03089645 COMPLETED
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
MedImmune LLC
NCT02955251 COMPLETED
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
AbbVie
NCT03407976 TERMINATED
Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
University of Utah
NCT02348320 COMPLETED
Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Washington University School of Medicine
NCT02812875 COMPLETED
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Curis, Inc.
NCT03343613 TERMINATED
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Eli Lilly and Company
NCT02512237 TERMINATED
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
Zhejiang Medicine Co., Ltd.
NCT03164603 COMPLETED
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
NewLink Genetics Corporation
NCT02881190 COMPLETED
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
NCT02837991 TERMINATED
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Celldex Therapeutics
NCT02992977 TERMINATED
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
Agenus Inc.
NCT03256331 TERMINATED
Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients
Belx Bio-Pharmaceutical (Taiwan) Corporation
NCT04332549 WITHDRAWN
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
Sun Pharma Advanced Research Company Limited
NCT03235570 COMPLETED
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
Incyte Corporation
NCT02648711 TERMINATED
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
NewLink Genetics Corporation
NCT03644056 COMPLETED
Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors
ImmuneOncia Therapeutics Inc.
NCT02507544 COMPLETED
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TaiRx, Inc.
NCT04126668 COMPLETED
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
AnewPharma
NCT03027284 COMPLETED
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
NCT03733587 COMPLETED
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
Genexine, Inc.
NCT03478995 COMPLETED
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Genexine, Inc.
NCT03547388 COMPLETED
Moderate Whole Body Hyperthermia for Patients Undergoing Re-irradiation for Head and Neck Cancer -Influence on the Tumor Microenvironment
Charite University, Berlin, Germany
NCT03677531 COMPLETED
Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy
OHSU Knight Cancer Institute
NCT03700294 TERMINATED
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
ADC Therapeutics S.A.
NCT03920839 WITHDRAWN
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
NCT02452775 TERMINATED
Autologous OC-L Vaccine and Ovarian Cancer
Abramson Cancer Center at Penn Medicine
NCT03403049 COMPLETED
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Albert Einstein College of Medicine
NCT02529553 COMPLETED
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
NCT02665416 COMPLETED
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Hoffmann-La Roche
NCT02363829 COMPLETED
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
Abramson Cancer Center at Penn Medicine
NCT04118842 COMPLETED
A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin
AstraZeneca
NCT03680560 TERMINATED
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Cogent Biosciences, Inc.
NCT02540551 TERMINATED
Sentinel Node Detection in Ovarian Cancer
Maastricht University Medical Center
NCT02681796 COMPLETED
Epidural Analgesia Use in Pancreatic Resections
Washington University School of Medicine
NCT02946671 COMPLETED
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
NCT03277209 TERMINATED
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
Weill Medical College of Cornell University
NCT03242993 COMPLETED
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
University of Lausanne Hospitals
NCT02551185 COMPLETED
ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Celgene
NCT03258515 COMPLETED
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
AstraZeneca
NCT03425773 COMPLETED
Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care
Cellid Co., Ltd.
NCT02466802 COMPLETED
Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Virginia Commonwealth University
NCT02630251 TERMINATED
Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors
GlaxoSmithKline
NCT02650713 COMPLETED
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
Hoffmann-La Roche
NCT03052205 COMPLETED
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Idera Pharmaceuticals, Inc.
NCT02576665 TERMINATED
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
NCT03306420 TERMINATED
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
EMD Serono Research & Development Institute, Inc.
NCT02800889 WITHDRAWN
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
CTI BioPharma
NCT02383212 COMPLETED
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
NCT02743637 COMPLETED
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
SynDevRx, Inc.
NCT03676101 COMPLETED
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
NCT03159585 COMPLETED
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Zhujiang Hospital
NCT02350673 COMPLETED
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT02476552 COMPLETED
Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer
Tesaro, Inc.
NCT02620839 TERMINATED
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
Pamela Munster
NCT02358200 TERMINATED
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Pamela Munster
NCT03326986 COMPLETED
Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)
Merck Sharp & Dohme LLC
NCT03042910 COMPLETED
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
Pfizer
NCT04193319 COMPLETED
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT02391480 COMPLETED
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
AbbVie
NCT02614456 COMPLETED
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
Fox Chase Cancer Center
NCT02751918 COMPLETED
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Bayer
NCT02679131 TERMINATED
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Acrotech Biopharma Inc.
NCT03057366 COMPLETED
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT02518958 COMPLETED
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
EpicentRx, Inc.
NCT02661815 TERMINATED
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
Dana-Farber Cancer Institute
NCT02553499 TERMINATED
Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)
Merck Sharp & Dohme LLC
NCT03126864 TERMINATED
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02267707 TERMINATED
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
Celgene
NCT02857166 COMPLETED
Study of JS001 in Participants With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
NCT03619616 COMPLETED
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
NCT02471846 COMPLETED
A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT03120130 SUSPENDED
Study of Amblyomin-X in Advanced Solid Tumor
União Química Farmacêutica Nacional S/A
NCT02559492 TERMINATED
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
NCT02759666 COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
Atridia Pty Ltd.
NCT02711345 TERMINATED
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
Novartis Pharmaceuticals
NCT03182257 TERMINATED
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
Ono Pharmaceutical Co. Ltd
NCT03081819 COMPLETED
A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer
Kyunghee University Medical Center
NCT03427073 TERMINATED
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Almac Discovery
NCT02644278 COMPLETED
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
EMD Serono Research & Development Institute, Inc.
NCT02705482 COMPLETED
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
MedImmune LLC
NCT02737072 TERMINATED
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
Eli Lilly and Company
NCT02629549 TERMINATED
Intraoperative Imaging of Pituitary Adenomas by OTL
University of Pennsylvania
NCT03286296 COMPLETED
LZM009 to Treat Patients With Advanced Solid Tumors
Livzon Pharmaceutical Group Inc.
NCT02778126 COMPLETED
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
Eli Lilly and Company
NCT02300610 COMPLETED
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT02707328 TERMINATED
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
The Cooper Health System
NCT03494231 TERMINATED
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
Henlix, Inc
NCT03677960 TERMINATED
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
NCT02389751 COMPLETED
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
M.D. Anderson Cancer Center
NCT04026321 COMPLETED
Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US
Livzon Pharmaceutical Group Inc.
NCT02952989 TERMINATED
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Seagen Inc.
NCT03188328 TERMINATED
Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas
Alfasigma S.p.A.
NCT03349255 TERMINATED
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Aeon Therapeutics (Shanghai) Co., Ltd.
NCT02367352 TERMINATED
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Millennium Pharmaceuticals, Inc.
NCT03313557 COMPLETED
AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
AstraZeneca
NCT03362723 COMPLETED
A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Hoffmann-La Roche
NCT02437227 COMPLETED
A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours
Royal Marsden NHS Foundation Trust
NCT02642016 COMPLETED
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
Celldex Therapeutics
NCT03144466 TERMINATED
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer
Royal Marsden NHS Foundation Trust
NCT02476123 COMPLETED
Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Kyowa Kirin Co., Ltd.
NCT02309177 COMPLETED
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Celgene
NCT02250781 COMPLETED
Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
NCT02324621 COMPLETED
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
NCT02825563 COMPLETED
A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT03138408 TERMINATED
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
AbbVie
NCT03175497 COMPLETED
Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors
Taizhou EOC Pharma Co., Ltd.
NCT02622932 COMPLETED
Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT02548390 TERMINATED
Study of Intravenous RXDX-107 in Patients With Solid Tumors
Hoffmann-La Roche
NCT02540876 COMPLETED
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
University of Chicago
NCT02672865 COMPLETED
Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer
Loma Linda University
NCT02565758 COMPLETED
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
AbbVie
NCT02717572 COMPLETED
18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
Washington University School of Medicine
NCT03192943 COMPLETED
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
Bristol-Myers Squibb
NCT02703298 COMPLETED
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients
TaiRx, Inc.
NCT02483858 COMPLETED
Study of Oral PQR309 in Patients With Advanced Solid Tumors
PIQUR Therapeutics AG
NCT03311477 COMPLETED
A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors
AbbVie
NCT02813902 WITHDRAWN
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
Massachusetts General Hospital
NCT02458339 COMPLETED
Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
The University of Texas Health Science Center, Houston
NCT02745769 COMPLETED
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Eli Lilly and Company
NCT02444793 TERMINATED
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Pfizer
NCT02601274 TERMINATED
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
Hutchison Medipharma Limited
NCT02973399 TERMINATED
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Esanex Inc.
NCT02345174 COMPLETED
Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors
GlaxoSmithKline
NCT02688101 COMPLETED
Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
Collaborative Medicinal Development Pty Limited
NCT02555644 COMPLETED
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Eli Lilly and Company
NCT03011320 COMPLETED
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
Endocyte
NCT03202992 COMPLETED
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
NCT02731742 TERMINATED
Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)
Merck Sharp & Dohme LLC
NCT02582931 COMPLETED
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
Washington University School of Medicine
NCT02418624 COMPLETED
Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer
The Netherlands Cancer Institute
NCT02963389 COMPLETED
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients
Dong-A ST Co., Ltd.
NCT03450109 COMPLETED
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
Luye Pharma Group Ltd.
NCT02556463 TERMINATED
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
MedImmune LLC
NCT02860780 COMPLETED
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
NCT03145909 TERMINATED
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
AbbVie
NCT03153163 COMPLETED
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
Hoffmann-La Roche
NCT02966171 TERMINATED
A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
Hutchison Medipharma Limited
NCT02268825 TERMINATED
Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers
University of Utah
NCT02636426 COMPLETED
Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study
Amsterdam UMC, location VUmc
NCT02508441 TERMINATED
Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors
Andes Biotechnologies
NCT03496519 WITHDRAWN
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
University of Colorado, Denver
NCT02845414 WITHDRAWN
Study of CD133KDEL Toxin in the Treatment for Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT03320525 TERMINATED
Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)
Herlev Hospital
NCT02442531 COMPLETED
A Study of CriPec® Docetaxel Given to Patients With Solid Tumours
Cristal Therapeutics
NCT02939846 WITHDRAWN
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
GlaxoSmithKline
NCT02650635 TERMINATED
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Mayo Clinic
NCT03330990 COMPLETED
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Hoffmann-La Roche
NCT03285607 WITHDRAWN
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Washington University School of Medicine
NCT02673736 TERMINATED
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
Plexxikon
NCT02780011 WITHDRAWN
Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Eric Bernicker, MD
NCT02386111 TERMINATED
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
NCT03111069 WITHDRAWN
Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children
M.D. Anderson Cancer Center
NCT02987504 TERMINATED
Study of Samalizumab in Patients With Advanced Cancer
Alexion Pharmaceuticals, Inc.
NCT02839694 WITHDRAWN
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
National Cancer Institute (NCI)
NCT03082053 COMPLETED
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
ASLAN Pharmaceuticals
NCT03077477 WITHDRAWN
Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
Aminex Therapeutics, Inc.
NCT02485119 COMPLETED
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
Bayer
NCT02760797 COMPLETED
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Hoffmann-La Roche
NCT02323893 COMPLETED
Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans
CellSight Technologies, Inc.
NCT02690350 TERMINATED
An Open Study Assessing the Safety and Tolerability of U3-1784
Daiichi Sankyo
NCT02222363 TERMINATED
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors
Vivolux AB
NCT02833506 WITHDRAWN
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
NCT02275039 COMPLETED
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
City of Hope Medical Center
NCT02543645 TERMINATED
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
NCT03502395 COMPLETED
Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion
Assiut University
NCT02592785 COMPLETED
Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Bayer
NCT02558140 COMPLETED
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
NCT02671955 TERMINATED
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
Janssen Research & Development, LLC
NCT02349139 TERMINATED
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
Asana BioSciences
NCT03422874 WITHDRAWN
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Dartmouth-Hitchcock Medical Center
NCT02318394 COMPLETED
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
MedImmune LLC
NCT02359058 COMPLETED
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Eli Lilly and Company
NCT03205891 WITHDRAWN
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
M.D. Anderson Cancer Center
NCT02296879 COMPLETED
A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types
Young Suk Park
NCT02828930 COMPLETED
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
Hoffmann-La Roche
NCT02593708 TERMINATED
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Michelle Melisko
NCT03247283 COMPLETED
Pharmacokinetics and Metabolism Study in Healthy Male Participants
Bristol-Myers Squibb
NCT02303366 COMPLETED
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
Peter MacCallum Cancer Centre, Australia
NCT03007771 WITHDRAWN
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
Washington University School of Medicine
NCT02658708 COMPLETED
Bright Light on Fatigue in Women Being Treated for Breast Cancer
Washington University School of Medicine
NCT03283046 WITHDRAWN
Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
NCT02745756 WITHDRAWN
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03246009 COMPLETED
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
Tianjin SinoBiotech Ltd.
NCT02674555 WITHDRAWN
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
Astellas Pharma Global Development, Inc.
NCT02082665 COMPLETED
Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam
GlaxoSmithKline
NCT02526316 COMPLETED
Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers
Oryx GmbH & Co. KG
NCT02428036 COMPLETED
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
Takara Bio Inc.
NCT02412462 COMPLETED
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
Alethia Biotherapeutics
NCT02915172 WITHDRAWN
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT02429804 TERMINATED
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Stanford University
NCT02812056 WITHDRAWN
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
M.D. Anderson Cancer Center
NCT02216669 WITHDRAWN
Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer
Maastricht Radiation Oncology
NCT02836171 COMPLETED
Effect of Itraconazole on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
NCT02836821 COMPLETED
Effect of Rifampicin on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
NCT03062982 COMPLETED
Food-Effect and Metabolism Study in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
NCT02536469 COMPLETED
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
NCT02640365 COMPLETED
A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group
NCT02264886 COMPLETED
Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies
Washington University School of Medicine
NCT02442063 COMPLETED
Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions
Bayer
NCT02353026 COMPLETED
Phase I Study of Intravenous Artesunate for Solid Tumors
Georgetown University
NCT02536391 COMPLETED
Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
Genentech, Inc.
NCT02380313 WITHDRAWN
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
NCT02876627 COMPLETED
Effect Aerobic Training on Women With Breast Cancer After Chemotherapy
University of Isfahan
NCT02432612 WITHDRAWN
A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer
GW Pharmaceuticals Ltd
NCT02470559 WITHDRAWN
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Barbara Ann Karmanos Cancer Institute
NCT02537561 WITHDRAWN
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Washington University School of Medicine
NCT02292732 WITHDRAWN
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
GlaxoSmithKline
NCT02563951 COMPLETED
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Maxinase Life Sciences Ltd.
NCT02312804 WITHDRAWN
Ph Ib/BGJ398/Cervix and Other Solid Tumors
The University of Texas Health Science Center at San Antonio
NCT02048943 WITHDRAWN
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Roswell Park Cancer Institute
NCT06457503 RECRUITING
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Coherus Oncology, Inc.
NCT03016741 ACTIVE NOT RECRUITING
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Northwestern University
NCT05376878 RECRUITING
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
City of Hope Medical Center
NCT07426484 NOT YET RECRUITING
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
NCT06764095 RECRUITING
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
NCT07042581 RECRUITING
A Study of Revaree Plus in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05203172 RECRUITING
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
NCT06786429 NOT YET RECRUITING
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Eunice Dube
NCT07312370 NOT YET RECRUITING
Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing: A Randomized Controlled Trial
LanZhou University
NCT07303816 NOT YET RECRUITING
Statins to Prevent Cancer Associated Blood Clots
Brigham and Women's Hospital
NCT07262957 RECRUITING
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT07272512 RECRUITING
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
Shanghai Zhongshan Hospital
NCT06016855 RECRUITING
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
NCT05255003 RECRUITING
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Tzu-Fei Wang
NCT05525767 RECRUITING
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
Hebei Medical University Fourth Hospital
NCT06251076 RECRUITING
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
NCT07158164 RECRUITING
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Rutgers, The State University of New Jersey
NCT03229200 ACTIVE NOT RECRUITING
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
NCT07217600 RECRUITING
Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy
Chongqing University Cancer Hospital
NCT07214714 NOT YET RECRUITING
Hemodynamic and Cardiac Effects of Dexmedetomidine Versus Fentanyl by Intravenous Infusion as Adjuncts to General Anesthesia in Patients Undergoing Major Abdominal Cancer Surgeries.
Assiut University
NCT06934057 RECRUITING
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris
NCT07124351 RECRUITING
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Cedars-Sinai Medical Center
NCT07162259 NOT YET RECRUITING
Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
Yan Xue
NCT05651282 ACTIVE NOT RECRUITING
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
University of British Columbia
NCT04532606 RECRUITING
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Peking University First Hospital
NCT06897527 NOT YET RECRUITING
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
GlaxoSmithKline
NCT06903312 RECRUITING
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT07010393 NOT YET RECRUITING
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Fujian Medical University
NCT07001709 RECRUITING
Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)
Deventer Ziekenhuis
NCT06603870 RECRUITING
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Ottawa Hospital Research Institute
NCT03573960 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Eisai Pharmaceuticals India Pvt. Ltd
NCT03844360 RECRUITING
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Wei Zhao
NCT06897917 NOT YET RECRUITING
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Henan Cancer Hospital
NCT06887933 NOT YET RECRUITING
A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
GlaxoSmithKline
NCT05465031 RECRUITING
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Silesian Centre for Heart Diseases
NCT06871787 NOT YET RECRUITING
Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
Istanbul University
NCT05245877 RECRUITING
Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
Helsinki University Central Hospital
NCT06824792 NOT YET RECRUITING
Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System
NING LI
NCT06820255 RECRUITING
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT06627036 RECRUITING
Dermoscopy vs Standard Marking for the Completeness of Excision of Keratinocyte Skin Cancers: The ClearMark Trial
Hull University Teaching Hospitals NHS Trust
NCT06408688 RECRUITING
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
University Hospital, Basel, Switzerland
NCT06706921 RECRUITING
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06118710 RECRUITING
Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment
Erasmus Medical Center
NCT06145321 ACTIVE NOT RECRUITING
Continuous Versus Bolus Administration of G-CSF in Children With Cancer
Chang Gung Memorial Hospital
NCT05148494 RECRUITING
TES RCT Fleet Enema vs Oral Mechanical Bowel Prep
Nova Scotia Health Authority
NCT06498037 RECRUITING
Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.
Erasmus Medical Center
NCT05078671 RECRUITING
Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness
Radboud University Medical Center
NCT05957822 RECRUITING
Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery
Konkuk University Medical Center
NCT06381557 NOT YET RECRUITING
Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules
Qiang Fu
NCT05440240 RECRUITING
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
Regionshospitalet Silkeborg
NCT05452213 RECRUITING
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
Institut fuer Frauengesundheit
NCT05185505 RECRUITING
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
The Methodist Hospital Research Institute
NCT04281667 ACTIVE NOT RECRUITING
Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery
Helsinki University Central Hospital
NCT02775227 ACTIVE NOT RECRUITING
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
Helsinki University Central Hospital
NCT03151213 COMPLETED
Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver
Sherief Abd-Elsalam
NCT07022938 COMPLETED
Nutritional Supplement for Treating Chemotherapy Induced Neuropathy
Aristotle University Of Thessaloniki
NCT04952766 COMPLETED
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
Centre Hospitalier Régional d'Orléans
NCT04319198 COMPLETED
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
NCT05834569 TERMINATED
Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients
Korea University Guro Hospital
NCT04513522 COMPLETED
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Bristol-Myers Squibb
NCT01932125 COMPLETED
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Hoffmann-La Roche
NCT04347122 TERMINATED
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction
University of Kansas Medical Center
NCT06924229 COMPLETED
Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment
Sohag University
NCT04724460 COMPLETED
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
Takeshi Morimoto
NCT06023368 WITHDRAWN
Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray
Marianne Hutti
NCT05688384 COMPLETED
Patient-Controlled Sedation in Port Implantation (PACSPI-2)
Region Jönköping County
NCT06630910 COMPLETED
New Technique of Pancreaticojejunostomy During Whipple Operation
Theodor Bilharz Research Institute
NCT06576336 COMPLETED
A Randomized Clinical Trial About Use of 3D Laparoscopy Versus 2D Laparoscopy in Adrenal Surgery
University of Palermo
NCT05054998 COMPLETED
Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT04574947 COMPLETED
Lidocaine And Neuromonitoring in Thyroid Surgery
Saint Petersburg State University, Russia
NCT06316908 COMPLETED
Permanent Celiac Plexus Block: Comparison of Pain Score in Unilateral and Bilateral Posterior Percutaneous Approach
Sindh Institute of Urology and Transplantation
NCT04931615 COMPLETED
ARTISS a Single-centre Randomised Control Study
Mid and South Essex NHS Foundation Trust
NCT05075538 TERMINATED
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
Jules Bordet Institute
NCT03858166 TERMINATED
Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
Shandong University
NCT04707196 COMPLETED
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
Eli Lilly and Company
NCT03895502 COMPLETED
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
Takeshi Morimoto
NCT03469271 COMPLETED
Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
Mayo Clinic
NCT05061654 WITHDRAWN
CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
Hamad Medical Corporation
NCT02359175 COMPLETED
Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study
Odense University Hospital
NCT04072068 COMPLETED
Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
Gruppo Oncologico Italiano di Ricerca Clinica
NCT03145012 COMPLETED
Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity
Nova Scotia Health Authority
NCT02549677 COMPLETED
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
Ruijin Hospital
NCT03333655 COMPLETED
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
Hoffmann-La Roche
NCT02691793 COMPLETED
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
Samsung Medical Center
NCT02688881 COMPLETED
Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
Samsung Medical Center
NCT04074460 COMPLETED
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study
Peter MacCallum Cancer Centre, Australia
NCT04479579 COMPLETED
Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
McMaster University
NCT02334722 COMPLETED
1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
University of Florida
NCT04779567 COMPLETED
Usefulness of Acetaminophen Associated With Strong Opioids for Acute Pain in Cancer Patients
Pontificia Universidad Catolica de Chile
NCT02444572 COMPLETED
Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®
Les Laboratoires des Médicaments Stériles
NCT03980704 COMPLETED
Preoperative High Protein vs Immunodiet in Surgical Cancer Patients
Stanley Dudrick's Memorial Hospital
NCT03040024 TERMINATED
Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients
Emory University
NCT02459964 COMPLETED
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
M.D. Anderson Cancer Center
NCT03469310 COMPLETED
Minimizing Narcotic Analgesics After Endocrine Surgery
Minerva A Romero Arenas
NCT03063255 COMPLETED
Comparison of Obturator Nerve Blockade and Neuromuscular Blockade
University of Florida
NCT03639415 WITHDRAWN
Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain
Fujian Cancer Hospital
NCT04607525 COMPLETED
Dexmedetomidine Infusion Effect on Hemodynamic Variables During Craniotomy
Ain Shams University
NCT03723447 COMPLETED
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
Cedars-Sinai Medical Center
NCT02555748 COMPLETED
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
Institut Claudius Regaud
NCT04699760 COMPLETED
The Effects of n-3 LCPUFAs in Patients With Colorectal Cancer
University of Copenhagen
NCT03210376 COMPLETED
Neuromuscular Blockade on Shoulder Pain of Elderly
M.D. Anderson Cancer Center
NCT03176849 COMPLETED
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Phoenix Children's Hospital
NCT03138967 COMPLETED
Investigation of Sugammadex in Outpatient Urological Procedures
M.D. Anderson Cancer Center
NCT03397914 COMPLETED
Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections
National Cancer Institute, Egypt
NCT03199911 COMPLETED
Topical Antibiotic Prophylaxis for Eyelids
University of California, San Francisco
NCT02744664 COMPLETED
Cryotherapy Combine Icotinib for Advanced NSCLC Treatment
Fuda Cancer Hospital, Guangzhou
NCT02627560 COMPLETED
The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy
St. Olavs Hospital
NCT02815319 COMPLETED
Schedules of Dexamethasone in Patients Incorrectly Taking Dexamethasone Premedication (REaCT-dexamethasone)
Ottawa Hospital Research Institute
NCT03176199 COMPLETED
A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
NCT03176121 COMPLETED
Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
NCT04187755 COMPLETED
Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever
Indonesia University
NCT03583944 COMPLETED
A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
Eisai Inc.
NCT02721576 TERMINATED
A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC
Shandong Cancer Hospital and Institute
NCT02721563 COMPLETED
A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC
Shandong Cancer Hospital and Institute
NCT02721550 TERMINATED
A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC
Shandong Cancer Hospital and Institute
NCT02819921 TERMINATED
Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
Seoul National University Hospital
NCT02623959 TERMINATED
Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis
M.D. Anderson Cancer Center
NCT03514550 COMPLETED
Effects of Anesthesia on Immunity in Cancer
Meshalkin Research Institute of Pathology of Circulation
NCT02869321 COMPLETED
Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy
Central Hospital, Nancy, France
NCT02895529 TERMINATED
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
Xian-Janssen Pharmaceutical Ltd.
NCT03355079 TERMINATED
Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy
Fresenius Kabi
NCT02350543 TERMINATED
Peri-operative Aspirin Continuation Versus Discontinuation
Rabin Medical Center
NCT02839889 TERMINATED
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
Hospice of Henderson County, Inc.
NCT03172988 TERMINATED
Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery
Peking University First Hospital
NCT02944604 COMPLETED
The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
Peking University
NCT02660229 COMPLETED
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
Mundipharma Korea Ltd
NCT02800330 COMPLETED
The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
Erasmus Medical Center
NCT03586154 COMPLETED
Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain
Mansoura University
NCT02581176 COMPLETED
Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
University Hospital, Akershus
NCT02962999 COMPLETED
Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation
Cukurova University
NCT02532634 COMPLETED
Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
Kangdong Sacred Heart Hospital
NCT02009306 COMPLETED
Nasal Fentanyl and Buccal Midazolam for Dying Patients
Gloucestershire Hospitals NHS Foundation Trust
NCT03384511 COMPLETED
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
NCT02909049 COMPLETED
Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy
Complexo Hospitalario Universitario de A Coruña
NCT02566096 COMPLETED
Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively
Assiut University
NCT02593942 COMPLETED
Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy
Yeditepe University Hospital
Data: ClinicalTrials.gov